Proteins binding to NKG2d, CD16 and CLEC12a
Multispecific binding proteins targeting NKG2D, CD16, and CLEC12A stimulate NK cells to enhance tumor cell death, addressing the limitations of current cancer treatments by providing a targeted and effective immunotherapy.
Patent Information
- Application Number
- JP2024102534
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-05-06
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, especially for aggressive forms, lack effectiveness and are associated with significant adverse side effects, and there is a need for new proteins that can target CLEC12A to enhance cancer immunotherapy.
Development of multispecific binding proteins that bind to NKG2D, CD16, and CLEC12A to stimulate NK cells, potentially enhancing tumor cell death through activation of natural killer cells.
The proteins effectively engage multiple activating receptors on NK cells, stimulating them to enhance tumor cell killing, offering a targeted and specific approach to cancer treatment with reduced side effects.
Smart Images

Figure 2024160215000001_ABST
Abstract
Description
[Technical Field]
[0001] This application claims priority to U.S. Provisional Application No. 63 / 020,798, filed May 6, 2020, which is incorporated herein by reference in its entirety.
[0002] Sequence Listing This application incorporates by reference the entirety of the Sequence Listing in computer-readable form (CRF) in ASCII text format. The Sequence Listing text file is titled "14247-540-228_SEQ_LISTING", was created on May 3, 2021, and is 291,375 bytes in size.
[0003] FIELD OF THE INVENTION This application relates to multispecific binding proteins that bind to NKG2D, CD16, and CLEC12A on cells, pharmaceutical compositions comprising such proteins, and methods of treatment using such proteins and pharmaceutical compositions, including the treatment of cancer. [Background technology]
[0004] Despite considerable research efforts, cancer continues to pose a significant clinical and financial burden in countries worldwide. According to the World Health Organization (WHO), it is the second leading cause of death. Surgery, radiation therapy, chemotherapy, biological therapy, immunotherapy, hormone therapy, stem cell transplantation, and precision medicine are among the existing treatments. Despite extensive research in these areas, highly effective therapeutic solutions have yet to be identified, particularly for the most aggressive cancers. Furthermore, many of the existing anti-cancer treatments have significant adverse side effects.
[0005] Cancer immunotherapy is desirable because it is highly specific and can use a patient's own immune system to promote the destruction of cancer cells. Fusion proteins, such as bispecific T cell engagers, are a cancer immunotherapy that have been described in the literature, which bind to tumor cells and T cells to promote tumor cell destruction. Antibodies that bind to specific tumor-associated antigens have been described in the literature. See, for example, WO2016 / 134371 and WO2015 / 095412.
[0006] Natural killer (NK) cells are components of the innate immune system and account for approximately 15% of circulating lymphocytes. NK cells infiltrate virtually all tissues and were originally characterized for their ability to effectively kill tumor cells without the need for prior sensitization. Activated NK cells kill target cells in a manner similar to cytotoxic T cells, i.e., via cytolytic granules containing perforin and granzymes, as well as death receptor pathways. Activated NK cells also secrete proinflammatory cytokines, such as IFN-γ and chemokines, which promote the recruitment of other leukocytes to target tissues.
[0007] NK cells respond to signals through various activating and inhibitory receptors on their surface. For example, when NK cells encounter healthy autologous cells, their activity is inhibited by the activation of killer cell immunoglobulin-like receptors (KIRs). Alternatively, when NK cells encounter foreign or cancer cells, they are activated through their activating receptors (e.g., NKG2D, NCR, DNAM1). NK cells are also activated by the CD16 receptor on their surface and by the constant regions of some immunoglobulins. The overall sensitivity of NK cells to activation depends on the sum of stimulatory and inhibitory signals. NKG2D is a type II transmembrane protein expressed by essentially all natural killer cells, where it functions as an activating receptor. NKG2D is also found on T cells, where it functions as a costimulatory receptor. NK cell function is regulated through NKG2D. The ability to do so is useful in a variety of therapeutic situations, including malignancies.
[0008] C-type lectin domain family 12 member A (CLEC12A), also known as C-type lectin-like molecule-1 (CLL-1) or myeloid inhibitory C-type lectin-like receptor (MICL), is a member of the C-type lectin / C-type lectin-like domain (CTL / CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, including roles in cell adhesion, cell-cell signaling, glycoprotein turnover, and inflammation and immune responses. CLEC12A, a type II transmembrane glycoprotein, is overexpressed in more than 90% of acute myeloid leukemia patients in leukemic stem cells but not in normal hematopoietic cells. Despite numerous efforts by several biotechnology and pharmaceutical companies, the development of specific CLEC12A-targeting biologics has been hampered by the lack of antibodies with favorable development characteristics. The challenge of discovering CLEC12A antibodies may be due to the complexity of the antigen. CLEC12A is a monomeric, highly glycosylated protein with six potential N-glycosylation sites within its 201-amino acid extracellular domain. Four of the six N-glycosylation sites are clustered in the membrane-proximal domain of the molecule, potentially involved in target presentation on the cell surface. Variation in the glycosylation status of CLEC12A on the surface of different cell types has been reported (Marshall et al., (2006) Eur J Immunol. 36(8):2159-69). Thus, there remains a need in the field for new and useful proteins that bind to CLEC12A for use in the treatment of cancer. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] International Publication No. 2016 / 134371 [Patent Document 2] International Publication No. 2015 / 095412 [Non-patent literature]
[0010] [Non-Patent Document 1] Marshall et al.,(2006) Eur J Immunol.36(8):2159-69 Summary of the Invention
[0011] The present application provides multispecific binding proteins that bind to the NKG2D and CD16 receptors on natural killer cells, as well as CLEC12A. Such proteins can engage two or more NK-activating receptors and block natural ligands from binding to NKG2D. In certain embodiments, the proteins can stimulate human NK cells. In some embodiments, the proteins can stimulate NK cells in humans and other species, such as rodents and cynomolgus monkeys. Also provided are formulations comprising any one of the proteins disclosed herein; cells comprising one or more nucleic acids expressing the proteins; and methods for enhancing tumor cell death using the proteins.
[0012] Thus, in one aspect, the present application provides a protein comprising: (a) a first antigen-binding site that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) an antibody Fc domain or portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16; wherein the second antigen-binding site that binds to CLEC12A comprises: (i) a complementarity-determining region 1 (CDR1), a complementarity-determining region 2 (CDR2), and a complementarity-determining region 3 (CDR3), each comprising the amino acid sequences of SEQ ID NOs: 137, 272, and 273, respectively; a heavy chain variable domain (VH) comprising CDR1, CDR2, and CDR3, each comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142; (ii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively; (iii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 251, 196, and 246, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively; (v) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 166, and 223, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 240, 226, and 179, respectively; (v) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 206, 166, and 241, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 245, 239, and 179, respectively; (vi) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 236, and 223, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 152, 226, and 179, respectively; (vii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 159, 170, and 183, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 186, 188, and 189, respectively; (viii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 197, 202, and 207, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 211, 212, and 214, respectively; (ix) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 220, 222, and 257, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 224, 225, and 227, respectively; or (x) VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 230, 231, and 232, respectively; and VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 233, 234, and 235, respectively.
[0013] In some embodiments, the second antigen-binding site that binds to CLEC12A comprises a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 272, and 273, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In some embodiments, the second antigen-binding site that binds to CLEC12A comprises a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively.
[0014] In certain embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 335, and the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 336. In certain embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 270, and the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 271. In certain embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 178, and the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 289. In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 335, and the VL comprises the amino acid sequence of SEQ ID NO: 336. In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 270, and the VL comprises the amino acid sequence of SEQ ID NO: 271. In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 178, and the VL comprises the amino acid sequence of SEQ ID NO: 289. In certain embodiments, the VH and VL comprise the amino acid sequences of SEQ ID NOs: 143 and 144; 147 and 144; 244 and 144; 178 and 144; 256 and 144; 143 and 163; 143 and 167; 143 and 171; or 174 and 175, respectively.
[0015] In some embodiments, the second antigen-binding site is present as a single chain fragment variable (scFv), wherein the scFv comprises an amino acid sequence selected from SEQ ID NOs: 274, 145, 146, 149, 150, 153, 154, 156, 157, 160, 161, 164, 165, 168, 169, 172, 173, 176, 177, 180, and 181. In certain embodiments, the scFv comprises the amino acid sequence of SEQ ID NO: 274. In certain embodiments, the scFv comprises the amino acid sequence of SEQ ID NO: 180.
[0016] In some embodiments, the second antigen binding site that binds to CLEC12A comprises a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 251, 196, and 246, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively.
[0017] In certain embodiments, the second antigen-binding site that binds to CLEC12A comprises: (i) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 195, 196, and 187, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively; (ii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively; or (iii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 213, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively.
[0018] In a specific embodiment, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO:148, and the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO:203.
[0019] In certain embodiments, the VH comprises the amino acid sequence of SEQ ID NO: 148, and the VL comprises the amino acid sequence of SEQ ID NO: 203. In certain embodiments, the VH and VL comprise the amino acid sequences of SEQ ID NOs: 162 and 203; 210 and 203; 162 and 218; 148 and 218; or 210 and 218, respectively. In some embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence selected from SEQ ID NOs: 184, 185, 204, 205, 208, 209, 215, 216, 252, 253, 254, and 255. In certain embodiments, the scFv comprises the amino acid sequence of SEQ ID NO: 204.
[0020] In certain embodiments, the second antigen binding site of the preceding embodiments binds to CLEC12A in a glycosylation-independent manner.
[0021] In another aspect, the present application provides a protein comprising: (a) a first antigen-binding site that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) an antibody Fc domain or portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16; wherein the second antigen-binding site binds to CLEC12A in a glycosylation-independent manner. Combine with.
[0022] In some embodiments of the proteins disclosed herein, the second antigen-binding site has a dissociation constant (K) of 20 nM or less, as measured by surface plasmon resonance (SPR). D In certain embodiments, the second antigen-binding site binds to human CLEC12A with a K of 1 nM or less as measured by SPR. D In a specific embodiment, the second antigen-binding site binds to human CLEC12A comprising a K244Q substitution.
[0023] In some embodiments of the proteins disclosed herein, the proteins comprise an antibody Fc domain or portion thereof sufficient to bind to CD16.
[0024] In some embodiments of the proteins disclosed herein, the first antigen-binding site that binds to NKG2D is a Fab fragment and the second antigen-binding site that binds to CLEC12A is an scFv.
[0025] In some embodiments of the proteins disclosed herein, the first antigen-binding site that binds to NKG2D is an scFv and the second antigen-binding site that binds to CLEC12A is a Fab fragment.
[0026] In some embodiments of the proteins disclosed herein, the protein further comprises an additional antigen-binding site that binds to CLEC12A. In certain embodiments, the first antigen-binding site that binds to NKG2D is an scFv, and the second and additional antigen-binding sites that bind to CLEC12A are each Fab fragments. In certain embodiments, the first antigen-binding site that binds to NKG2D is an scFv, and the second and additional antigen-binding sites that bind to CLEC12A are each scFv. In certain embodiments, the amino acid sequences of the second and additional antigen-binding sites are identical. In certain embodiments, the amino acid sequences of the second and additional antigen-binding sites are different.
[0027] In another aspect, the present application provides a protein comprising: (a) a first antigen-binding site that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) an antibody Fc domain or portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16; Here, the first antigen-binding site that binds to NKG2D is a Fab fragment, and the second antigen-binding site that binds to CLEC12A is an scFv.
[0028] In some embodiments of the proteins disclosed herein, the scFv that binds NKG2D is linked to an antibody constant domain, or a portion thereof, sufficient to bind CD16 via a hinge comprising Ala-Ser or Gly-Ser. In certain embodiments, the hinge further comprises the amino acid sequence Thr-Lys-Gly.
[0029] In some embodiments of the proteins disclosed herein, each scFv that binds to CLEC12A is linked to an antibody constant domain, or portion thereof, sufficient to bind to CD16 via a hinge comprising Ala-Ser or Gly-Ser. In certain embodiments, the hinge further comprises the amino acid sequence Thr-Lys-Gly.
[0030] In some embodiments of the proteins disclosed herein, within an scFv that binds to NKG2D, the heavy chain variable domain of the scFv forms a disulfide bridge with the light chain variable domain of the scFv. In certain embodiments, the disulfide bridge is The amino acid sequence is formed between C44 of the heavy chain variable domain and C100 of the light chain variable domain, numbered under the amino acid sequence.
[0031] In some embodiments of the proteins disclosed herein, within each scFv that binds to CLEC12A, the heavy chain variable domain of the scFv forms a disulfide bridge with the light chain variable domain of the scFv. In certain embodiments, the disulfide bridge is formed between C44 of the heavy chain variable domain and C100 of the light chain variable domain, and is numbered under the Kabat numbering scheme.
[0032] In some embodiments of the proteins disclosed herein, in an scFv that binds to NKG2D, the heavy chain variable domain is linked to the light chain variable domain via a flexible linker. In certain embodiments, the flexible linker comprises (G4S)4.
[0033] In some embodiments of the proteins disclosed herein, within each scFv that binds to CLEC12A, the heavy chain variable domain is linked to the light chain variable domain via a flexible linker. In certain embodiments, the flexible linker comprises (G4S)4.
[0034] In some embodiments of the proteins disclosed herein, in an scFv that binds to NKG2D, the heavy chain variable domain is positioned C-terminal to the light chain variable domain.
[0035] In some embodiments of the proteins disclosed herein, within each scFv that binds to CLEC12A, the heavy chain variable domain is positioned C-terminal to the light chain variable domain.
[0036] In some embodiments of the proteins disclosed herein, in an scFv that binds to NKG2D, the heavy chain variable domain is positioned N-terminal to the light chain variable domain.
[0037] In some embodiments of the proteins disclosed herein, within each scFv that binds to CLEC12A, the heavy chain variable domain is positioned N-terminal to the light chain variable domain.
[0038] In some embodiments of the proteins disclosed herein, the Fab fragment that binds to NKG2D is not positioned between the antigen binding site and the Fc or portion thereof.
[0039] In some embodiments of the proteins disclosed herein, the Fab fragment that binds to CLEC12A is not positioned between the antigen binding site and the Fc or portion thereof.
[0040] In some embodiments of the proteins disclosed herein, the first antigen-binding site that binds to NKG2D comprises a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 81, 82, and 112, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site that binds to NKG2D comprises: (i) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 81, 82, and 97, respectively; a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively; or (ii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 81, 82, and 84, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
[0041] In some embodiments of the proteins disclosed herein, the VH of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO: 95, and the VL of the first antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO: 85. In certain embodiments, the VH of the first antigen-binding site comprises the amino acid sequence of SEQ ID NO: 95; and the VL of the first antigen-binding site comprises the amino acid sequence of SEQ ID NO: 85.
[0042] In some embodiments of the proteins disclosed herein, the antibody Fc domain is a human IgG1 antibody Fc domain. In some embodiments, the antibody Fc domain, or portion thereof, comprises an amino acid sequence at least 90% identical to SEQ ID NO: 118. In certain embodiments, at least one polypeptide chain of the antibody Fc domain comprises one or more mutations compared to SEQ ID NO: 118 at one or more positions selected from Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411, and K439, numbered according to the EU numbering system. In certain embodiments, at least one polypeptide chain of the antibody Fc domain comprises any one of the following amino acids: Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, L351K, L351D, L351Y, S354C, E356K, E357Q, E357L, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T366L, T366M, T366K, T366R ... 66W, T366S, L368E, L368A, L368D, K370S, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, T394F, D399R, D399K, D399V, S400K, S400R, D401K, F405A, F405T, Y407A, Y407I, Y407V, K409F, K409W, K409D, T411D, T411E, K439D, and K439E, relative to SEQ ID NO: 118.In certain embodiments, one polypeptide chain of the antibody heavy chain constant region comprises one or more mutations relative to SEQ ID NO: 118 at one or more positions selected from Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, K392, T394, D399, S400, D401, F405, Y407, K409, T411, and K439; The other polypeptide chain of the heavy chain constant region comprises one or more mutations compared to SEQ ID NO: 136 at one or more positions selected from Q347, Y349, L351, S354, E356, E357, S364, T366, L368, K370, N390, K392, T394, D399, D401, F405, Y407, K409, T411, and K439, numbered according to the EU numbering system. In a specific embodiment, one polypeptide chain of the antibody heavy chain constant region comprises K360E and K409W substitutions relative to SEQ ID NO: 118; and the other polypeptide chain of the antibody heavy chain constant region comprises Q347R, D399V, and F405T substitutions compared to SEQ ID NO: 136, numbered according to the EU numbering system. In certain embodiments, one polypeptide chain of the antibody heavy chain constant region comprises a Y349C substitution relative to SEQ ID NO: 118; and the other polypeptide chain of the antibody heavy chain constant region comprises a S354C substitution compared to SEQ ID NO: 136 numbered according to the EU numbering system.
[0043] In another aspect, the present application provides a protein comprising: (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 259; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 260; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 261.
[0044] In another aspect, the present application provides a protein comprising: (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 276; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 260; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 261.
[0045] In another aspect, the present application provides a pharmaceutical composition comprising a protein disclosed herein and a pharmaceutically acceptable carrier.
[0046] In another aspect, the present application provides a pharmaceutical formulation comprising a protein disclosed herein and a buffer having a pH of 7.0 or greater. In some embodiments, the pH of the formulation is between 7.0 and 8.0. In some embodiments, the buffer comprises citrate. In certain embodiments, the citrate has a concentration of 10 to 20 mM. In some embodiments, the buffer further comprises phosphate. In some embodiments, the buffer further comprises a sugar or sugar alcohol. In certain embodiments, the sugar or sugar alcohol is a disaccharide. In certain embodiments, the disaccharide is sucrose. In some embodiments, the sugar or sugar alcohol has a concentration of 200 to 300 mM in the pharmaceutical formulation. In certain embodiments, the sugar or sugar alcohol has a concentration of about 250 mM in the pharmaceutical formulation. In some embodiments, the buffer further comprises a non-ionic surfactant. In certain embodiments, the non-ionic surfactant comprises a polysorbate. In certain embodiments, the polysorbate is polysorbate 80. In some embodiments, the concentration of polysorbate 80 in the pharmaceutical formulation is 0.005% to 0.05%. In certain embodiments, the concentration of polysorbate 80 in the pharmaceutical formulation is about 0.01%. In some embodiments, the concentration of NaCl, if present, is about 1 mM or less in the pharmaceutical formulation. In some embodiments, the concentration of the protein is 10 to 200 mg / mL. In certain embodiments, the concentration of the protein is about 20 mg / mL.
[0047] In some embodiments, the pharmaceutical formulation comprises about 20 mM citrate, about 250 mM sucrose, and about 0.01% polysorbate 80 at pH 7.0. In a particular embodiment, the pharmaceutical formulation comprises about 20 mg / mL protein, about 20 mM potassium phosphate, about 10 mM sodium citrate, and about 125 mM sodium chloride at pH 7.8.
[0048] In another aspect, the present application provides a cell comprising one or more nucleic acids encoding the proteins disclosed herein.
[0049] In another aspect, the present application provides a method of enhancing tumor cell death, the method comprising exposing tumor cells and natural killer cells to an effective amount of a protein, pharmaceutical composition, or pharmaceutical formulation disclosed herein.
[0050] In another aspect, the present application provides a method of treating cancer, the method comprising administering an effective amount of a protein, pharmaceutical composition, or pharmaceutical formulation thereof disclosed herein to a subject in need thereof. In some embodiments, the cancer is a hematological malignancy. In certain embodiments, the hematological malignancy is selected from the group consisting of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), myeloproliferative neoplasm (MPN), lymphoma, non-Hodgkin's lymphoma, and classical Hodgkin's lymphoma.
[0051] In some embodiments, the AML is selected from undifferentiated acute myeloblastic leukemia, minimally differentiated acute myeloblastic leukemia, differentiated acute myeloblastic leukemia, acute promyelocytic leukemia (APL), acute myelomonocytic leukemia, acute myelomonocytic leukemia with eosinophilia, acute monocytic leukemia, acute erythroleukemia, acute megakaryoblastic leukemia (AMKL), acute basophilic leukemia, acute panmyelosis with fibrosis, and blastic plasmacytoid dendritic cell neoplasm (BPDCN). In embodiments, AML is characterized by expression of CLL-1 on AML leukemia stem cells (LSCs). In certain embodiments, the LSCs further express a cell membrane marker selected from CD34, CD38, CD123, TIM3, CD25, CD32, and CD96.
[0052] In some embodiments, the AML is minimal residual disease (MRD). In certain embodiments, the MRD is characterized by the presence or absence of a mutation selected from FLT3-ITD ((Fms-like tyrosine kinase 3)-internal tandem duplication (ITD)), NPM1 (nucleophosmin 1), DNMT3A (DNA methyltransferase gene DNMT3A), and IDH (isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2)).
[0053] In certain embodiments, the MDS is selected from MDS with multilineage dysplasia (MDS-MLD), MDS with single lineage dysplasia (MDS-SLD), MDS with ringed sideroblasts (MDS-RS), MDS with excess blasts (MDS-EB), MDS with isolated del(5q), and MDS, unclassified (MDS-U). In certain embodiments, the MDS is primary MDS or secondary MDS.
[0054] In some embodiments, the ALL is selected from B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the MPN is selected from polycythemia vera, essential thrombocythemia (ET), and myelofibrosis. In some embodiments, the non-Hodgkin's lymphoma is selected from B-cell lymphoma and T-cell lymphoma. In some embodiments, the lymphoma is selected from chronic lymphocytic leukemia (CLL), lymphoblastic lymphoma (LPL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), primary mediastinal large B-cell lymphoma (PMBL), follicular lymphoma, mantle cell lymphoma, hairy cell leukemia, plasma cell myeloma (PCM) or multiple myeloma (MM), mature T / NK-cell neoplasms, and histiocytic neoplasms. In certain embodiments, the cancer expresses CLEC12A. [Brief explanation of the drawings]
[0055] [Figure 1] 1 is a diagram of a heterodimeric, multispecific antibody, e.g., a trispecific binding protein (TriNKET). Each arm can represent either an NKG2D-binding domain or a binding domain corresponding to a tumor-associated antigen. In some embodiments, the NKG2D-binding domain and the tumor-associated antigen-binding domain can share a common light chain.
[0056] [Figure 2A]Five exemplary formats of multispecific binding proteins, e.g., trispecific binding proteins (TriNKETs), are illustrated. As shown in A, either the NKG2D-binding domain or the tumor-associated antigen-binding domain may be in scFv format (left arm). An antibody comprising an scFv targeting NKG2D, a Fab fragment targeting a tumor-associated antigen, and a heterodimerized antibody constant region is referred to herein as F3-TriNKET. An antibody comprising an scFv targeting a tumor-associated antigen, a Fab fragment targeting NKG2D, and a heterodimerized antibody constant region / domain (which binds to CD16) is referred to herein as F3'-TriNKET (E). As shown in B, both the NKG2D-binding domain and the tumor-associated antigen-binding domain may be in scFv format. C-D are illustrations of antibodies with three antigen-binding sites, including two antigen-binding sites that bind tumor-associated antigens and an NKG2D-binding site fused to a heterodimerized antibody constant region. These antibody formats are referred to herein as F4-TriNKET. C illustrates two tumor-associated antigen-binding sites in Fab fragment format and an NKG2D-binding site in scFv format. D illustrates a tumor-associated antigen-binding site in scFv format and an NKG2D-binding site in scFv format. E represents a trispecific antibody (TriNKET) comprising a tumor-targeting scFv, an NKG2D-targeting Fab fragment, and a heterodimerizing antibody constant region / domain ("CD domain") that binds to CD16. This antibody format is referred to herein as F3'-TriNKET. In certain exemplary multispecific binding proteins, heterodimerization mutations on the antibody constant regions include K360E and K409W on one constant domain; and Q347R, D399V, and F405T (shown as a triangular lock-and-key shape in the CD domain) on the opposite constant domain. The bold bar between the heavy and light chain variable domains of the Fab fragment represents a disulfide bond. [Figure 2B]Five exemplary formats of multispecific binding proteins, e.g., trispecific binding proteins (TriNKETs), are illustrated. As shown in A, either the NKG2D-binding domain or the tumor-associated antigen-binding domain may be in scFv format (left arm). An antibody comprising an scFv targeting NKG2D, a Fab fragment targeting a tumor-associated antigen, and a heterodimerized antibody constant region is referred to herein as F3-TriNKET. An antibody comprising an scFv targeting a tumor-associated antigen, a Fab fragment targeting NKG2D, and a heterodimerized antibody constant region / domain (which binds to CD16) is referred to herein as F3'-TriNKET (E). As shown in B, both the NKG2D-binding domain and the tumor-associated antigen-binding domain may be in scFv format. C-D are illustrations of antibodies with three antigen-binding sites, including two antigen-binding sites that bind tumor-associated antigens and an NKG2D-binding site fused to a heterodimerized antibody constant region. These antibody formats are referred to herein as F4-TriNKET. C illustrates two tumor-associated antigen-binding sites in Fab fragment format and an NKG2D-binding site in scFv format. D illustrates a tumor-associated antigen-binding site in scFv format and an NKG2D-binding site in scFv format. E represents a trispecific antibody (TriNKET) comprising a tumor-targeting scFv, an NKG2D-targeting Fab fragment, and a heterodimerizing antibody constant region / domain ("CD domain") that binds to CD16. This antibody format is referred to herein as F3'-TriNKET. In certain exemplary multispecific binding proteins, heterodimerization mutations on the antibody constant regions include K360E and K409W on one constant domain; and Q347R, D399V, and F405T (shown as a triangular lock-and-key shape in the CD domain) on the opposite constant domain. The bold bar between the heavy and light chain variable domains of the Fab fragment represents a disulfide bond. [Figure 2C]Five exemplary formats of multispecific binding proteins, e.g., trispecific binding proteins (TriNKETs), are illustrated. As shown in A, either the NKG2D-binding domain or the tumor-associated antigen-binding domain may be in scFv format (left arm). An antibody comprising an scFv targeting NKG2D, a Fab fragment targeting a tumor-associated antigen, and a heterodimerized antibody constant region is referred to herein as F3-TriNKET. An antibody comprising an scFv targeting a tumor-associated antigen, a Fab fragment targeting NKG2D, and a heterodimerized antibody constant region / domain (which binds to CD16) is referred to herein as F3'-TriNKET (E). As shown in B, both the NKG2D-binding domain and the tumor-associated antigen-binding domain may be in scFv format. C-D are illustrations of antibodies with three antigen-binding sites, including two antigen-binding sites that bind tumor-associated antigens and an NKG2D-binding site fused to a heterodimerized antibody constant region. These antibody formats are referred to herein as F4-TriNKET. C illustrates two tumor-associated antigen-binding sites in Fab fragment format and an NKG2D-binding site in scFv format. D illustrates a tumor-associated antigen-binding site in scFv format and an NKG2D-binding site in scFv format. E represents a trispecific antibody (TriNKET) comprising a tumor-targeting scFv, an NKG2D-targeting Fab fragment, and a heterodimerizing antibody constant region / domain ("CD domain") that binds to CD16. This antibody format is referred to herein as F3'-TriNKET. In certain exemplary multispecific binding proteins, heterodimerization mutations on the antibody constant regions include K360E and K409W on one constant domain; and Q347R, D399V, and F405T (shown as a triangular lock-and-key shape in the CD domain) on the opposite constant domain. The bold bar between the heavy and light chain variable domains of the Fab fragment represents a disulfide bond. [Figure 2D]Five exemplary formats of multispecific binding proteins, e.g., trispecific binding proteins (TriNKETs), are illustrated. As shown in A, either the NKG2D-binding domain or the tumor-associated antigen-binding domain may be in scFv format (left arm). An antibody comprising an scFv targeting NKG2D, a Fab fragment targeting a tumor-associated antigen, and a heterodimerized antibody constant region is referred to herein as F3-TriNKET. An antibody comprising an scFv targeting a tumor-associated antigen, a Fab fragment targeting NKG2D, and a heterodimerized antibody constant region / domain (which binds to CD16) is referred to herein as F3'-TriNKET (E). As shown in B, both the NKG2D-binding domain and the tumor-associated antigen-binding domain may be in scFv format. C-D are illustrations of antibodies with three antigen-binding sites, including two antigen-binding sites that bind tumor-associated antigens and an NKG2D-binding site fused to a heterodimerized antibody constant region. These antibody formats are referred to herein as F4-TriNKET. C illustrates two tumor-associated antigen-binding sites in Fab fragment format and an NKG2D-binding site in scFv format. D illustrates a tumor-associated antigen-binding site in scFv format and an NKG2D-binding site in scFv format. E represents a trispecific antibody (TriNKET) comprising a tumor-targeting scFv, an NKG2D-targeting Fab fragment, and a heterodimerizing antibody constant region / domain ("CD domain") that binds to CD16. This antibody format is referred to herein as F3'-TriNKET. In certain exemplary multispecific binding proteins, heterodimerization mutations on the antibody constant regions include K360E and K409W on one constant domain; and Q347R, D399V, and F405T (shown as a triangular lock-and-key shape in the CD domain) on the opposite constant domain. The bold bar between the heavy and light chain variable domains of the Fab fragment represents a disulfide bond. [Figure 2E]Five exemplary formats of multispecific binding proteins, e.g., trispecific binding proteins (TriNKETs), are illustrated. As shown in A, either the NKG2D-binding domain or the tumor-associated antigen-binding domain may be in scFv format (left arm). An antibody comprising an scFv targeting NKG2D, a Fab fragment targeting a tumor-associated antigen, and a heterodimerized antibody constant region is referred to herein as F3-TriNKET. An antibody comprising an scFv targeting a tumor-associated antigen, a Fab fragment targeting NKG2D, and a heterodimerized antibody constant region / domain (which binds to CD16) is referred to herein as F3'-TriNKET (E). As shown in B, both the NKG2D-binding domain and the tumor-associated antigen-binding domain may be in scFv format. C-D are illustrations of antibodies with three antigen-binding sites, including two antigen-binding sites that bind tumor-associated antigens and an NKG2D-binding site fused to a heterodimerized antibody constant region. These antibody formats are referred to herein as F4-TriNKET. C illustrates two tumor-associated antigen-binding sites in Fab fragment format and an NKG2D-binding site in scFv format. D illustrates a tumor-associated antigen-binding site in scFv format and an NKG2D-binding site in scFv format. E represents a trispecific antibody (TriNKET) comprising a tumor-targeting scFv, an NKG2D-targeting Fab fragment, and a heterodimerizing antibody constant region / domain ("CD domain") that binds to CD16. This antibody format is referred to herein as F3'-TriNKET. In certain exemplary multispecific binding proteins, heterodimerization mutations on the antibody constant regions include K360E and K409W on one constant domain; and Q347R, D399V, and F405T (shown as a triangular lock-and-key shape in the CD domain) on the opposite constant domain. The bold bar between the heavy and light chain variable domains of the Fab fragment represents a disulfide bond.
[0057] [Figure 3]This represents a triomab form of TriNKET, a trifunctional bispecific antibody that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light chain and one heavy chain, derived from two parent antibodies. The triomab form can be a heterodimeric construct containing one half rat antibody and one half mouse antibody.
[0058] [Figure 4] This represents a KiH Common Light Chain form of TriNKET, which includes knobs-into-holes (KIH) technology. KiH is a heterodimer containing two Fab fragments that bind to targets 1 and 2, and an Fc stabilized by a heterodimerization mutation. TriNKET in KiH format can be a heterodimeric construct with two Fab fragments that bind to targets 1 and 2, containing two different heavy chains and a common light chain that pairs with both heavy chains.
[0059] [Figure 5] A dual variable domain immunoglobulin (DVD-Ig™) form of TriNKET is represented, which joins the target binding domains of two monoclonal antibodies via a flexible natural linker to generate a tetravalent IgG-like molecule. DVD-Ig™ is a homodimeric construct in which the variable domain targeting antigen 2 is fused to the N-terminus of the variable domain of a Fab fragment targeting antigen 1. The DVD-Ig™ form contains a normal Fc.
[0060] [Figure 6] This is a representation of TriNKET in the orthogonal Fab fragment interface (Ortho-Fab) form, which is a heterodimeric construct containing two Fab fragments that bind to target 1 and target 2 fused to an Fc. Light chain (LC)-heavy chain (HC) pairing is ensured by the orthogonal interface. Heterodimerization is ensured by mutations in the Fc.
[0061] [Figure 7] This is a presentation of TriNKET in a 2-in-1 Ig format.
[0062] [Figure 8] Representation of the ES form of TriNKET, which is a heterodimeric construct containing two different Fab fragments that bind to target 1 and target 2 fused to an Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc.
[0063] [Figure 9] 1 is a diagram of a Fab arm-swapped form of TriNKET: an antibody in which the Fab fragment arms have been exchanged by swapping the heavy chain and associated light chain (half molecule) with a heavy-light chain pair from another molecule, resulting in bispecificity. The Fab arm-swapped form (cFae) is a heterodimer containing two Fab fragments that bind to targets 1 and 2, and an Fc stabilized by a heterodimerization mutation.
[0064] [Figure 10] 1. Presentation of TriNKET in the form of a SEED Body, a heterodimer containing two Fab fragments that bind to targets 1 and 2, and an Fc stabilized by a heterodimerization mutation.
[0065] [Figure 11] This figure shows the LuZ-Y form of TriNKET, which uses a leucine zipper to induce heterodimerization of two different HCs. The LuZ-Y form is a heterodimer containing two different scFabs that bind to targets 1 and 2 fused to Fc. Heterodimerization is ensured by the leucine zipper motif fused to the C-terminus of the Fc.
[0066] [Figure 12] This is a presentation of TriNKET in the form of Cov-X-Body.
[0067] [Figure 13]A-B are representations of the κλ-Body form of TriNKET, which is a heterodimeric construct with two different Fab fragments fused to an Fc stabilized by heterodimerization mutations: one Fab fragment targeting antigen 1 contains a kappa LC, and the second Fab fragment targeting antigen 2 contains a lambda LC. A is an exemplary representation of one form of κλ-Body. B is an exemplary representation of another κλ-Body.
[0068] [Figure 14] An Oasc-Fab heterodimer construct containing a Fab fragment that binds to target 1 and an scFab that binds to target 2, both fused to an Fc domain. Heterodimerization is ensured by mutations in the Fc domain.
[0069] [Figure 15] DuetMab is a heterodimeric construct containing two different Fab fragments that bind to antigens 1 and 2, and an Fc stabilized by heterodimerization mutations. Fab fragments 1 and 2 contain differential S-S bridges that ensure correct pairing of the light and heavy chains.
[0070] [Figure 16] CrossmAb, which is a heterodimeric construct with two different Fab fragments that bind to targets 1 and 2, and an Fc stabilized by a heterodimerization mutation. The CL and CH1 domains, as well as the VH and VL domains, are switched, e.g., CH1 is fused in-line with the VL and CL is fused in-line with the VH.
[0071] [Figure 17] Fit-Ig, which is a homodimeric construct in which the Fab fragment that binds antigen 2 is fused to the N-terminus of the HC of the Fab fragment that binds antigen 1. This construct contains wild-type Fc.
[0072] [Figure 18-1] 1 is a series of traces showing Bio-Layer Interferometry (BLI) profiles of antibodies collected from mouse hybridoma supernatants that bind to hCLEC12A. [Figure 18-2] 1 is a series of traces showing Bio-Layer Interferometry (BLI) profiles of antibodies collected from mouse hybridoma supernatants that bind to hCLEC12A.
[0073] [Figure 19] 19A and 19B are a series of sensorgrams showing SPR profiles of antibodies collected from mouse mAb subclones that bind to hCLEC12A (FIG. 19A) and cCLEC12A (FIG. 19B).
[0074] [Figure 20] 1 is a line graph showing binding of purified CLEC12A subclones to the PL21 AML cell line.
[0075] [Figure 21] 1 is a series of sensorgrams showing the SPR profiles of antibodies 16B8.C8 and 9F11.B7 binding to glycosylated, deglycosylated, and desialylated hCLEC12A.
[0076] [Figure 22-1] 1 is a series of sensorgrams showing the SPR profile of TriNKET derived from antibody 16B8.C8. [Figure 22-2] 1 is a series of sensorgrams showing the SPR profile of TriNKET derived from antibody 16B8.C8. [Figure 22-3] 1 is a series of sensorgrams showing the SPR profile of TriNKET derived from antibody 16B8.C8. [Figure 22-4] 1 is a series of sensorgrams showing the SPR profile of TriNKET derived from antibody 16B8.C8.
[0077] [Figure 23] 1 is a line graph showing binding of hCLEC12A-targeting TriNKET F3'-1304, F3'-1295, and control CLEC12A-TriNKET to the hCLEC12A-expressing cell line RMA-hCLEC12A.
[0078] [Figure 24] 1 is a line graph showing NK cell-mediated lysis of the CLEC12A-expressing cancer cell line HL60 in the presence of F3'-1295 and the control CLEC12A-TriNKET.
[0079] [Figure 25] 1 is a line graph showing differential scanning calorimetry (DSC) analysis of TriNKET F3'-1295 and F3'-1602.
[0080] [Figure 26-1] 1 is a series of sensorgrams showing the SPR profiles of TriNKET F3'-1295 and F3'-1602. [Figure 26-2] 1 is a series of sensorgrams showing the SPR profiles of TriNKET F3'-1295 and F3'-1602.
[0081] [Figure 27] 1 is a line graph showing the binding of hCLEC12A-targeting TriNKET F3'-1295, F3'-1602, and control CLEC12A-TriNKET to the hCLEC12A-expressing cell line Ba / F3 (A), wild-type Ba / F3 (B), cancer line HL60 (C), and cancer line PL21 (D).
[0082] [Figure 28] 28A and 28B are line graphs showing NK cell-mediated lysis of CLEC12A-expressing cancer cell lines PL21 (FIG. 28A) and HL60 (FIG. 28B) in the presence of F3′-1295, F3′-1602, and control CLEC12A-TriNKET.
[0083] [Figure 29] 29A and 29B are line graphs showing the isoelectric points (pI) of F3'-1295 (FIG. 29A) and F3'-1602 (FIG. 29B) as determined by capillary isoelectric focusing (cIEF).
[0084] [Figure 30] Flow cytometry-based multispecific reagent (PSR) analysis of F3'-1602 TriNKET and F3'-1295 TriNKET is shown.
[0085] [Figure 31] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and F3-TriNKET AB0010.
[0086] [Figure 32] 1 is a line graph showing binding of hF3'-1602 TriNKET and F3-TriNKET AB0010 to hCLEC12A-expressing Ba / F3 (A), the cancer line HL60 (B), and wild-type Ba / F3 (C).
[0087] [Figure 33] 1 is a line graph showing NK cell-mediated lysis of the CLEC12A-expressing cancer cell line PL21 using KHYG-CD16V cells (A) and primary NK cells (B) in the presence of hF3'-1602 TriNKET and F3-TriNKET AB0010.
[0088] [Figure 34] 1 is a line graph showing binding of 9F11.B7 and hF3′-1602 TriNKET and TriNKET derived from F3-TriNKET AB0010 to hCLEC12A-expressing Ba / F3 (A) and cancer line HL60 (B).
[0089] [Figure 35]1 is a line graph showing NK cell-mediated lysis of the CLEC12A-expressing cancer cell line HL60 in the presence of TriNKET derived from 9F11.B7.
[0090] [Figure 36] 1 is a line graph showing NK cell-mediated lysis of the CLEC12A-expressing cancer cell line HL60 using KHYG-CD16V cells (A) and primary NK cells (B) in the presence of hF3′-1602 TriNKET and AB0192.
[0091] [Figure 37] 1 is a line graph showing NK cell-mediated lysis of CLEC12A-expressing cancer cell lines PL21 (A) and THP-1 (B) in the presence of hF3'-1602 TriNKET and parental mAb.
[0092] [Figure 38] 1 is a line graph showing the binding of hF3'-1602 TriNKET to cancer cell lines HL60 (A) and PL21 (B).
[0093] [Figure 39A] 1 is a line graph showing binding of CLEC12A-targeting TriNKET, parental mAb, and AB0237 NKG2D dead arm variant TriNKET to hCLEC12A-expressing Ba / F3 (A), and cancer cell lines HL60 (B) and PL21 (C). [Figure 39B] 1 is a line graph showing binding of CLEC12A-targeting TriNKET, parental mAb, and AB0237 NKG2D dead arm variant TriNKET to hCLEC12A-expressing Ba / F3 (A), and cancer cell lines HL60 (B) and PL21 (C). [Figure 39C] 1 is a line graph showing binding of CLEC12A-targeting TriNKET, parental mAb, and AB0237 NKG2D dead arm variant TriNKET to hCLEC12A-expressing Ba / F3 (A), and cancer cell lines HL60 (B) and PL21 (C).
[0094] [Figure 40] 40A-40B are bar graphs showing surface retention of CLEC12A-targeting TriNKET and parental mAbs on cell lines PL21 (FIG. 40A) and HL60 (FIG. 40B).
[0095] [Figure 41] 41A and 41B are line graphs showing NK cell-mediated lysis of CLEC12A-expressing cancer cell lines PL21 (FIG. 41A) and HL60 (FIG. 41B) in the presence of hF3′-1602 TriNKET, AB0192, and parental mAb.
[0096] [Figure 42] 42A and 42B are line graphs showing NK cell-mediated lysis of CLEC12A-expressing cancer cell lines PL21 (FIG. 42A) and HL60 (FIG. 42B) in the presence of hF3′-1602 TriNKET.
[0097] [Figure 43] 1 is a line graph showing CD8-T cell-mediated lysis of the CLEC12A-expressing cancer cell line PL21 in the presence of hF3'-1602 TriNKET, parental mAb, or its NKG2D-dead variant.
[0098] [Figure 44] 1 is a series of histograms showing binding of hF3'-1602 TriNKET (gray), parental mAb (white), and control IgG (black) to blood cells.
[0099] [Figure 45-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to recombinant human CD64. [Figure 45-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to recombinant human CD64.
[0100] [Figure 46-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to CD32aH131. [Figure 46-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to CD32aH131.
[0101] [Figure 47-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to the human CD32A R131 allele (FCγRIIa R131). [Figure 47-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to the human CD32A R131 allele (FCγRIIa R131).
[0102] [Figure 48] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to the human CD16a high affinity allele V158 (FCγRIIIa V158).
[0103] [Figure 49-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to the human CD16a low affinity allele F158 (FCγRIIIa F158). [Figure 49-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to the human CD16a low affinity allele F158 (FCγRIIIa F158).
[0104] [Figure 50-1]1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb). [Figure 50-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb). [Figure 50-3] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb). [Figure 50-4] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb). [Figure 50-5] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb). [Figure 50-6] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb). [Figure 50-7] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb). [Figure 50-8] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD32b (FCγRIIb).
[0105] [Figure 51-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb). [Figure 51-2]1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb). [Figure 51-3] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb). [Figure 51-4] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb). [Figure 51-5] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb). [Figure 51-6] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb). [Figure 51-7] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb). [Figure 51-8] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human CD16b (FCγRIIIb).
[0106] [Figure 52-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) CD16. [Figure 52-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) CD16. [Figure 52-3]1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) CD16. [Figure 52-4] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) CD16.
[0107] [Figure 53-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human FcRn measured at pH 6.0. [Figure 53-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human FcRn measured at pH 6.0. [Figure 53-3] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human FcRn measured at pH 6.0. [Figure 53-4] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to human FcRn measured at pH 6.0.
[0108] [Figure 54-1] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) FcRn measured at pH 6.0. [Figure 54-2] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) FcRn measured at pH 6.0. [Figure 54-3]1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) FcRn measured at pH 6.0. [Figure 54-4] 1 is a series of sensorgrams showing the SPR profiles of hF3'-1602 TriNKET and trastuzumab control binding to cynomolgus monkey (cyno) FcRn measured at pH 6.0.
[0109] [Figure 55-1] 1 is a series of sensorgrams showing the SPR profile of hF3'-1602 TriNKET binding to human CLEC12A. [Figure 55-2] 1 is a series of sensorgrams showing the SPR profile of hF3'-1602 TriNKET binding to human CLEC12A.
[0110] [Figure 56-1] 1 is a series of sensorgrams showing the SPR profile of hF3'-1602 TriNKET binding to human NKG2D. [Figure 56-2] 1 is a series of sensorgrams showing the SPR profile of hF3'-1602 TriNKET binding to human NKG2D.
[0111] [Figure 57-1] 1 is a series of sensorgrams showing the SPR profile of hF3'-1602 TriNKET binding to recombinant cynomolgus monkey (cyno) NKG2D (cNKG2D) extracellular domain (ECD). [Figure 57-2] 1 is a series of sensorgrams showing the SPR profile of hF3'-1602 TriNKET binding to recombinant cynomolgus monkey (cyno) NKG2D (cNKG2D) extracellular domain (ECD).
[0112] [Figure 58]1 is a line graph showing target binding determined by SPR for occupancy of one TriNKET arm in binding of the other TriNKET arm.
[0113] [Figure 59-1] 1 is a line graph showing target binding determined by SPR for the synergistic effect of NKG2D TriNKET arms and CD16a. [Figure 59-2] 1 is a line graph showing target binding determined by SPR for the synergistic effect of NKG2D TriNKET arms and CD16a.
[0114] [Figure 60-1] 6A-6D are line graphs showing binding of hCLEC12A-TriNKET F3'-1295, F3'-1602, and control CLEC12A-TriNKET to the hCLEC12A-expressing cell line Ba / F3 (FIG. 60A), wild-type Ba / F3 (FIG. 60B), cancer line HL60 (FIG. 60C), and cancer line PL21 (FIG. 60D). [Figure 60-2] 6A-6D are line graphs showing binding of hCLEC12A-TriNKET F3'-1295, F3'-1602, and control CLEC12A-TriNKET to the hCLEC12A-expressing cell line Ba / F3 (FIG. 60A), wild-type Ba / F3 (FIG. 60B), cancer line HL60 (FIG. 60C), and cancer line PL21 (FIG. 60D). [Figure 60-3] 6A-6D are line graphs showing binding of hCLEC12A-TriNKET F3'-1295, F3'-1602, and control CLEC12A-TriNKET to the hCLEC12A-expressing cell line Ba / F3 (FIG. 60A), wild-type Ba / F3 (FIG. 60B), cancer line HL60 (FIG. 60C), and cancer line PL21 (FIG. 60D).
[0115] [Figure 61-1] Flow cytometry-based multispecific reagent (PSR) analysis of F3'-1602 TriNKET. [Figure 61-2]Flow cytometry-based multispecific reagent (PSR) analysis of F3'-1602 TriNKET.
[0116] [Figure 62] 1 is a bar graph showing the relative binding (Z-score) of F3'-1602 TriNKET at 1 to human CLEC12A compared to the entire human proteome microarray.
[0117] [Figure 63] A model of the hydrophobic patch of the hF3'-1602 TriNKET CLEC12A binding arm is shown.
[0118] [Figure 64-1] 1 is a bar graph based on a model of the CDR length, surface hydrophobicity, and surface charge of the hF3′-1602 TriNKET CLEC12A binding arm. [Figure 64-2] 1 is a bar graph based on a model of the CDR length, surface hydrophobicity, and surface charge of the hF3′-1602 TriNKET CLEC12A binding arm. [Figure 64-3] 1 is a bar graph based on a model of the CDR length, surface hydrophobicity, and surface charge of the hF3′-1602 TriNKET CLEC12A binding arm.
[0119] [Figure 65] A model of the hydrophobic patch of the hF3'-1602 TriNKET NKG2D binding arm is shown.
[0120] [Figure 66-1] 1 is a bar graph based on a model of the CDR length, surface hydrophobicity, and surface charge of the hF3'-1602 TriNKET NKG2D binding arm. [Figure 66-2] 1 is a bar graph based on a model of the CDR length, surface hydrophobicity, and surface charge of the hF3'-1602 TriNKET NKG2D binding arm. [Figure 66-3]1 is a bar graph based on a model of the CDR length, surface hydrophobicity, and surface charge of the hF3'-1602 TriNKET NKG2D binding arm.
[0121] [Figure 67] 1 is a line graph showing hydrophobic interaction chromatography (HIC) analysis of hF3'-1602 TriNKET.
[0122] [Figure 68] 1 is a line graph showing the pI determined by cIEF for hF3'-1602 TriNKET.
[0123] [Figure 69-1] 10 is a series of flow cytometry plots showing sequence liability-corrected variants of hF3'-1602 binding to hCLEC12A. [Figure 69-2] 10 is a series of flow cytometry plots showing sequence liability-corrected variants of hF3'-1602 binding to hCLEC12A. [Figure 69-3] 10 is a series of flow cytometry plots showing sequence liability-corrected variants of hF3'-1602 binding to hCLEC12A. [Figure 69-4] 10 is a series of flow cytometry plots showing sequence liability-corrected variants of hF3'-1602 binding to hCLEC12A. [Figure 69-5] 10 is a series of flow cytometry plots showing sequence liability-corrected variants of hF3'-1602 binding to hCLEC12A.
[0124] [Figure 70] 1 is a line graph showing NK cell-mediated lysis of the CLEC12A-expressing cancer cell line PL21 in the presence of hF3'-1602 TriNKET and liability-correcting variants.
[0125] [Figure 71]A series of colored sensorgrams showing the binding of hCLEC12A at 3-fold serial dilutions (300 nM to 0.41 nM) to F3'-1602 in HST formulation. The black overlay shows a 1:1 kinetic fit of the raw data.
[0126] [Figure 72-1] This is a series of graphs showing the binding of F3'-1602 to hNKG2D in an HST formulation. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value. [Figure 72-2] This is a series of graphs showing the binding of F3'-1602 to hNKG2D in an HST formulation. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value.
[0127] [Figure 73] 1 is a series of colored sensorgrams showing binding of F3'-1602 in HST formulation to hCD16aV158.
[0128] [Figure 74] 1 is a graph showing the percentage of lysis of PL21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of stressed and control samples of F3'-1602 in HST formulations.
[0129] [Figure 75] 1 is a series of extracted ion chromatograms of the CDRH3 peptide in control and stressed F3'-1602.
[0130] [Figure 76]
[0023] Figure 1 is a series of colored sensorgrams showing the binding of hCLEC12A to F3'-1602 in a phosphate / citrate / NaCl formulation. The black overlay shows a 1:1 kinetic fit of the raw data.
[0131] [Figure 77-1] This is a series of graphs showing the binding of F3'-1602 in a phosphate / citrate / NaCl formulation to hNKG2D. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value. [Figure 77-2] This is a series of graphs showing the binding of F3'-1602 in a phosphate / citrate / NaCl formulation to hNKG2D. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value.
[0132] [Figure 78] 1 is a series of color sensorgrams showing binding of F3'-1602 in phosphate / citrate / NaCl formulations to hCD16a V158.
[0133] [Figure 79] 1 is a graph showing the percentage of lysis of PL21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of stressed and control samples of F3'-1602 in a phosphate / citrate / NaCl formulation.
[0134] [Figure 80] A series of colored sensorgrams showing the binding of 3-fold serial dilutions (300 nM to 0.41 nM) of hCLEC12A to F3'-1602 after 4 weeks of incubation at 40°C in the CST formulation. The black overlay shows a 1:1 kinetic fit of the raw data.
[0135] [Figure 81-1] A series of colored sensorgrams showing the binding of 3-fold serial dilutions (300 nM to 0.41 nM) of hCLEC12A to F3'-1602 after 4 weeks of incubation in CST formulation at 2-8 °C and 25 °C. The black overlay shows a 1:1 kinetic fit of the raw data. [Figure 81-2] A series of colored sensorgrams showing the binding of 3-fold serial dilutions (300 nM to 0.41 nM) of hCLEC12A to F3'-1602 after 4 weeks of incubation in CST formulation at 2-8 °C and 25 °C. The black overlay shows a 1:1 kinetic fit of the raw data.
[0136] [Figure 82-1] This is a series of graphs showing the binding of F3'-1602 to hNKG2D in a CST formulation. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value. [Figure 82-2]This is a series of graphs showing the binding of F3'-1602 to hNKG2D in a CST formulation. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value.
[0137] [Figure 83] 1 is a series of colored sensorgrams showing the binding of F3'-1602 in a CST formulation to hCD16aV158.
[0138] [Figure 84] 10 is a graph showing the percentage of lysis of PL21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of stressed and control samples of F3'-1602 in a CST formulation.
[0139] [Figure 85] cIEF profile of F3'-1602 after incubation under stress at pH 5.0.
[0140] [Figure 86] Figure 10 shows the cIEF profile of F3'-1602 after incubation under stress at pH 8.0.
[0141] [Figure 87] A series of colored sensorgrams showing binding of hCLEC12A at 3-fold serial dilutions (300 nM to 0.41 nM) to F3'-1602 after stress at pH 5. The black overlay shows a 1:1 kinetic fit of the raw data.
[0142] [Figure 88]A series of colored sensorgrams showing binding of hCLEC12A at 3-fold serial dilutions (300 nM to 0.41 nM) to F3'-1602 after stress at pH 8. The black overlay shows a 1:1 kinetic fit of the raw data.
[0143] [Figure 89-1] This is a series of graphs showing the binding of F3'-1602 to hNKG2D after a pH 5 stress. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value. [Figure 89-2] This is a series of graphs showing the binding of F3'-1602 to hNKG2D after a pH 5 stress. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value.
[0144] [Figure 90-1] This is a series of graphs showing the binding of F3'-1602 to hNKG2D after a pH 8 stress. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value. [Figure 90-2]This is a series of graphs showing the binding of F3'-1602 to hNKG2D after a pH 8 stress. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value.
[0145] [Figure 91] 1 is a graph showing the percentage of lysis of PL21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of F3'-1602 after pH 5 stress.
[0146] [Figure 92] 1 is a graph showing the percentage of lysis of PL21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of F3'-1602 after pH 8 stress.
[0147] [Figure 93]
[0033] Figure 1 is a series of colored sensorgrams showing the binding of hCLEC12A to F3'-1602 after forced oxidative stress. The black overlay shows a 1:1 kinetic fit of the raw data.
[0148] [Figure 94-1] This is a series of graphs showing the binding of F3'-1602 to hNKG2D after forced oxidative stress. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value. [Figure 94-2]This is a series of graphs showing the binding of F3'-1602 to hNKG2D after forced oxidative stress. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value.
[0149] [Figure 95] 1 is a graph showing the percentage of lysis of PL21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of F3'-1602 after forced oxidative stress.
[0150] [Figure 96]
[0023] Figure 1 is a series of color sensorgrams showing the binding of hCLEC12A to F3'-1602 after a low pH hold. The black overlay shows a 1:1 kinetic fit of the raw data.
[0151] [Figure 97-1] This is a series of graphs showing the binding of F3'-1602 to HNKG2D after a low pH hold. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value. [Figure 97-2]This is a series of graphs showing the binding of F3'-1602 to HNKG2D after a low pH hold. The top panel is a colored sensorgram representing the raw data of F3'-1602 injected onto captured mFc-hNKG2D (9.77 nM to 5 μM). The black overlay shows a 1:1 kinetic fit of the raw data. The bottom panel represents steady-state response measurements plotted against the corresponding analyte concentration. The blue line represents the steady-state KD value.
[0152] [Figure 98] 1 is a series of colored sensorgrams showing binding of F3'-1602 to hCD16a V158 after a low pH hold.
[0153] [Figure 99] 1 is a graph showing the percentage of lysis of PL21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of F3'-1602 after a low pH hold.
[0154] [Figure 100] 1 is a graph showing the solubility of F3'-1602 in PEG-6000 in 10 mM sodium acetate buffer pH 5.0.
[0155] [Figure 101] 1 is a graph showing the percentage of F3'-1602 monomer content as a function of concentration.
[0156] [Figure 102] 102A and 102B are graphs showing the rate of lysis of PL-21 cells by NKG2D- and CD16a-expressing KHYG-1-CD16a cells in the presence of TriNKET F3'-1602 in F3' format (FIG. 102A) and TriNKET AB0010 in F3 format (FIG. 102B) after heat stress conditions.
[0157] [Figure 103A]Schematic of yeast display affinity maturation library construction. A: Replacement of pET1596 scFvCDRH3 with a BamHI restriction enzyme site. B: Insertion of CDRH3 mutant library oligos at the previously introduced BamHI restriction site. C: Electroporation of the BamHI-linearized plasmid and library oligos into yeast followed by homologous recombination in yeast. [Figure 103B] Schematic of yeast display affinity maturation library construction. A: Replacement of pET1596 scFvCDRH3 with a BamHI restriction enzyme site. B: Insertion of CDRH3 mutant library oligos at the previously introduced BamHI restriction site. C: Electroporation of the BamHI-linearized plasmid and library oligos into yeast followed by homologous recombination in yeast. [Figure 103C] Schematic of yeast display affinity maturation library construction. A: Replacement of pET1596 scFvCDRH3 with a BamHI restriction enzyme site. B: Insertion of CDRH3 mutant library oligos at the previously introduced BamHI restriction site. C: Electroporation of the BamHI-linearized plasmid and library oligos into yeast followed by homologous recombination in yeast.
[0158] [Figure 104-1] The discovery process from mouse immunization to AB0089 is shown. The top panel shows CLEC12A binding results by surface plasmon resonance (SPR). The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells. The binding affinity and EC50 of each variant are shown. BM, backmutation. [Figure 104-2] The discovery process from mouse immunization to AB0089 is shown. The top panel shows CLEC12A binding results by surface plasmon resonance (SPR). The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells. The binding affinity and EC50 of each variant are shown. BM, backmutation. [Figure 104-3]The discovery process from mouse immunization to AB0089 is shown. The top panel shows CLEC12A binding results by surface plasmon resonance (SPR). The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells. The binding affinity and EC50 of each variant are shown. BM, backmutation. [Figure 104-4] The discovery process from mouse immunization to AB0089 is shown. The top panel shows CLEC12A binding results by surface plasmon resonance (SPR). The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells. The binding affinity and EC50 of each variant are shown. BM, backmutation.
[0159] [Figure 105-1] FACS analysis of CDRH3 yeast library 17 is shown. First round of selection of affinity-matured yeast display library sorted with 1 nM CLEC12A-His (A). Second round of selection sorted with 1 nM CLEC12A-His (B). Third round of selection sorted with 0.1 nM CLEC12A-His (C). Binding of library 17-R3 displayed on yeast cells to 1 nM CLEC12A (D). Binding of original clone pET1596 displayed on yeast cells to 10 nM CLEC12A (E). [Figure 105-2] FACS analysis of CDRH3 yeast library 17 is shown. First round of selection of affinity-matured yeast display library sorted with 1 nM CLEC12A-His (A). Second round of selection sorted with 1 nM CLEC12A-His (B). Third round of selection sorted with 0.1 nM CLEC12A-His (C). Binding of library 17-R3 displayed on yeast cells to 1 nM CLEC12A (D). Binding of original clone pET1596 displayed on yeast cells to 10 nM CLEC12A (E). [Figure 105-3]FACS analysis of CDRH3 yeast library 17 is shown. First round of selection of affinity-matured yeast display library sorted with 1 nM CLEC12A-His (A). Second round of selection sorted with 1 nM CLEC12A-His (B). Third round of selection sorted with 0.1 nM CLEC12A-His (C). Binding of library 17-R3 displayed on yeast cells to 1 nM CLEC12A (D). Binding of original clone pET1596 displayed on yeast cells to 10 nM CLEC12A (E).
[0160] [Figure 106-1] Figure 1 shows FACS analysis of CDRH2 yeast library 30. Starting yeast display library (GDYGDSLDY (SEQ ID NO: 322) CDRH3) (A) was generated by randomizing CDRH2 constructed on the background of the best clone identified from library 17. Sorting was performed with 1 nM CLEC12A-His in both rounds. Flow cytometry analysis after round 1 (B) and round 2 (C) selection with CLEC12A-His, respectively. Binding of pET1596 displayed on yeast cells with 10 nM CLEC12A-His (D). [Figure 106-2] Figure 1 shows FACS analysis of CDRH2 yeast library 30. Starting yeast display library (GDYGDSLDY (SEQ ID NO: 322) CDRH3) (A) was generated by randomizing CDRH2 constructed on the background of the best clone identified from library 17. Sorting was performed with 1 nM CLEC12A-His in both rounds. Flow cytometry analysis after round 1 (B) and round 2 (C) selection with CLEC12A-His, respectively. Binding of pET1596 displayed on yeast cells with 10 nM CLEC12A-His (D).
[0161] [Figure 107-1] Comparison of improved affinity clones identified from library 30 (A) with pET1596 (B) and AB0237 (C). [Figure 107-2] Comparison of improved affinity clones identified from library 30 (A) with pET1596 (B) and AB0237 (C). [Figure 107-3] Comparison of improved affinity clones identified from library 30 (A) with pET1596 (B) and AB0237 (C).
[0162] [Figure 108] Schematic diagram of AB0089. Heterodimerization mutations and engineered interchain disulfide bridges ensure efficient chain pairing of IgG1Fc. The scFv is derived from humanized and sequence liability corrected CLEC12A mAb16B8.C8. The scFv is stabilized by an engineered disulfide bridge between VH and VL.
[0163] [Figure 109] X-ray crystal structure of the EW-RVTFc heterodimer. Superposition of the overall structure of the EW-RVT Fc heterodimer with the human wild-type (WT) IgG1 Fc homodimer (PDB ID: 3AVE) (Figure 109A). Zoom-in of the W-VT interaction pair region (Figure 109B). Zoom-in of the ER interaction pair region (Figure 109C).
[0164] [Figure 110] The crystal structure of the EW-RVTS-S heterodimeric Fc is shown with a close-up of the asymmetric disulfide bond formed between residues 349C (CH3A) and 354C (CH3B).
[0165] [Figure 111] Ribbon diagram models of the CLEC12A-binding scFv in three different orientations (top panels) and the corresponding surface charge distribution in the same orientation (bottom panels) are shown. Three orientations are shown: both the front (left panel: front view; center panel: back view) and antigen-engaging surface (right panel: top view).
[0166] [Figure 112]Analysis of the CDR length and surface hydrophobic patch of the CLEC12A-targeting arm of AB0089 is shown. The arrow indicates the line where the CLEC12A-targeting scFv of AB0089 is located relative to the advanced clinical-stage mAb. The inner two dotted lines indicate 2 SD (greater than 95% of the reference molecules in this region). The outermost two dotted lines indicate 3 SD (greater than 99.7% of the reference molecules in this region).
[0167] [Figure 113-1] Analysis of patches containing positive (left) and negative charges (center) and the symmetry of these charges around the CDR region (right) are shown. Surface charge and charge symmetry analysis of the CLEC12A-targeting arm of AB0089. The arrow indicates the line where the CLEC12A-targeting scFv of AB0089 lies relative to the advanced clinical-stage mAb. Each plot has two dashed lines—one narrow and one closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region). [Figure 113-2] Analysis of patches containing positive (left) and negative charges (center) and the symmetry of these charges around the CDR region (right) are shown. Surface charge and charge symmetry analysis of the CLEC12A-targeting arm of AB0089. The arrow indicates the line where the CLEC12A-targeting scFv of AB0089 lies relative to the advanced clinical-stage mAb. Each plot has two dashed lines—one narrow and one closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region).
[0168] [Figure 114] Shown is an NKG2D-binding Fab with ribbon diagrams in three different orientations, both front (left panel: front view, middle panel: back view) and antigen-binding surface (right panel: top view).
[0169] [Figure 115]1 shows an analysis of the CDR length and surface hydrophobic patch of the NKG2D-targeting arm of AB0089. The arrow indicates the line where the NKG2D-targeting arm of AB0089 is located relative to advanced clinical-stage mAbs. The two inner dotted lines indicate 2 SD (greater than 95% of the reference molecules in this region). The two outermost dotted lines indicate 3 SD (greater than 99.7% of the reference molecules in this region).
[0170] [Figure 116-1] Figure 1 shows a surface charge analysis and hydrophobicity analysis of the NKG2D-targeting arm of AB0089. The arrow indicates the position of the NKG2D-targeting arm of AB0089 relative to a database of 377 late-stage therapeutic antibodies. Each plot has two dashed lines—one narrower, the other closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region). [Figure 116-2] Figure 1 shows a surface charge analysis and hydrophobicity analysis of the NKG2D-targeting arm of AB0089. The arrow indicates the position of the NKG2D-targeting arm of AB0089 relative to a database of 377 late-stage therapeutic antibodies. Each plot has two dashed lines—one narrower, the other closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region).
[0171] [Figure 117-1] Figure 1 shows the human acceptor framework used in AB0089 compared to other clinical-stage therapeutic mAbs. Benchmarking the framework used in AB0089 against frequently used human germline sequences in a clinical-stage antibody database containing 400+ mAbs from Phase I+. [Figure 117-2]Figure 1 shows the human acceptor framework used in AB0089 compared to other clinical-stage therapeutic mAbs. Benchmarking the framework used in AB0089 against frequently used human germline sequences in a clinical-stage antibody database containing 400+ mAbs from Phase I+.
[0172] [Figure 118-1] A cartoon representation of AB0089 showing the chain composition of the molecule (A) and the location of chains H, S, and L of AB0089 on the Treg-modulating EpiMatrix protein immunogenicity scale (B) is shown. [Figure 118-2] A cartoon representation of AB0089 showing the chain composition of the molecule (A) and the location of chains H, S, and L of AB0089 on the Treg-modulating EpiMatrix protein immunogenicity scale (B) is shown.
[0173] [Figure 119] 1 shows a flow diagram of the TriNKET purification process.
[0174] [Figure 120] MabSelect Protein A capture elution chromatogram is shown.
[0175] [Figure 121] SEC analysis of Protein A eluate that was pH adjusted and filtered for IEX loading.
[0176] [Figure 122] SDS-PAGE analysis of the AB0089 Protein A load, flow-through, and eluate is shown. Based on absorbance readings, 15 μl was loaded into the "Protein A Load" and "Protein A FT" lanes, and 2 μg was loaded into the "Protein A Elution Lane." The major band at approximately 120 kDa corresponds to AB0089.
[0177] [Figure 123] Poros XS cation exchange chromatogram is shown.
[0178] [Figure 124] Figure 1 shows SDS-PAGE analysis of the load and elution fractions of AB0089 CIEX. Based on absorbance readings, the lane contains approximately 2.0 μg of protein. The major band at approximately 120 kDa is AB0089.
[0179] [Figure 125] Shown are reducing ("R") and non-reducing ("NR") SDS-PAGE of AB0089 lot AB0089-002. The three chains of the molecule (S, H, and L) are labeled in the R lane. F3' in the NR lane refers to AB0089.
[0180] [Figure 126] SEC analysis of purified AB0089 lot AB0089-002 is shown, showing 100% monomer as determined by integrated peak area.
[0181] [Figure 127] 1 shows the intact mass analysis of AB0089 lot AB0089-002. LC-MS analysis of intact AB0089 showed an observed mass (126,130.0 Da) in good agreement with the theoretical mass of 126,129.1 Da.
[0182] [Figure 128-1] CE-SDS analysis of AB0089, R (left panel) and CE-SDS analysis of AB0089, NR (right panel) are shown. [Figure 128-2] CE-SDS analysis of AB0089, R (left panel) and CE-SDS analysis of AB0089, NR (right panel) are shown.
[0183] [Figure 129] The charge profile of AB0089 by cIEF is shown, which shows that AB0089 exhibited a major peak at a pI of 8.52±0.0.
[0184] [Figure 130] Chromatogram of hydrophobicity analysis of AB0089 by HIC is shown, which indicates that AB0089 is highly pure and homogeneous.
[0185] [Figure 131] Figure 1 shows the thermal stability of AB0089 assessed by DSC analysis in three different formulations: PBS pH 7.4 (A), HST pH 6.0 (A), and CST, pH 7.0 (A).
[0186] [Figure 132] 1 shows the predicted disulfide map of AB0089.
[0187] [Figure 133] Extracted ion chromatograms (XIC) of the engineered disulfide pair of scFv (non-reduced and reduced) and the most intense charge state of the peptide pair are shown.
[0188] [Figure 134] 1 shows the identification of the CH3-CH3 intermolecular Fc-engineering disulfide.
[0189] [Figure 135-1] 1 shows the binding of human CLEC12A to AB0089 as tested by SPR. [Figure 135-2] 1 shows the binding of human CLEC12A to AB0089 as tested by SPR.
[0190] [Figure 136] This shows that the intermolecular binding of AB0089 and tepositamab bases in CLEC12A is consistent with a two-state model.
[0191] [Figure 137] Figure 1 shows FACS assessment of AB0089 binding to CLEC12A-expressing isogenic and AML cancer cell lines (PL-21 and HL-60).
[0192] [Figure 138-1] Binding of AB0089 to genetic variant CLEC12A(Q244) (center panel) compared to CLEC12A(K244)WT (left panel) and cynomolgus monkey (cyno) CLEC12A (cCLEC12A) (right panel) is shown. [Figure 138-2] Binding of AB0089 to genetic variant CLEC12A(Q244) (center panel) compared to CLEC12A(K244)WT (left panel) and cynomolgus monkey (cyno) CLEC12A (cCLEC12A) (right panel) is shown.
[0193] [Figure 139-1] AB0089 binding to differentially glycosylated CLEC12A: hCLEC12A untreated (left panel), hCLEC12A desialylated (middle panel), and hCLEC12A fully deglycosylated (right panel) is shown. [Figure 139-2] AB0089 binding to differentially glycosylated CLEC12A: hCLEC12A untreated (left panel), hCLEC12A desialylated (middle panel), and hCLEC12A fully deglycosylated (right panel) is shown.
[0194] [Figure 140-1] Figure 1 shows the binding of AB0089 to human NKG2D tested by SPR. Top panel: Colored sensorgrams represent raw data. Black overlay shows 1:1 kinetic fit. Bottom panel: Steady-state affinity fit. Data from four independent Biacore channels are shown. Lines represent steady-state KD values. [Figure 140-2] Figure 1 shows the binding of AB0089 to human NKG2D tested by SPR. Top panel: Colored sensorgrams represent raw data. Black overlay shows 1:1 kinetic fit. Bottom panel: Steady-state affinity fit. Data from four independent Biacore channels are shown. Lines represent steady-state KD values. [Figure 140-3] Figure 1 shows the binding of AB0089 to human NKG2D tested by SPR. Top panel: Colored sensorgrams represent raw data. Black overlay shows 1:1 kinetic fit. Bottom panel: Steady-state affinity fit. Data from four independent Biacore channels are shown. Lines represent steady-state KD values.
[0195] [Figure 141-1] Binding of AB0089 and trastuzumab to recombinant human CD16a (V158) is shown. [Figure 141-2] Binding of AB0089 and trastuzumab to recombinant human CD16a (V158) is shown. [Figure 141-3] Binding of AB0089 and trastuzumab to recombinant human CD16a (V158) is shown.
[0196] [Figure 142-1] Binding of AB0089 and trastuzumab to recombinant human CD64 (FcγRI) is shown. [Figure 142-2] Binding of AB0089 and trastuzumab to recombinant human CD64 (FcγRI) is shown. [Figure 142-3] Binding of AB0089 and trastuzumab to recombinant human CD64 (FcγRI) is shown. [Figure 142-4] Binding of AB0089 and trastuzumab to recombinant human CD64 (FcγRI) is shown.
[0197] [Figure 143-1] 1 shows the binding of AB0089 and trastuzumab to cynomolgus monkey CD64 (FcγRI). [Figure 143-2] 1 shows the binding of AB0089 and trastuzumab to cynomolgus monkey CD64 (FcγRI). [Figure 143-3] 1 shows the binding of AB0089 and trastuzumab to cynomolgus monkey CD64 (FcγRI). [Figure 143-4] 1 shows the binding of AB0089 and trastuzumab to cynomolgus monkey CD64 (FcγRI).
[0198] [Figure 144-1] 1 shows the binding of AB0089 and trastuzumab to human CD32a H131 (FcγRIIa H131). [Figure 144-2] 1 shows the binding of AB0089 and trastuzumab to human CD32a H131 (FcγRIIa H131).
[0199] [Figure 145-1] 1 shows the binding of AB0089 and trastuzumab to human CD32a R131 (FcγRIIa R131). [Figure 145-2] 1 shows the binding of AB0089 and trastuzumab to human CD32a R131 (FcγRIIa R131). [Figure 145-3] 1 shows the binding of AB0089 and trastuzumab to human CD32a R131 (FcγRIIa R131). [Figure 145-4] 1 shows the binding of AB0089 and trastuzumab to human CD32a R131 (FcγRIIa R131).
[0200] [Figure 146-1] 1 shows the binding of AB0089 and trastuzumab to recombinant human CD16a F158 (FcγRIIIa F158). [Figure 146-2] 1 shows the binding of AB0089 and trastuzumab to recombinant human CD16a F158 (FcγRIIIa F158). [Figure 146-3] 1 shows the binding of AB0089 and trastuzumab to recombinant human CD16a F158 (FcγRIIIa F158). [Figure 146-4] 1 shows the binding of AB0089 and trastuzumab to recombinant human CD16a F158 (FcγRIIIa F158).
[0201] [Figure 147-1] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII). [Figure 147-2] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII). [Figure 147-3] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII). [Figure 147-4] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII).
[0202] [Figure 148-1] Binding of AB0089 and trastuzumab to recombinant human CD32b (FcγRII) is shown. [Figure 148-2] Binding of AB0089 and trastuzumab to recombinant human CD32b (FcγRII) is shown. [Figure 148-3] Binding of AB0089 and trastuzumab to recombinant human CD32b (FcγRII) is shown. [Figure 148-4] Binding of AB0089 and trastuzumab to recombinant human CD32b (FcγRII) is shown.
[0203] [Figure 149-1] Binding of AB0089 and trastuzumab to recombinant human CD16b (FcγRIIIb) is shown. [Figure 149-2] Binding of AB0089 and trastuzumab to recombinant human CD16b (FcγRIIIb) is shown. [Figure 149-3] Binding of AB0089 and trastuzumab to recombinant human CD16b (FcγRIIIb) is shown. [Figure 149-4] Binding of AB0089 and trastuzumab to recombinant human CD16b (FcγRIIIb) is shown.
[0204] [Figure 150-1] 1 shows the binding of AB0089 and trastuzumab to recombinant human FcRn. [Figure 150-2] 1 shows the binding of AB0089 and trastuzumab to recombinant human FcRn. [Figure 150-3] 1 shows the binding of AB0089 and trastuzumab to recombinant human FcRn. [Figure 150-4] 1 shows the binding of AB0089 and trastuzumab to recombinant human FcRn.
[0205] [Figure 151-1] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey FcRn. [Figure 151-2] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey FcRn. [Figure 151-3] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey FcRn. [Figure 151-4] 1 shows the binding of AB0089 and trastuzumab to recombinant cynomolgus monkey FcRn.
[0206] [Figure 152] This indicates that strong binding occurs when AB0089 simultaneously engages CD16a and NKG2D.
[0207] [Figure 153-1] AB0089 simultaneous engagement of the binding arms of CLEC12A and NKG2D is shown. [Figure 153-2] AB0089 simultaneous engagement of the binding arms of CLEC12A and NKG2D is shown.
[0208] [Fig. 154]Figure 11 summarizes the comparison of the binding epitope of AB0089 relative to AB0237, AB0192, and three CLEC12A-binding reference TriNKETs by SPR. The interaction of AB0089 with hCLEC12A was blocked by AB0237 and two control molecules, cFAE-A49 CLL1-Merus and cFAE-A49 Tepoditamab, but not by Genentech-h6E7-based molecules, indicating that the AB0089 binding epitope overlaps with Merus-CLL1 and Tepoditamab.
[0209] [Figure 155] 1 shows the efficacy of AB0089 in a KHYG-1-CD16aV-mediated cytotoxicity assay using HL60 and PL21 cells.
[0210] [Figure 156] We show that AB0089 potently enhances primary NK-mediated cytolysis of cancer cells, surpassing that of the parental mAb.
[0211] [Figure 157A] Shown is a PSR assay (Figure 157A) and a schematic of PSR binding AB0089 compared to an antibody with known PSR binding (rituximab) and an antibody with no known non-specificity (trastuzumab) (Figure 157B). [Figure 157B-1] Shown is a PSR assay (Figure 157A) and a schematic of PSR binding AB0089 compared to an antibody with known PSR binding (rituximab) and an antibody with no known non-specificity (trastuzumab) (Figure 157B). [Figure 157B-2] Shown is a PSR assay (Figure 157A) and a schematic of PSR binding AB0089 compared to an antibody with known PSR binding (rituximab) and an antibody with no known non-specificity (trastuzumab) (Figure 157B).
[0212] [Figure 158]Figure 1 shows the relative binding (Z-score) of AB0089 at 1 μg / ml to human CLEC12A compared to the entire human proteome microarray. Plot showing relative binding Z-score (y-axis) versus the top 24 identified binding partners of AB0089 (x-axis). hCLEC12a is plotted at position 1 with a Z-score of 150.61.
[0213] [Figure 159] SEC analysis of AB0089 after 4 weeks at pH 6.0 and 40° C. in HST compared to a control sample, demonstrating that AB0089 exhibited high stability.
[0214] [Figure 160-1] CE-SDS analysis of AB0089 after 4 weeks in HST at pH 6.0 at 40° C. compared to control: non-reduced (NR) (left panel) and reduced (R) (right panel). [Figure 160-2] CE-SDS analysis of AB0089 after 4 weeks in HST at pH 6.0 at 40° C. compared to control: non-reduced (NR) (left panel) and reduced (R) (right panel).
[0215] [Figure 161A] Figure 161 shows that AB0089 is stable in HST at pH 6.0 at 40°C after 4 weeks and does not affect binding to hCLEC12A (Figure 161A), hNKG2D (Figure 161B), or hCD16aV (Figure 161C). [Figure 161B] Figure 161 shows that AB0089 is stable in HST at pH 6.0 at 40°C after 4 weeks and does not affect binding to hCLEC12A (Figure 161A), hNKG2D (Figure 161B), or hCD16aV (Figure 161C). [Figure 161C] Figure 161 shows that AB0089 is stable in HST at pH 6.0 at 40°C after 4 weeks and does not affect binding to hCLEC12A (Figure 161A), hNKG2D (Figure 161B), or hCD16aV (Figure 161C).
[0216] [Figure 162] HST, pH 6.0 at 40°C after 4 weeks showing AB0089 efficacy.
[0217] [Figure 163] SEC analysis showed that AB0089 exhibited high stability after 4 weeks of incubation at CST, pH 7.0, and 40°C compared to the control sample.
[0218] [Figure 164-1] Compared to the control sample, no fragmentation of AB0089 was observed by CE-SDS after 4 weeks at 40°C at pH 7.0 in CST. NR (left panel) and R (right panel). [Figure 164-2] Compared to the control sample, no fragmentation of AB0089 was observed by CE-SDS after 4 weeks at 40°C at pH 7.0 in CST. NR (left panel) and R (right panel).
[0219] [Figure 165A] Figure 161 shows that AB0089 is stable in CST at pH 7.0 after 4 weeks at 40°C and does not affect binding to hCLEC12A (Figure 161A), hNKG2D (Figure 161B), or hCD16aV (Figure 161C). [Figure 165B] Figure 161 shows that AB0089 is stable in CST at pH 7.0 after 4 weeks at 40°C and does not affect binding to hCLEC12A (Figure 161A), hNKG2D (Figure 161B), or hCD16aV (Figure 161C). [Figure 165C] Figure 161 shows that AB0089 is stable in CST at pH 7.0 after 4 weeks at 40°C and does not affect binding to hCLEC12A (Figure 161A), hNKG2D (Figure 161B), or hCD16aV (Figure 161C).
[0220] [Figure 166]This shows that prolonged heat stress did not affect the efficacy of AB0089 after 4 weeks at 40°C at pH 7.0 in CST compared to the control.
[0221] [Figure 167] Extracted ion chromatogram of tryptic peptides containing the CDRH3 of the CLEC12a-targeting arm of AB0089, showing that, based on manual inspection of peak shapes, no evidence of aspartate isomerization of peptides containing the CLEC12A-bound CDRH3 was observed.
[0222] [Figure 168] SEC analysis, which shows no difference in monomer content between oxidized AB0089 and the control sample after forced oxidation.
[0223] [Figure 169-1] No fragmentation of AB0089 was observed by CE-SDS after forced oxidation compared to the control sample. NR (left panel) and R (right panel). [Figure 169-2] No fragmentation of AB0089 was observed by CE-SDS after forced oxidation compared to the control sample. NR (left panel) and R (right panel).
[0224] [Figure 170A] Figure 170 shows that oxidative stress did not significantly affect the active protein content or affinity for hCLEC12A (Figure 170A, top panel), hNKG2D (Figure 170B, middle panel), and hCD16Av (Figure 170C, bottom panel). [Figure 170B] Figure 170 shows that oxidative stress did not significantly affect the active protein content or affinity for hCLEC12A (Figure 170A, top panel), hNKG2D (Figure 170B, middle panel), and hCD16Av (Figure 170C, bottom panel). [Figure 170C]Figure 170 shows that oxidative stress did not significantly affect the active protein content or affinity for hCLEC12A (Figure 170A, top panel), hNKG2D (Figure 170B, middle panel), and hCD16Av (Figure 170C, bottom panel).
[0225] [Figure 171] This indicates that AB0089 is stable under forced oxidation.
[0226] [Figure 172] SEC analysis shows that AB0089 is stable under high pH stress (pH 8.0, 40°C, 2 weeks).
[0227] [Figure 173-1] CE-SDS analysis showing that AB0089 showed low levels of degradation after prolonged high pH stress (pH 8, 40°C, 2 weeks). NR (left panel) and R (right panel). [Figure 173-2] CE-SDS analysis showing that AB0089 showed low levels of degradation after prolonged high pH stress (pH 8, 40°C, 2 weeks). NR (left panel) and R (right panel).
[0228] [Fig. 174] cIEF showing that AB0089 exhibited an acidic shift after prolonged high pH exposure (pH 8, 40° C., 2 weeks).
[0229] [Figure 175A] Figure 175A shows that there was no significant difference in the amount of active protein or affinity for hCLEC12A (Figure 175A, top panel), hNKG2D (Figure 175B, middle panel), or hCD16aV (Figure 175C, bottom panel) between stressed and control samples after prolonged high pH 8.0 stress (pH 8, 40°C, 2 weeks). [Figure 175B]Figure 175A shows that there was no significant difference in the amount of active protein or affinity for hCLEC12A (Figure 175A, top panel), hNKG2D (Figure 175B, middle panel), or hCD16aV (Figure 175C, bottom panel) between stressed and control samples after prolonged high pH 8.0 stress (pH 8, 40°C, 2 weeks). [Figure 175C] Figure 175A shows that there was no significant difference in the amount of active protein or affinity for hCLEC12A (Figure 175A, top panel), hNKG2D (Figure 175B, middle panel), or hCD16aV (Figure 175C, bottom panel) between stressed and control samples after prolonged high pH 8.0 stress (pH 8, 40°C, 2 weeks).
[0230] [Figure 176] This shows that the efficacy of AB0089 was reduced by approximately half after prolonged high pH stress (pH 8, 40°C, 2 weeks).
[0231] [Figure 177] SEC analysis shows that AB0089 is highly stable under low pH stress (pH 5.0, 40°C, 2 weeks).
[0232] [Figure 178-1] CE-SDS analysis of AB0089 after prolonged low pH stress (pH 5.0, 40°C, 2 weeks), showing that low levels of AB0089 degradation were detected by non-reducing (left panel) and reducing (right panel) CE-SDS. [Figure 178-2] CE-SDS analysis of AB0089 after prolonged low pH stress (pH 5.0, 40°C, 2 weeks), showing that low levels of AB0089 degradation were detected by non-reducing (left panel) and reducing (right panel) CE-SDS.
[0233] [Figure 179] cIEF analysis showing that AB0089 exposed to low pH stress exhibits a slight acidic shift in the charge profile.
[0234] [Figure 180-1] Figure 180A shows that after prolonged low pH stress (pH 5.0, 40°C, 2 weeks), there was no significant difference in active protein content or AB0089 affinity for hCLEC12A (Figure 180A, top panel), hNKG2D (Figure 180B, middle panel), or hCD16aV (Figure 180C, bottom panel). [Figure 180-2] Figure 180A shows that after prolonged low pH stress (pH 5.0, 40°C, 2 weeks), there was no significant difference in active protein content or AB0089 affinity for hCLEC12A (Figure 180A, top panel), hNKG2D (Figure 180B, middle panel), or hCD16aV (Figure 180C, bottom panel). [Figure 180-3] Figure 180A shows that after prolonged low pH stress (pH 5.0, 40°C, 2 weeks), there was no significant difference in active protein content or AB0089 affinity for hCLEC12A (Figure 180A, top panel), hNKG2D (Figure 180B, middle panel), or hCD16aV (Figure 180C, bottom panel).
[0235] [Figure 181] This shows that the efficacy of AB0089 remains similar to that of the control sample after prolonged low pH stress (pH 5.0, 40° C., 2 weeks).
[0236] [Figure 182] Extracted ion chromatogram of tryptic peptides containing the CDRH3 of the CLEC12a-targeting arm of AB0089, which showed no evidence of aspartate isomerization in peptides containing the CLEC12A-bound CDRH3 after prolonged exposure to low pH (pH 5.0) based on manual inspection of peak shapes.
[0237] [Figure 183] SEC analysis showing that AB0089 is stable after 6 cycles of freeze / thaw.
[0238] [Figure 184-1] CE-SDS analysis of AB0089 after six freeze / thaw cycles showing no detectable loss of purity with reduced (right panel) or non-reduced CE-SDS (left panel). [Figure 184-2] CE-SDS analysis of AB0089 after six freeze / thaw cycles showing no detectable loss of purity with reduced (right panel) or non-reduced CE-SDS (left panel).
[0239] [Figure 185-1] SEC analysis shows that AB0089 is stable after agitation stress (300 rpm at room temperature in a deep-well plate for 3 days). [Figure 185-2] SEC analysis shows that AB0089 is stable after agitation stress (300 rpm at room temperature in a deep-well plate for 3 days).
[0240] [Figure 186] SEC analysis shows that AB0089 allowed concentrations of over 175 mg / ml with minimal percent loss of monomer.
[0241] [Figure 187] 1 is a graph showing that AB0089 can be modified in concentration (up to 178 mg / ml) without loss of monomer.
[0242] [Figure 188] SEC analysis of Protein A eluate before and after low pH hold, demonstrating that AB0089 is highly stable under the low pH hold / viral inactivation conditions used in biologics manufacturing.
[0243] [Figure 189] 1 shows that the charge profile of AB0089 remains unchanged after the low pH hold.
[0244] [Figure 190-1] 1 shows that the affinity of AB0089 for hCLEC12a, hNKG2D, and CD16aV was not affected by low pH maintenance. [Figure 190-2] 1 shows that the affinity of AB0089 for hCLEC12a, hNKG2D, and CD16aV was not affected by low pH maintenance. [Figure 190-3] 1 shows that the affinity of AB0089 for hCLEC12a, hNKG2D, and CD16aV was not affected by low pH maintenance.
[0245] [Figure 191] This shows that the potency of AB0089 was unchanged after the low pH hold step.
[0246] [Figure 192-1] SEC analysis showing that no change in % monomer profile was observed after the low pH hold. [Figure 192-2] SEC analysis showing that no change in % monomer profile was observed after the low pH hold.
[0247] [Figure 193] This shows that low pH hold did not significantly affect the charge profile of AB0089.
[0248] [Figure 194] These results demonstrate that AB0089 potently enhances human NK cytotoxicity of PL21 AML cells. Purified human NK cells were rested overnight and then co-cultured with labeled PL21 target cells the following day for the DELFIA assay. Dose titrations of CLEC12A TriNKET AB0089 or the parent mAb AB0305, starting at 10 nM, were prepared and added to the co-cultures. Assays were performed using a total of six healthy NK cell donors. Representative results are shown. Specific lysis was plotted against the concentration of test substance, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0249] [Figure 195] These results demonstrate that AB0192 potently enhances human NK cytotoxicity of HL60 AML cells. Purified human NK cells were rested overnight and then co-cultured with labeled HL60 target cells the following day for the DELFIA assay. Dose titrations of CLEC12A TriNKET AB0089 or the parent mAb AB0305, starting at 10 nM, were prepared and added to the co-cultures. Assays were performed using a total of four healthy NK cell donors. Representative results are shown. Specific lysis was plotted against the concentration of test substance, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0250] [Figure 196] These results demonstrate that AB0192 potently enhances human NK cytotoxicity of PL21 AML cells. Purified human NK cells were rested overnight and then co-cultured with labeled PL21 target cells the following day for the DELFIA assay. Dose titrations of CLEC12A TriNKET AB0192 or the parent mAb AB0306, starting at 10 nM, were prepared and added to the co-cultures. Assays were performed using a total of six healthy NK cell donors. Representative results are shown. Specific lysis was plotted against the concentration of test substance, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0251] [Figure 197]These results demonstrate that AB0192 potently enhances human NK cytotoxicity of HL60 AML cells. Purified human NK cells were rested overnight and then co-cultured with labeled HL60 target cells the following day for the DELFIA assay. Dose titrations of CLEC12A TriNKET AB0192 or the parent mAb AB0306, starting at 10 nM, were prepared and added to the co-cultures. Assays were performed using a total of four healthy NK cell donors. Representative results are shown. Specific lysis was plotted against the concentration of test substance, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0252] [Figure 198] This demonstrates that AB0089 activity is not affected by the presence of soluble MIC-A. Purified human NK cells were rested overnight and prepared the following day in co-culture wells with DELFIA-labeled PL21 target cells. Dose titrations of AB0089 and AB0305 were prepared, and soluble MIC-A-Fc was added to each test substance titration series at 20 ng / mL. Dose escalation was fit to a four-parameter nonlinear regression model. Data points represent the mean ± standard deviation.
[0253] [Figure 199] We demonstrate that AB0089 induces IFNγ production and degranulation by human NK cells against PL21 AML cells. Frozen PBMCs were thawed and co-cultured with PL21 target cells in the presence of dose titrations of AB0089, AB0305, or F3'-palivizumab. After incubation, cells were prepared for FACS analysis of CD107a degranulation and IFNγ intracellular accumulation. Figures shown are representative of three PBMC donors tested. The percentage of induced IFNγ+CD107+ NK cells was plotted against concentration, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0254] [Figure 200]AB0089 has been shown to induce IFNγ production and degranulation by human NK cells against HL60 AML cells. Frozen PBMCs were thawed and co-cultured with HL60 target cells in the presence of dose titrations of AB0089, AB0305, or F3'-palivizumab. After incubation, cells were prepared for FACS analysis of CD107a degranulation and IFNγ intracellular accumulation. Figures shown are representative of three PBMC donors tested. The percentage of induced IFNγ+CD107+ NK cells was plotted against concentration, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0255] [Figure 201] We demonstrate that CLEC12A TriNKET induces M0-macrophage ADCP activity against PL21 AML cells. In vitro-generated M0 macrophages were labeled with cell tracing violet and cocultured with cell tracing CFSE-labeled PL21 target cells at an E:T ratio of 8:1. After 2 hours, cells were prepared for flow cytometry analysis. Double-positive cell tracing violet / CFSE cells were considered phagocytic events. Assays were performed using macrophages from three independent donors, and the figures shown are representative results. The percentage of target cell phagocytosis was plotted against the concentration of test substance, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0256] [Figure 202]This shows that AB0089 does not stimulate CDC against PL21 AML cells. AB0089 was incubated with BATDA-labeled PL21 cells in cell culture medium containing 5% human serum for 60 minutes. A human IgG1 isotype control served as a negative control, while anti-MHC class I clone W6 / 32 was used as a positive control. Specific lysis of target cells was plotted against concentration, and the data were fitted to a four-parameter nonlinear regression model to generate potency values. Data points represent the mean ± standard deviation.
[0257] [Figure 203A] Figure 2 shows the binding of CLEC12A-TriNKET to cell lines expressing CLEC12A. Dose-response binding of CLEC12A TriNKET and their parental mAbs was analyzed in Ba / F3 cells overexpressing human CLEC12A (A). Human cancer cell lines (B) HL60 and (C) PL21 with endogenous expression of CLEC12A were used to confirm the results in transfected cell lines. The figures shown represent the results of three independent experiments summarized in Table 201. [Figure 203B] Figure 2 shows the binding of CLEC12A-TriNKET to cell lines expressing CLEC12A. Dose-response binding of CLEC12A TriNKET and their parental mAbs was analyzed in Ba / F3 cells overexpressing human CLEC12A (A). Human cancer cell lines (B) HL60 and (C) PL21 with endogenous expression of CLEC12A were used to confirm the results in transfected cell lines. The figures shown represent the results of three independent experiments summarized in Table 201. [Figure 203C] Figure 2 shows the binding of CLEC12A-TriNKET to cell lines expressing CLEC12A. Dose-response binding of CLEC12A TriNKET and their parental mAbs was analyzed in Ba / F3 cells overexpressing human CLEC12A (A). Human cancer cell lines (B) HL60 and (C) PL21 with endogenous expression of CLEC12A were used to confirm the results in transfected cell lines. The figures shown represent the results of three independent experiments summarized in Table 201.
[0258] [Figure 204] Figure 2 shows CLEC12A surface retention on AML cell lines exposed to CLEC12A TriNKET. CLEC12A surface retention on (A) HL60 and (B) PL21 cells was measured after exposure to test substances at 40 nM for 2 hours at 37°C. Test substances were used at saturating concentrations and detected using a human IgGFc-specific secondary antibody. Staining intensity after 2 hours at 37°C was normalized to the staining intensity of the same test substance on cells incubated on ice for 2 hours to derive the percentage of CLEC12A retained on the cell surface. Data bars represent the mean of duplicate wells, and error bars represent the standard deviation. The figures shown represent the results of three independent experiments, summarized in Table 202.
[0259] [Figure 205] AB0089 binding normalized to AB0237 after 2 hours at 37°C is shown. Binding of AB0089 and AB0237 was compared on HL60 cells after 2 hours of incubation on ice or at 37°C. Histograms represent: (1st from top to bottom) AB0237 2 hours at 37°C, (2nd from top to bottom) AB0237 2 hours on ice, (3rd from top to bottom) AB0089 2 hours at 37°C, (4th from top to bottom) AB0089 2 hours on ice. Binding of all test substances was detected with an anti-human IgGFc fluorophore-conjugated antibody.
[0260] [Figure 206] This shows that AB0089 binds to CLEC12A+ blasts across 10 primary AML patient samples. Primary AML bone marrow and PBMC samples were obtained from a commercial supplier (see Table 3). Samples were prepared for flow cytometry analysis according to the antibody panel in Table 1. Histograms represent staining of AML blasts as follows: #4 from top to bottom = hIgG1 isotype control, #3 from top to bottom = AB0305-CF568, #2 from top to bottom = AB0089-CF568, #1 from top to bottom = anti-CLEC12 50C1-CF568.
[0261] [Figure 207] This figure shows that AB0089 binds to CLEC12A+CD34+CD38- cells across 10 primary AML patient samples. Primary AML bone marrow and PBMC samples were obtained from a commercial supplier. See Table 200. Samples were prepared for flow cytometry analysis according to the antibody panel in Table 198. Samples were further gated on the CD34+CD38- subpopulation to enrich for leukemic stem cells. Histograms show staining for CD34+CD38- blasts as follows: 4th from top to bottom = hIgG1 isotype control, 3rd from top to bottom = AB0305-CF568, 2nd from top to bottom = AB0089-CF568, 1st from top to bottom = anti-CLEC12 50C1-CF568.
[0262] [Figure 208-1] The pathway from immunization to AB0192 is shown. The top panel shows CLEC12A binding by SPR. The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells. [Figure 208-2] The pathway from immunization to AB0192 is shown. The top panel shows CLEC12A binding by SPR. The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells. [Figure 208-3] The pathway from immunization to AB0192 is shown. The top panel shows CLEC12A binding by SPR. The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells. [Figure 208-4] The pathway from immunization to AB0192 is shown. The top panel shows CLEC12A binding by SPR. The bottom panel shows binding to CLEC12A+ PL-21 AML cancer cells.
[0263] [Figure 209]A schematic diagram of AB0192 is shown. Proprietary heterodimerization mutations and engineered interchain disulfide bridges ensure efficient chain pairing of IgG1Fc. The scFv is derived from humanized and sequence liability corrected CLEC12A mAb9F11.B7. The scFv is stabilized by an engineered disulfide bridge between VH and VL.
[0264] [Figure 210] The amino acid sequences of the three polypeptide chains that make up AB0192 are shown. Chain S: anti-CLEC12 AscFv-CH2-CH3 (humanized sequence, CDRs in bold and not underlined, back mutations in bold and underlined, engineered scFv disulfides in italics and bold, and Fc mutations for heterodimerization and engineered CH3 disulfide not in bold and underlined). Chain H: anti-NKGD VH-CH1-CH2-CH3 (fully human, CDRs in bold and not underlined, Fc mutations for heterodimerization and engineered CH3 disulfide not in bold and underlined). Chain L: anti-NKGD VL-CL (fully human, CDRs in bold and not underlined).
[0265] [Figure 211-1] Figure 1 shows the human acceptor framework used in AB0192 compared to other clinical-stage therapeutic mAbs. Benchmarking the framework used in AB0192 against frequently used human germline sequences in a clinical-stage antibody database containing 400+ mAbs from Phase I+. [Figure 211-2] Figure 1 shows the human acceptor framework used in AB0192 compared to other clinical-stage therapeutic mAbs. Benchmarking the framework used in AB0192 against frequently used human germline sequences in a clinical-stage antibody database containing 400+ mAbs from Phase I+.
[0266] [Figure 212]Ribbon diagram models of the CLEC12A-binding scFv in three different orientations (top panels) and the corresponding surface charge distribution in the same orientations (bottom panels) are shown. The charge distribution of the anti-CLEC12A scFv is polarized ("top view," bottom panels), with negatively charged residues primarily located in CDRH3 and CDRL2. Three orientations are shown: both the front (left panel: front view; center panel: back view) and antigen-engaging surface (right panel: top view).
[0267] [Figure 213] Analysis of the CDR length and surface hydrophobic patch of the CLEC12A-targeting arm of AB0192 is shown. The arrow indicates where the CLEC12A-targeting scFv of AB0192 is located relative to the advanced clinical-stage mAb. The inner dotted line indicates 2 SD (greater than 95% of the reference molecules in this region). The outermost dotted line indicates 3 SD (greater than 99.7% of the reference molecules in this region).
[0268] [Figure 214-1] Analysis of patches containing positive and negative charges, as well as the symmetry of these charges around the CDR regions, is shown. Arrows indicate where the CLEC12A-targeting scFv of AB0192 is located relative to the advanced clinical-stage mAb. Each plot has two dashed lines—one narrow and one closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region). [Figure 214-2] Analysis of patches containing positive and negative charges, as well as the symmetry of these charges around the CDR regions, is shown. Arrows indicate where the CLEC12A-targeting scFv of AB0192 is located relative to the advanced clinical-stage mAb. Each plot has two dashed lines—one narrow and one closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region).
[0269] [Figure 215] Ribbon diagram models of NKG2D-binding Fab arms in three different orientations (top panels) and their corresponding surface charge distributions in the same orientations (bottom panels) are shown. Three orientations are shown: both the front (left panel: front view; center panel: back view) and antigen-binding surface (right panel: top view).
[0270] [Figure 216] The patch of CDR length and surface hydrophobicity analysis of the NKG2D-targeting arm of AB0192 is shown. The arrow indicates where the NKG2D-targeting Fab of AB0192 is located relative to the advanced clinical-stage mAb. The inner dotted line indicates 2 SD (>95% of the reference molecules in this region). The outermost dotted line indicates 3 SD (>99.7% of the reference molecules in this region).
[0271] [Figure 217-1] Analysis of patches containing positive and negative charges, as well as the symmetry of these charges around the CDR regions, is shown. Arrows indicate the position of the NKG2D-targeting Fab of AB0192 in a database of 377 late-stage therapeutic antibodies. Each plot has two dashed lines—one narrow and one closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region). [Figure 217-2] Analysis of patches containing positive and negative charges, as well as the symmetry of these charges around the CDR regions, is shown. Arrows indicate the position of the NKG2D-targeting Fab of AB0192 in a database of 377 late-stage therapeutic antibodies. Each plot has two dashed lines—one narrow and one closer to the solid line. A dashed line closer to the solid line indicates 2 SD (>95% of the reference molecules in this region), while a dashed line even closer to the solid line indicates 3 SD (>99.7% of the reference molecules in this region).
[0272] [Figure 218-1]A and B show the location of AB0192 chains on the Treg-regulated EpiMatrix protein immunogenicity scale. A shows a cartoon representation of AB0192. B shows the location of chains H, S, and L of AB0192 on the Treg-regulated immunogenicity protein scale. [Figure 218-2] A and B show the location of AB0192 chains on the Treg-regulated EpiMatrix protein immunogenicity scale. A shows a cartoon representation of AB0192. B shows the location of chains H, S, and L of AB0192 on the Treg-regulated immunogenicity protein scale.
[0273] [Figure 219-1] Figure 1 shows a schematic of the two-step platform purification of AB0192. Left panel: SDS-PAGE analysis of AB0192 before and after the first step of the purification process (Protein A Capture). Middle panel: SEC analysis of AB0192 after the Protein A step and after the cIEX step. Right panel: Reducing and non-reducing SDS-PAGE of purified AB0192. [Figure 219-2] Figure 1 shows a schematic of the two-step platform purification of AB0192. Left panel: SDS-PAGE analysis of AB0192 before and after the first step of the purification process (Protein A Capture). Middle panel: SEC analysis of AB0192 after the Protein A step and after the cIEX step. Right panel: Reducing and non-reducing SDS-PAGE of purified AB0192. [Figure 219-3] Figure 1 shows a schematic of the two-step platform purification of AB0192. Left panel: SDS-PAGE analysis of AB0192 before and after the first step of the purification process (Protein A Capture). Middle panel: SEC analysis of AB0192 after the Protein A step and after the cIEX step. Right panel: Reducing and non-reducing SDS-PAGE of purified AB0192. [Figure 219-4]Figure 1 shows a schematic of the two-step platform purification of AB0192. Left panel: SDS-PAGE analysis of AB0192 before and after the first step of the purification process (Protein A Capture). Middle panel: SEC analysis of AB0192 after the Protein A step and after the cIEX step. Right panel: Reducing and non-reducing SDS-PAGE of purified AB0192.
[0274] [Figure 220]
[0033] Figure 1 shows the intact mass analysis of AB0192 (Lot AB0192-005) using LC-MS analysis. AB0192 theoretical mass = 126,429.5 Da. AB0192 Lot AB0192-005 observed mass = 126,429.9 Da.
[0275] [Figure 221] SEC (Superdex 200) analysis of purified AB0192 (Lot AB0192-005) is shown, which showed >99% monomer as determined by integrated peak area.
[0276] [Figure 222-1] The purity of AB0192 (lot AB0192-005) by CE-SDS under non-reducing conditions ("NR"; left panel) and reducing conditions ("R"; right panel) is shown. [Figure 222-2] The purity of AB0192 (lot AB0192-005) by CE-SDS under non-reducing conditions ("NR"; left panel) and reducing conditions ("R"; right panel) is shown.
[0277] [Figure 223] 1 shows the cIEF profile of AB0192 (lot AB0192-005).
[0278] [Figure 224] 1 shows the hydrophobicity analysis of AB0192 by HIC.
[0279] [Figure 225-1]Figures 225A-C show the DSC analysis of AB0192 in three different buffer systems: PBS pH 7.4 (A), HST, pH 6.0 (B) and CST, pH 7.0 (C). [Figure 225-2] Figures 225A-C show the DSC analysis of AB0192 in three different buffer systems: PBS pH 7.4 (A), HST, pH 6.0 (B) and CST, pH 7.0 (C). [Figure 225-3] Figures 225A-C show the DSC analysis of AB0192 in three different buffer systems: PBS pH 7.4 (A), HST, pH 6.0 (B) and CST, pH 7.0 (C).
[0280] [Figure 226] 1 shows the predicted disulfide map of AB0192.
[0281] [Figure 227] Extracted ion chromatograms (XIC) of the engineered disulfide pair of scFv (non-reduced and reduced) and the most intense charge state of the peptide pair are shown.
[0282] [Figure 228] The presence of a CH3-CH3 intermolecular Fc-engineered disulfide is shown.
[0283] [Figure 229-1] 1 shows the binding of AB0192 to human CLEC12A as tested by SPR. [Figure 229-2] 1 shows the binding of AB0192 to human CLEC12A as tested by SPR.
[0284] [Figure 230-1] 1 shows the binding of AB0192 to a genetic variant of human CLEC12A(Q244) compared to CLEC12A(K244)WT and cynomolgus monkey cyno CLEC12A tested by SPR. [Figure 230-2]1 shows the binding of AB0192 to a genetic variant of human CLEC12A(Q244) compared to CLEC12A(K244)WT and cynomolgus monkey cyno CLEC12A tested by SPR.
[0285] [Figure 231-1] 1 shows the binding of AB0192 to differentially glycosylated CLEC12A tested by SPR. [Figure 231-2] 1 shows the binding of AB0192 to differentially glycosylated CLEC12A tested by SPR.
[0286] [Figure 232] 1 shows binding of AB0192 to CLEC12A+ isogenic, as well as HL60 and PL21 AML cells.
[0287] [Figure 233-1] 1 shows the binding of AB0192 to human NKG2D as tested by SPR. [Figure 233-2] 1 shows the binding of AB0192 to human NKG2D as tested by SPR. [Figure 233-3] 1 shows the binding of AB0192 to human NKG2D as tested by SPR.
[0288] [Figure 234-1] 1 shows the binding of AB0192 to the hCD16a V158 allele. [Figure 234-2] 1 shows the binding of AB0192 to the hCD16a V158 allele. [Figure 234-3] 1 shows the binding of AB0192 to the hCD16a V158 allele.
[0289] [Figure 235]This shows that AB0192 binds simultaneously to CD16a and NKG2D, resulting in strong binding. AB0192 is injected over NKG2D (middle line shown on the right side of the graph), CD16a (lower line shown on the right side of the graph), or mixed CD16a and NKG2D (upper line shown on the right side of the graph). Note that the surfaces were not optimized for maximum affinity.
[0290] [Figure 236-1] The figures show that captured AB0192 is sequentially saturated with hCLEC12A and hNKG2D. Targets were injected sequentially over AB0192 captured on a Biacore chip. The top panel shows binding of hCLEC12A (100 nM) followed by hNKG2D (7 μM) to captured AB0192. The bottom panel shows the reverse order of target binding (human NKG2D binding followed by hCLEC12A). The relative binding stoichiometries (compared to binding of each target to unoccupied captured AB0192) are shown in Table 218. [Figure 236-2] The figures show that captured AB0192 is sequentially saturated with hCLEC12A and hNKG2D. Targets were injected sequentially over AB0192 captured on a Biacore chip. The top panel shows binding of hCLEC12A (100 nM) followed by hNKG2D (7 μM) to captured AB0192. The bottom panel shows the reverse order of target binding (human NKG2D binding followed by hCLEC12A). The relative binding stoichiometries (compared to binding of each target to unoccupied captured AB0192) are shown in Table 218.
[0291] [Figure 237-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight. [Figure 237-2]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight. [Figure 237-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight. [Figure 237-4] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight.
[0292] [Figure 238-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight. [Figure 238-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight. [Figure 238-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight. [Figure 238-4] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD64 (FcγRI). The difference in apparent maximum binding response between the molecules is due to the difference in molecular weight.
[0293] [Figure 239-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 239-2]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 239-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 239-4] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 239-5] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 239-6] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 239-7]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 239-8] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) H131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight.
[0294] [Figure 240-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 240-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 240-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 240-4]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 240-5] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 240-6] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 240-7] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 240-8] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32a (FcγRIIa) R131 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight.
[0295] [Figure 241-1]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 241-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 241-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 241-4] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 241-5] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 241-6] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 241-7] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 241-8] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16a (FcγRIIIa) F158 allele. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight.
[0296] [Figure 242-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 242-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 242-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 242-4]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey CD16 (FcγRIII). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight.
[0297] [Figure 243-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 243-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 243-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 243-4] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 243-5] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 243-6]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 243-7] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 243-8] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD32b (FcγRIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight.
[0298] [Figure 244-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16b (FcγRIIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 244-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16b (FcγRIIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 244-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16b (FcγRIIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 244-4]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human CD16b (FcγRIIIb). The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight.
[0299] [Figure 245-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 245-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 245-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 245-4] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 245-5] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 245-6]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 245-7] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight. [Figure 245-8] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant human FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to differences in molecular weight.
[0300] [Figure 246-1] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to their different molecular weights. [Figure 246-2] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to their different molecular weights. [Figure 246-3] Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to their different molecular weights. [Figure 246-4]Figure 1 shows the binding of AB0192 and trastuzumab to recombinant cynomolgus monkey FcRn. The top panel for each molecule represents the raw binding sensorgram, while the bottom panel represents the fit to a steady-state affinity model. The difference in apparent maximum binding response between the molecules is due to their different molecular weights.
[0301] [Figure 247] 1 shows epitope binning of AB0192 against other CLEC12A-binding TriNKETs.
[0302] [Figure 248] 1 shows the potency of AB0192 in a primary NK-mediated cytotoxicity assay compared to the corresponding mAb control.
[0303] [Figure 249A] A and B show the nonspecific analysis of AB0192 in the PSR assay. A: Schematic of the PSR assay; B: PSR binding of AB0089 compared to an antibody with known PSR binding (rituximab) and an antibody without known nonspecificity (trastuzumab). [Figure 249B-1] A and B show the nonspecific analysis of AB0192 in the PSR assay. A: Schematic of the PSR assay; B: PSR binding of AB0089 compared to an antibody with known PSR binding (rituximab) and an antibody without known nonspecificity (trastuzumab). [Figure 249B-2] A and B show the nonspecific analysis of AB0192 in the PSR assay. A: Schematic of the PSR assay; B: PSR binding of AB0089 compared to an antibody with known PSR binding (rituximab) and an antibody without known nonspecificity (trastuzumab).
[0304] [Figure 250]Figure 1 shows the relative Z-score of AB0089 in the HuProt™ human proteome microarray assay. Plot showing relative binding Z-score (y-axis) versus the top 24 identified binding partners of AB0089 (x-axis). hCLEC12a is plotted at position 1 with a Z-score of 150.06.
[0305] [Figure 251-1] SEC analysis of AB0192 after 4 weeks in HST at pH 6.0 and 40° C. compared to the control. [Figure 251-2] SEC analysis of AB0192 after 4 weeks in HST at pH 6.0 and 40° C. compared to the control.
[0306] [Figure 252-1] CE-SDS analysis of AB0192 after 4 weeks in HST at pH 6.0 and 40°C compared to control. The non-reduced condition is shown in the left panel. The reduced condition is shown in the right panel. [Figure 252-2] CE-SDS analysis of AB0192 after 4 weeks in HST at pH 6.0 and 40°C compared to control. The non-reduced condition is shown in the left panel. The reduced condition is shown in the right panel.
[0307] [Figure 253-1] AB0192 is stable in HST after stress at pH 6.0 and 40°C for 4 weeks; it shows no effect on CLEC12A, NKG2D, or CD16a binding. [Figure 253-2] AB0192 is stable in HST after stress at pH 6.0 and 40°C for 4 weeks; there is no effect on the binding of CLEC12A, NKG2D, or CD16a. [Figure 253-3] AB0192 is stable in HST after stress at pH 6.0 and 40°C for 4 weeks; there is no effect on the binding of CLEC12A, NKG2D, or CD16a.
[0308] [Figure 254] Figure 1 shows that there was no difference in potency between control and stressed samples of AB0192 in HST at pH 6.0 and 40°C after 4 weeks in the KHYG-1-CD16a-mediated cytotoxicity assay.
[0309] [Figure 255-1] SEC analysis shows minimal aggregation of AB0192 after 4 weeks at 40°C at pH 7.0 in CST. [Figure 255-2] SEC analysis shows minimal aggregation of AB0192 after 4 weeks at 40°C at pH 7.0 in CST.
[0310] [Figure 256-1] As measured by CE-SDS analysis, AB0192 shows minimal fragmentation after 4 weeks at 40°C in CST at pH 7.0 compared to the control. [Figure 256-2] As measured by CE-SDS analysis, AB0192 shows minimal fragmentation after 4 weeks at 40°C in CST at pH 7.0 compared to the control.
[0311] [Figure 257-1] AB0192 is stable in CST at pH 7.0 after 4 weeks of 40°C stress; there is no effect on CLEC12A, NKG2D, or CD16a binding. [Figure 257-2] AB0192 is stable in CST at pH 7.0 after 4 weeks of 40°C stress; there is no effect on CLEC12A, NKG2D, or CD16a binding. [Figure 257-3] AB0192 is stable in CST at pH 7.0 after 4 weeks of 40°C stress; there is no effect on CLEC12A, NKG2D, or CD16a binding.
[0312] [Figure 258]1 shows that there was no difference in potency between control and stressed samples of AB0192 after 4 weeks at pH 7.0 and 40° C. in the KHYG-1-CD16a cytotoxicity assay in CST.
[0313] [Figure 259-1] SEC analysis of AB0192 after forced oxidative stress compared to control shows no significant decrease in monomer content. [Figure 259-2] SEC analysis of AB0192 after forced oxidative stress compared to control shows no significant decrease in monomer content.
[0314] [Figure 260-1] CE-SDS analysis of AB0192 after forced oxidation compared to the control is shown, demonstrating that purity remains high. [Figure 260-2] CE-SDS analysis of AB0192 after forced oxidation compared to the control is shown, demonstrating that purity remains high.
[0315] [Figure 261-1] This shows that AB0192 is stable after oxidative stress (pH 5.0, 40°C, 14 days); binding of CLEC12A, NKG2D, or CD16a was not affected. The slight differences in maximum binding signals reflect differences in capture levels. [Figure 261-2] This shows that AB0192 is stable after oxidative stress (pH 5.0, 40°C, 14 days); binding of CLEC12A, NKG2D, or CD16a was not affected. The slight differences in maximum binding signals reflect differences in capture levels. [Figure 261-3] This shows that AB0192 is stable after oxidative stress (pH 5.0, 40°C, 14 days); binding of CLEC12A, NKG2D, or CD16a was not affected. The slight differences in maximum binding signals reflect differences in capture levels.
[0316] [Figure 262] 1 shows that the potency of AB0192 after forced oxidation in the KHYG-1-CD16a-mediated cytotoxicity assay was similar to that of the control sample.
[0317] [Figure 263-1] SEC analysis of AB0192 after long-term low pH exposure (pH 5.0, 40° C., 14 days) shows no loss of monomer. [Figure 263-2] SEC analysis of AB0192 after long-term low pH exposure (pH 5.0, 40° C., 14 days) shows no loss of monomer.
[0318] [Figure 264-1] Figure 1 shows CE-SDS analysis of AB0192 after prolonged low pH stress (pH 5.0, 40°C, 14 days), showing less than a 1% difference in purity detected by non-reduced and reduced CE-SDS. The non-reduced condition is shown in the left panel. The reduced condition is shown in the right panel. [Figure 264-2] Figure 1 shows CE-SDS analysis of AB0192 after prolonged low pH stress (pH 5.0, 40°C, 14 days), showing less than a 1% difference in purity detected by non-reduced and reduced CE-SDS. The non-reduced condition is shown in the left panel. The reduced condition is shown in the right panel.
[0319] [Figure 265-1] AB0192 was stable after low pH stress (pH 5.0, 40°C, 14 days); binding of CLEC12A, NKG2D, or CD16a was not affected. [Figure 265-2] AB0192 was stable after low pH stress (pH 5.0, 40°C, 14 days); binding of CLEC12A, NKG2D, or CD16a was not affected. [Figure 265-3]AB0192 was stable after low pH stress (pH 5.0, 40°C, 14 days); binding of CLEC12A, NKG2D, or CD16a was not affected.
[0320] [Figure 266] Charge analysis of AB0192 after long-term low pH stress (pH 5.0, 40°C, 14 days) by cIEF shows no difference between control and pH 5 stressed samples.
[0321] [Figure 267] Figure 1 shows that the potency of AB0192 after prolonged pH 5.0 stress was unchanged compared to the control in the KHYG-1-CD16a cytotoxicity assay.
[0322] [Figure 268-1] SEC analysis of AB0192 after prolonged high pH stress (pH 8.0, 40° C., 14 days) is shown, which indicates that there was a 1.6% loss of monomer. [Figure 268-2] SEC analysis of AB0192 after prolonged high pH stress (pH 8.0, 40° C., 14 days) is shown, which indicates that there was a 1.6% loss of monomer.
[0323] [Figure 269-1] CE-SDS analysis of AB0192 after prolonged high pH stress (pH 8.0, 40°C, 14 days) shows that slight differences in purity were detected under non-reducing (left) and reducing (right) conditions. [Figure 269-2] CE-SDS analysis of AB0192 after prolonged high pH stress (pH 8.0, 40°C, 14 days) shows that slight differences in purity were detected under non-reducing (left) and reducing (right) conditions.
[0324] [Figure 270-1] AB0192 is stable after high pH stress; it does not affect the binding of CLEC12A, NKG2D, or CD16a. [Figure 270-2] AB0192 is stable after high pH stress; it does not affect the binding of CLEC12A, NKG2D, or CD16a. [Figure 270-3] AB0192 is stable after high pH stress; it does not affect the binding of CLEC12A, NKG2D, or CD16a.
[0325] [Fig. 271] Charge analysis of AB0192 after long-term high pH stress (pH 8.0, 40°C, 14 days) by cIEF shows an acidic shift in the stressed sample at pH 8 compared to the control sample.
[0326] [Fig. 272] This indicates that the potency of AB0192 after prolonged exposure to high pH 8.0 stress, as assessed by the KHYG-1-CD16aV cytotoxicity assay, was not significantly affected.
[0327] [Figure 273-1] SEC analysis of AB0192 after 6 cycles of freeze / thaw compared to a control showing no loss of monomer. [Figure 273-2] SEC analysis of AB0192 after 6 cycles of freeze / thaw compared to a control showing no loss of monomer.
[0328] [Figure 274-1] CE-SDS analysis of AB0192 after freeze-thaw stress is shown, demonstrating that purity is not reduced under either reducing (right panel) or non-reducing (left panel) conditions. [Figure 274-2] CE-SDS analysis of AB0192 after freeze-thaw stress is shown, demonstrating that purity is not reduced under either reducing (right panel) or non-reducing (left panel) conditions.
[0329] [Figure 275-1]SEC analysis of AB0192 after agitation stress compared to control is shown, which showed no loss of monomer. [Figure 275-2] SEC analysis of AB0192 after agitation stress compared to control is shown, which showed no loss of monomer.
[0330] [Figure 276-1] CE-SDS analysis of AB0192 after agitation stress compared to control is shown, demonstrating that no increase in fragmentation was detected with reduction (right panel) or non-reduction (left panel). [Figure 276-2] CE-SDS analysis of AB0192 after agitation stress compared to control is shown, demonstrating that no increase in fragmentation was detected with reduction (right panel) or non-reduction (left panel).
[0331] [Figure 277-1] SEC analysis of the pH hold samples versus the control is shown, which indicated that no change in profile was observed after the low pH hold. [Figure 277-2] SEC analysis of the pH hold samples versus the control is shown, which indicated that no change in profile was observed after the low pH hold.
[0332] [Fig. 278] 1 shows a cIEF analysis of AB0192 after a low pH hold compared to a control, indicating that the low pH hold had no measurable effect on the charge profile of AB0192.
[0333] [Figure 279-1] This demonstrates that AB0192 is stable after low pH: there is no effect on CLEC12A, NKG2D, or CD16a binding. The slight differences in maximum binding signals reflect differences in capture levels. [Figure 279-2]This demonstrates that AB0192 is stable after low pH: there is no effect on CLEC12A, NKG2D, or CD16a binding. The slight differences in maximum binding signals reflect differences in capture levels. [Figure 279-3] This demonstrates that AB0192 is stable after low pH: there is no effect on CLEC12A, NKG2D, or CD16a binding. The slight differences in maximum binding signals reflect differences in capture levels.
[0334] [Figure 280] The potency of AB0192 after low pH hold was demonstrated in a KHYG1-CD16a-mediated cytotoxicity assay, which indicated that the potency of AB0192 was unchanged after the low pH hold step.
[0335] [Figure 281] Figure 1 shows the binding of AB0089 to hCLEC12A before and after the low pH hold. The small differences in absolute maximum signal reflect different capture levels of AB0089.
[0336] [Figure 282] This demonstrates the stability of AB0089 after the low pH hold. No difference was observed between the potency of the low pH hold and the control sample. DETAILED DESCRIPTION OF THE INVENTION
[0337] The present application provides multispecific binding proteins that bind to the NKG2D and CD16 receptors on natural killer cells and to tumor-associated antigens. In some embodiments, the multispecific proteins further comprise an additional antigen-binding site that binds to the tumor-associated antigen. The present application also provides pharmaceutical compositions comprising such multispecific binding proteins, as well as therapeutic methods using such multispecific proteins and pharmaceutical compositions, for purposes such as the treatment of autoimmune diseases and cancer. Various aspects of the multispecific binding proteins described in the present application are described in the sections below; however, various aspects of the multispecific binding proteins described in one particular section are not limited to any particular section.
[0338] To facilitate understanding of this application, a number of terms and phrases are defined below.
[0339] As used herein, the terms "a" and "an" mean "one or more" and include the plural forms unless the context is inappropriate.
[0340] As used herein, the term "antigen-binding site" refers to the portion of an immunoglobulin molecule involved in antigen binding. In human antibodies, the antigen-binding site is formed by amino acid residues from the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains, called "hypervariable regions," are inserted between more conserved adjacent stretches known as "framework regions" or "FRs." Thus, the term "FR" refers to the amino acid sequences naturally found between and adjacent to the hypervariable regions within immunoglobulins. In human antibody molecules, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are positioned relative to each other in three-dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are called "complementarity-determining regions" or "CDRs." In certain animals, such as camels and cartilaginous fish, the antigen-binding site is formed by a single antibody chain, providing a "single domain antibody." The antigen-binding site may be present in an intact antibody, in an antigen-binding fragment of an antibody that retains the antigen-binding surface, or in a recombinant polypeptide, such as an scFv, that uses a peptide linker to connect the heavy chain variable domain to the light chain variable domain in a single polypeptide.
[0341] As used herein, the term "tumor-associated antigen" refers to any antigen, including, but not limited to, cancer-associated proteins, glycoproteins, gangliosides, carbohydrates, and lipids. Such antigens may be expressed on malignant cells or in the tumor microenvironment, such as tumor-associated blood vessels, extracellular matrix, mesenchymal stroma, or immune infiltrates. In a preferred embodiment of the present disclosure, the term "tumor-associated antigen" refers to CLEC12A.
[0342] As used herein, the terms "subject" and "patient" refer to an organism treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (e.g., murine, simian, equine, bovine, porcine, canine, feline, etc.), and more preferably, humans.
[0343] As used herein, the term "effective amount" means an amount that produces beneficial or desired results. "An effective amount" refers to an amount of a compound (e.g., a compound of the present invention) sufficient to reduce or eliminate the effects of a disease or disorder. An effective amount may be administered in one or more administrations, applications, or dosages, and is not intended to be limited to a particular formulation or route of administration. As used herein, the term "treating" includes any effect, e.g., resulting in the improvement of a condition, disease, disorder, etc., e.g., lessening, reducing, modulating, ameliorating, or eliminating the condition, disease, disorder, etc., or the amelioration of symptoms thereof.
[0344] As used herein, the term "pharmaceutical composition" refers to a combination of an active agent with an inert or active carrier that inherently renders the composition suitable for in vivo or ex vivo therapeutic use.
[0345] As used herein, the term "pharmaceutically acceptable carrier" refers to any standard pharmaceutical carrier, such as phosphate-buffered saline, water, emulsions (e.g., oil-in-water or water-in-oil emulsions), and various types of wetting agents. The composition may also contain stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA
[1975] .
[0346] As used herein, the term "pharmaceutically acceptable salt" refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound described herein that, upon administration to a subject, can provide a compound described herein or its active metabolite or residue. As known to those skilled in the art, "salts" of compounds described herein can be derived from inorganic or organic acids and bases. Exemplary acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, ethanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, can be employed in the preparation of salts useful as intermediates in obtaining compounds described herein and their pharmaceutically acceptable acid addition salts.
[0347] Examples of bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and bases of formula NW4 + (Wherein W is C 1-4 Examples of compounds include those in which the alkyl group is substituted with the alkyl group.
[0348] Exemplary salts include, but are not limited to, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include, for example, Na + , NH4 + , and NW4 + (W in the formula is C 1-4 Examples of suitable cations include the anions of the compounds described herein combined with a suitable cation, such as an alkyl group.
[0349] For therapeutic uses, the salts of the compounds described herein are considered to be pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
[0350] As used herein, CLEC12A (also known as CLL-1, DCAL-2, MICL, and CD371) refers to the protein with Uniprot accession number Q5QGZ9 and related isoforms and orthologs.
[0351] Throughout the description, when compositions are described as having, including, or comprising particular components, or when processes and methods are described as having, including, or comprising particular steps, it is further contemplated that there are compositions according to the present application that consist essentially of or consist of the recited components, and that there are processes and methods according to the present application that consist essentially of or consist of the recited processing steps.
[0352] As a general matter, compositions specifying percentages are by weight unless otherwise specified. Furthermore, if a variable is not accompanied by a definition, the previous definition of that variable takes precedence. [Table 261-1] [Table 261-2] [Table 261-3]
[0353] I. Protein The present application provides multispecific binding proteins that bind to the NKG2D and CD16 receptors on natural killer cells, as well as CLEC12A. The multispecific binding proteins are useful in the pharmaceutical compositions and treatment methods described herein. Binding of the multispecific binding proteins to the NKG2D and CD16 receptors on natural killer cells enhances the activity of natural killer cells toward the destruction of tumor cells expressing tumor antigens. Binding of the multispecific binding proteins to tumor cells expressing tumor antigens brings these cells into proximity with natural killer cells, facilitating the direct and indirect destruction of tumor cells by natural killer cells. Multispecific binding proteins that bind to NKG2D, CD16, and other targets are disclosed in International Application Publication Nos. WO2018148445 and WO2019157366 (not incorporated by reference herein). Further description of some exemplary multispecific binding proteins is provided below.
[0354] The first component of the multispecific binding protein is an antigen-binding site that binds to NKG2D receptor-expressing cells, including but not limited to NK cells, γδ T cells, and CD8 + Upon binding of NKG2D, the multispecific binding protein can block natural ligands such as ULBP6 and MICA from binding to NKG2D and activating NK cells.
[0355] The second component of the multispecific binding protein is an antigen-binding site that binds to the tumor-associated antigen CLEC12A. Tumor-associated antigen-expressing cells may be found in solid tumor indications such as gastric cancer, esophageal cancer, lung cancer, breast cancer (e.g., triple-negative breast cancer), colorectal cancer, ovarian cancer, esophageal cancer, uterine cancer, cervical cancer, head and neck cancer, glioma, and pancreatic cancer, or certain hematological malignancies such as acute myeloid leukemia.
[0356] The third component of the multispecific binding protein is an antibody Fc domain or portion thereof or antigen-binding site that binds to cells expressing CD16, an Fc receptor on the surface of leukocytes, including natural killer cells, macrophages, neutrophils, eosinophils, mast cells, and follicular dendritic cells.
[0357] The additional antigen-binding sites of the multispecific binding protein may bind to the same tumor-associated antigen. In certain embodiments, the first antigen-binding site that binds to NKG2D is an scFv, and the second and additional antigen-binding sites that bind to the tumor-associated antigen are each Fab fragments. In certain embodiments, the first antigen-binding site that binds to NKG2D is an scFv, and the second and additional antigen-binding sites that bind to the tumor-associated antigen are each scFv. In certain embodiments, the first antigen-binding site that binds to NKG2D is a Fab fragment, and the second and additional antigen-binding sites that bind to the tumor-associated antigen are each scFv. In certain embodiments, the first antigen-binding site that binds to NKG2D is a Fab, and the second and additional antigen-binding sites that bind to the tumor-associated antigen are each Fab fragments.
[0358] The antigen-binding sites may each incorporate an antibody heavy chain variable domain and an antibody light chain variable domain (e.g. arranged like an antibody or fused together to form an scFv), or one or more of the antigen-binding sites may be integrated into a V chain variable domain, such as in a camel antibody. H H antibodies or V antibodies like those found in cartilaginous fish NAR It may also be a single domain antibody such as an antibody.
[0359] In some embodiments, the second antigen-binding site incorporates a light chain variable domain having an amino acid sequence identical to the amino acid sequence of the light chain variable domain present in the first antigen-binding site.
[0360] The multispecific binding proteins described herein can take a variety of formats. For example, one format is a heterodimeric multispecific antibody comprising a first immunoglobulin heavy chain, a first immunoglobulin light chain, a second immunoglobulin heavy chain, and a second immunoglobulin light chain (FIG. 1). The first immunoglobulin heavy chain comprises a first Fc (hinge-CH2-CH3) domain, a first heavy chain variable domain, and optionally a first CH1 heavy chain domain. The first immunoglobulin light chain comprises a first light chain variable domain and optionally a first light chain constant domain. The first immunoglobulin light chain, together with the first immunoglobulin heavy chain, forms an antigen-binding site that binds to NKG2D. The second immunoglobulin heavy chain comprises a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain, and optionally a second CH1 heavy chain domain. The second immunoglobulin light chain comprises a second light chain variable domain and optionally a second light chain constant domain. The second immunoglobulin light chain, together with the second immunoglobulin heavy chain, forms an antigen-binding site that binds to CLEC12A. In some embodiments, the first Fc domain and the second Fc domain together can bind to CD16 (Figure 1). In some embodiments, the first immunoglobulin light chain is identical to the second immunoglobulin light chain.
[0361] Another exemplary format comprises a heterodimeric multispecific antibody comprising a first immunoglobulin heavy chain, a second immunoglobulin heavy chain, and an immunoglobulin light chain (e.g., FIG. 2A). In some embodiments, the first immunoglobulin heavy chain comprises a first Fc (hinge-CH2-CH3) domain fused via either a linker or an antibody hinge to a single-chain variable fragment (scFv) composed of a heavy chain variable domain and a light chain variable domain (which, in pairs, bind NKG2D or bind CLEC12A). The second immunoglobulin heavy chain comprises a second Fc (hinge-CH2-CH3) domain, a second heavy chain variable domain, and a CH1 heavy chain domain. The immunoglobulin light chain comprises a light chain variable domain and a light chain constant domain. In some embodiments, the second immunoglobulin heavy chain is paired with an immunoglobulin light chain and binds to NKG2D or binds to a tumor-associated antigen, provided that when the first Fc domain is fused to an scFv that binds to NKG2D, the second immunoglobulin heavy chain paired with the immunoglobulin light chain binds to the tumor-associated antigen but not to NKG2D, or vice versa. In some embodiments, the scFv in the first immunoglobulin heavy chain binds to CLEC12A; and the heavy chain variable domain of the second immunoglobulin heavy chain and the light chain variable domain of the immunoglobulin light chain, when paired, bind to NKG2D (e.g., Figure 2E). In some embodiments, the scFv in the first immunoglobulin heavy chain binds to NKG2D; and the heavy chain variable domain of the second immunoglobulin heavy chain and the light chain variable domain of the immunoglobulin light chain, when paired, bind to CLEC12A. In some embodiments, the first Fc domain and the second Fc domain together can bind to CD16 (eg, Figure 2A).
[0362] Another exemplary format comprises a heterodimeric multispecific antibody comprising a first immunoglobulin heavy chain and a second immunoglobulin heavy chain (e.g., FIG. 2B). In some embodiments, the first immunoglobulin heavy chain comprises a first Fc (hinge-CH2-CH3) domain fused, via either a linker or an antibody hinge, to a single-chain variable fragment (scFv) composed of a heavy chain variable domain and a light chain variable domain (that pair together to bind NKG2D or that bind CLEC12A). In some embodiments, the second immunoglobulin heavy chain comprises a first Fc (hinge-CH2-CH3) domain fused, via either a linker or an antibody hinge, to a single-chain variable fragment (scFv) composed of a heavy chain variable domain and a light chain variable domain (that pair together to bind NKG2D or that bind CLEC12A). and a second Fc (hinge-CH2-CH3) domain fused to a single-chain variable fragment (scFv) composed of main and light chain variable domains (which, in pairs, bind NKG2D or bind a tumor-associated antigen), with the proviso that when the first Fc domain is fused to an scFv that binds NKG2D, the second Fc domain fused to the scFv binds a tumor-associated antigen but not NKG2D, and vice versa. In some embodiments, the first and second Fc domains together can bind CD16 (e.g., Figure 2B).
[0363] In some embodiments, the single-chain variable fragment (scFv) is linked to the antibody constant domain via a hinge sequence. In some embodiments, the hinge comprises the amino acids Ala-Ser or Gly-Ser. In some embodiments, the hinge connects the scFv that binds to NKG2D, and the antibody heavy chain constant domain comprises the amino acids Ala-Ser. In some embodiments, the hinge connects the scFv that binds to a tumor-associated antigen, and the antibody heavy chain constant domain comprises the amino acids Gly-Ser. In some other embodiments, the hinge comprises the amino acids Ala-Ser and Thr-Lys-Gly. The hinge sequence provides flexibility in binding to the target antigen, allowing for a balance between flexibility and optimal shape.
[0364] In some embodiments, the single-chain variable fragment (scFv) described above comprises a heavy chain variable domain and a light chain variable domain. In some embodiments, the heavy chain variable domain forms a disulfide bridge with the light chain variable domain to enhance the stability of the scFv. For example, a disulfide bridge may be formed between the C44 residue of the heavy chain variable domain and the C100 residue of the light chain variable domain (amino acid positions numbered according to Kabat). In some embodiments, the heavy chain variable domain is linked to the light chain variable domain via a flexible linker. Any suitable linker may be used, for example, a (G4S)4 linker ((GlyGlyGlyGlySer)4 (SEQ ID NO: 119). In some scFv embodiments, the heavy chain variable domain is located at the N-terminus of the light chain variable domain. In some scFv embodiments, the heavy chain variable domain is located at the C-terminus of the light chain variable domain.
[0365] The multispecific binding proteins described herein may further comprise one or more additional antigen-binding sites. The additional antigen-binding site(s) may be fused, optionally via a linker sequence, to the N-terminus of the constant region CH2 domain or the C-terminus of the constant region CH3 domain. In certain embodiments, the additional antigen-binding site(s) are in the form of a single-chain variable region (scFv), optionally disulfide-stabilized, resulting in a tetravalent or trivalent multispecific binding protein. For example, the multispecific binding protein comprises a first antigen-binding site that binds NKG2D, a second antigen-binding site that binds CLEC12A, an additional antigen-binding site that binds a tumor-associated antigen, and an antibody constant region or portion thereof (sufficient to bind to CD16 or a fourth antigen-binding site that binds CD16). Any of these antigen-binding sites may be in the form of a Fab fragment or an scFv, such as the scFvs described above.
[0366] In some embodiments, the additional antigen-binding site binds to an epitope of the tumor-associated antigen that is different from that of the second antigen-binding site. In some embodiments, the additional antigen-binding site binds to the same epitope as that of the second antigen-binding site. In some embodiments, the additional antigen-binding site comprises the same heavy and light chain CDR sequences as that of the second antigen-binding site. In some embodiments, the additional antigen-binding site comprises the same heavy and light chain variable domain sequences as that of the second antigen-binding site. In some embodiments, the additional antigen-binding site has the same amino acid sequence(s) as that of the second antigen-binding site. In some embodiments, the additional antigen-binding site comprises heavy and light chain variable domains that are different from the heavy and light chain variable domain sequences of the second antigen-binding site. In some embodiments, the additional antigen-binding site has an amino acid sequence that differs from the sequence of the second antigen-binding site. In some embodiments, the second antigen-binding site and the additional antigen-binding site bind to different tumor-associated antigens. In some embodiments, the second antigen-binding site and the additional antigen-binding site bind to different antigens. Exemplary formats are shown in Figures 2C and 2D. Thus, a multispecific binding protein can provide bivalent engagement of a tumor-associated antigen. Bivalent engagement of a tumor-associated antigen by a multispecific protein can stabilize the tumor-associated antigen on the tumor cell surface and enhance NK cell cytotoxicity against the tumor cells. Bivalent engagement of a tumor-associated antigen by a multispecific protein can confer stronger binding of the multispecific protein to tumor cells, thereby promoting a more potent NK cell cytotoxic response toward tumor cells, particularly toward tumor cells that express low levels of tumor-associated antigen.
[0367] Multispecific binding proteins can take additional formats. In some embodiments, the multispecific binding protein is in the form of a triomab, a trifunctional, bispecific antibody that maintains an IgG-like shape. This chimera consists of two half antibodies, each with one light chain and one heavy chain, derived from two parent antibodies.
[0368] In some embodiments, the multispecific binding protein is in KiH format, which includes knob-into-hole (KiH) technology. KiH includes C H The concept behind "Knobs-into-Holes (KiH)" Fc technology involves engineering the three domains to create "knobs" or "holes" in each heavy chain to promote heterodimerization. The concept behind "Knobs-into-Holes" (KiH) Fc technology is to replace small residues with bulky residues (e.g., T366W in EU numbering). CH3A The first step was to introduce a "knob" into one CH3 domain (CH3A) by replacing the adjacent residues closest to the knob with smaller residues (e.g., T366S / L368A / Y407V) to accommodate the "knob." CH3B A complementary "hole" surface was created on the other CH3 domain (CH3B) by replacing the CH3A with a "hole" mutation. The "hole" mutation was then analyzed using a structure-guided phage library screen (Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface). of a homodimer using a phage display library, J. Mol. Biol. (1997) 270(1):26-35). X-ray crystal structure of KiH Fc variant (Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, et al., Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction, J. Mol. Biol. (2014) 426(9):1947-57; Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K. Crystal structure of a novel asymmetrically engineered Fc A variant with improved affinity for FcγRs. Mol. Immunol. (2014) 58(1):132-8) demonstrated that heterodimerization is thermodynamically favored by hydrophobic interactions driven by steric complementarity at the core interface between the CH3 domains, whereas the knob-knob and hole-hole interfaces do not support homodimerization due to steric hindrance and disruption of favorable interactions, respectively.
[0369] In some embodiments, the multispecific binding protein is in the form of a dual variable domain immunoglobulin (DVD-Ig™), which combines the target binding domains of two monoclonal antibodies via a flexible, naturally occurring linker to form a tetravalent IgG-like molecule. This results in:
[0370] In some embodiments, the multispecific binding protein is in the form of an ortho-Fab interface (ortho-Fab). In the ortho-Fab IgG approach (Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, et al., Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol. (2014) 32(2):191-8), structure-based domain design involves the creation of LC and HC domains in only one Fab fragment, without modifying the other Fab fragment. VH-CH1 Complementary mutations are introduced at the interface.
[0371] In some embodiments, the multispecific binding protein is a 2-in-1 Ig format. In some embodiments, the multispecific binding protein is an ES format, which is a heterodimeric construct comprising two different Fab fragments that bind target 1 and target 2 fused to an Fc. Heterodimerization is ensured by electrostatic steering mutations in the Fc.
[0372] In some embodiments, the multispecific binding protein is in the form of a κλ-Body, a heterodimeric construct with two different Fab fragments fused to an Fc stabilized by heterodimerization mutations: Fab fragment 1, targeting antigen 1, contains a kappa LC, and Fab fragment 2, targeting antigen 2, contains a lambda LC. Figure 13A is an exemplary representation of one form of a κλ-Body. Figure 13B is an exemplary representation of another κλ-Body.
[0373] In some embodiments, the multispecific binding protein is in Fab arm exchanged form (an antibody that exchanges its heavy chain and attached light chain (half molecule) with a heavy chain-light chain pair from another molecule, thereby exchanging Fab fragment arms, resulting in a bispecific antibody).
[0374] In some embodiments, the multispecific binding protein is in the form of a SEED body. The strand exchange engineered domain (SEED) platform is designed to generate asymmetric, bispecific antibody-like molecules (the ability to expand the therapeutic applications of natural antibody therapy). This protein engineering platform is based on the exchange of structurally related sequences of immunoglobulins within the conserved CH3 domain. The SEED design allows for the efficient generation of AG / GA heterodimers, while disfavoring homodimerization of the AG and GA SEED CH3 domains. (Muda M. et al., Protein Eng. Des. Sel. (2011, 24(5):447-54)).
[0375] In some embodiments, the multispecific binding protein is of the LuZ-Y form, which uses a leucine zipper to induce heterodimerization of two different HCs (Wranik, BJ. et al., J. Biol. Chem. (2012), 287:43331-9).
[0376] In some embodiments, the multispecific binding protein is in the form of a Cov-X-Body. In a bispecific CovX-Body, two different peptides are linked using a branched azetidinone linker and site-specifically fused to a scaffold antibody under mild conditions. The pharmacophore is responsible for functional activity, while the antibody scaffold confers long half-life and Ig-like distribution. The pharmacophore can be chemically optimized or replaced with another pharmacophore to generate optimized or unique bispecific antibodies. (D oppalapudi VR et al., PNAS(2010), 107(52);22611-22616).
[0377] In some embodiments, the multispecific binding protein is in the form of an Oasc-Fab heterodimer, comprising a Fab fragment that binds target 1 and an scFab that binds target 2 fused to an Fc. Heterodimerization is ensured by mutations in the Fc.
[0378] In some embodiments, the multispecific binding protein is in the form of a DuetMab, which is a heterodimeric construct comprising two different Fab fragments that bind antigens 1 and 2, and an Fc stabilized by a heterodimerization mutation. Fab fragments 1 and 2 contain differential S-S bridges that ensure correct pairing of the LC and HC.
[0379] In some embodiments, the multispecific binding protein is in the form of a cross-mAb, which is a heterodimeric construct with two different Fab fragments that bind to targets 1 and 2 fused to an Fc stabilized by heterodimerization. The CL and CH1 domains, and the VH and VL domains are switched, e.g., CH1 is fused in frame with the VL and CL is fused in frame with the VH.
[0380] In some embodiments, the multispecific binding protein is in the Fit-Ig format, a homodimeric construct in which a Fab fragment that binds antigen 2 is fused to the N-terminus of the HC of a Fab fragment that binds antigen 1. This construct contains a wild-type Fc.
[0381] The individual components of the multispecific binding proteins are described in more detail below.
[0382] NKG2D-binding site Upon binding to the NKG2D and CD16 receptors and CLEC12A on natural killer cells, the multispecific binding protein may engage more than one NK-activating receptor and block binding of the natural ligand to NKG2D. In certain embodiments, the protein may stimulate human NK cells. In some embodiments, the protein may stimulate NK cells in humans and other species, such as rodents and cynomolgus monkeys. In some embodiments, the protein may stimulate NK cells in humans and other species, such as cynomolgus monkeys.
[0383] Table 1 lists peptide sequences of heavy and light chain variable domains that can combine to bind to NKG2D. In some embodiments, the heavy and light chain variable domains are arranged in a Fab format. In some embodiments, the heavy and light chain variable domains are fused together to form an scFv.
[0384] The NKG2D binding sites listed in Table 1 may differ in their binding affinity to NKG2D, but nevertheless, they all activate human NK cells.
[0385] Unless otherwise indicated, the CDR sequences set forth in Table 1 are determined according to Kabat numbering. [Table 1-1] [Table 1-2] Table 1-3 Table 1-4 Table 1-5 Table 1-6
Table 1-7
Table 1-10
[0386] In certain embodiments, the first antigen-binding site that binds to NKG2D (e.g., human NKG2D) comprises an antibody heavy chain variable domain (VH) comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH of an antibody disclosed in Table 1, and an antibody light chain variable domain (VL) comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL of the same antibody disclosed in Table 1. In certain embodiments, the first antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3 as determined by Kabat (see Kabat et al., (1991) Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242, Bethesda), Chothia (see, e.g., Chothia C & Lesk AM, (1987), J. Mol. Biol. 196:901-917), MacCallum (see MacCallum RM et al., (1996) J. Mol. Biol. 262:732-745), or any other method of CDR determination known in the art. The antibody VH and VL sequences are disclosed in Table 1. In certain embodiments, the first antigen-binding site comprises the heavy chain CDR1, CDR2, and CDR3, and the light chain CDR1, CDR2, and CDR3 of an antibody disclosed in Table 1.
[0387] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a heavy chain variable domain related to SEQ ID NO: 1, such as by having an amino acid sequence that is at least 90% (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 1 and / or by incorporating amino acid sequences identical to the sequences of CDR1 (SEQ ID NO: 2), CDR2 (SEQ ID NO: 3), and CDR3 (SEQ ID NO: 4) of SEQ ID NO: 1. The heavy chain variable domain with respect to SEQ ID NO: 1 can be combined with a different light chain variable domain to form the NKG2D-binding site. For example, a first antigen-binding site incorporating a heavy chain variable domain related to SEQ ID NO: 1 may further incorporate a light chain variable domain selected from sequences derived from SEQ ID NOs: 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 46. For example, the first antigen-binding site may have a light chain variable domain that is at least 90% (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, The present invention incorporates a heavy chain variable domain having an amino acid sequence that is at least 97%, at least 98%, at least 99%, or 100% identical to any one of the sequences selected from SEQ ID NOs: 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 46, and a light chain variable domain having an amino acid sequence that is at least 90% identical (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) to any one of the sequences selected from SEQ ID NOs: 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 46.
[0388] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 26, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 32. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 27 or 28, 29, and 30 or 31, respectively (e.g., SEQ ID NOs: 27, 29, and 30, respectively, or SEQ ID NOs: 28, 29, and 31, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 33, 34, and 35, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 27 or 28, 29, and 30 or 31, respectively (e.g., SEQ ID NOs: 27, 29, and 30, respectively, or SEQ ID NOs: 28, 29, and 31, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 33, 34, and 35, respectively.
[0389] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 36, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 42. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 37 or 38, 39, and 40 or 41, respectively (e.g., SEQ ID NOs: 37, 39, and 40, respectively, or SEQ ID NOs: 38, 39, and 41, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 43, 44, and 45, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 37 or 38, 39, and 40 or 41, respectively (e.g., SEQ ID NOs: 37, 39, and 40, respectively, or SEQ ID NOs: 38, 39, and 41, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 43, 44, and 45, respectively.
[0390] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 47, and a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 49. and a VL comprising an amino acid sequence that is at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VH. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 27, 29, and 48, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 34, and 51, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 27, 29, and 48, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 34, and 51, respectively.
[0391] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 52, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 58. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 53 or 54, 55, and 56 or 57, respectively (e.g., SEQ ID NOs: 53, 55, and 56, respectively, or SEQ ID NOs: 54, 55, and 57, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 59, 60, and 61, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 53 or 54, 55, and 56 or 57, respectively (e.g., SEQ ID NOs: 53, 55, and 56, respectively, or SEQ ID NOs: 54, 55, and 57, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 59, 60, and 61, respectively.
[0392] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 62, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 68. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 63 or 64, 65, and 66 or 67, respectively (e.g., SEQ ID NOs: 63, 65, and 66, respectively, or SEQ ID NOs: 64, 65, and 67, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 59, 60, and 69, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 63 or 64, 55, and 66 or 67, respectively (e.g., SEQ ID NOs: 63, 65, and 66, respectively, or SEQ ID NOs: 64, 65, and 67, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 59, 60, and 69, respectively.
[0393] In certain embodiments, the first antigen-binding site that binds to NKG2D has a sequence identity of at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least and a VL comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 92. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 53 or 54, 55, and 90 or 91, respectively (e.g., SEQ ID NOs: 53, 55, and 90, respectively, or SEQ ID NOs: 54, 55, and 91, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 93, 44, and 94, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 53 or 54, 55, and 90 or 91, respectively (e.g., SEQ ID NOs: 53, 55, and 90, respectively, or SEQ ID NOs: 54, 55, and 91, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 93, 44, and 94, respectively.
[0394] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 70, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 75. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 71 or 115, 72, and 73 or 74, respectively (e.g., SEQ ID NOs: 71, 72, and 73, respectively, or SEQ ID NOs: 115, 72, and 74, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 76, 77, and 78, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 71 or 115, 72, and 73 or 74, respectively (e.g., SEQ ID NOs: 71, 72, and 73, respectively, or SEQ ID NOs: 115, 72, and 74, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 76, 77, and 78, respectively.
[0395] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 79, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 85. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 83 or 84, respectively (e.g., SEQ ID NOs: 80, 82, and 83, respectively, or SEQ ID NOs: 81, 82, and 84, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 83 or 84, respectively (e.g., SEQ ID NOs: 80, 82, and 83, respectively, or SEQ ID NOs: 81, 82, and 84, respectively); and (b) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 8 and VL comprising CDR1, CDR2, and CDR3 comprising 7 amino acid sequences.
[0396] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 95, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 85. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 96 or 97, respectively (e.g., SEQ ID NOs: 80, 82, and 96, respectively, or SEQ ID NOs: 81, 82, and 97, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 96 or 97, respectively (e.g., SEQ ID NOs: 80, 82, and 96, respectively, or SEQ ID NOs: 81, 82, and 97, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
[0397] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 98, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 85. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 99 or 100, respectively (e.g., SEQ ID NOs: 80, 82, and 99, respectively, or SEQ ID NOs: 81, 82, and 100, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 96 or 97, respectively (e.g., SEQ ID NOs: 80, 82, and 99, respectively, or SEQ ID NOs: 81, 82, and 100, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
[0398] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 101, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 85. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 102 or 103, respectively (e.g., SEQ ID NOs: 80, 82, and 102, respectively, or SEQ ID NOs: 81, 82, and 103, respectively). In certain embodiments, the VL comprises CDR1, CDR2 and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 102 or 103, respectively (e.g., SEQ ID NOs: 80, 82, and 102, respectively, or SEQ ID NOs: 81, 82, and 103, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
[0399] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 104, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 85. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 105 or 106, respectively (e.g., SEQ ID NOs: 80, 82, and 105, respectively, or SEQ ID NOs: 81, 82, and 106, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 105 or 106, respectively (e.g., SEQ ID NOs: 80, 82, and 105, respectively, or SEQ ID NOs: 81, 82, and 106, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
[0400] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 107, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 85. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 108 or 109, respectively (e.g., SEQ ID NOs: 80, 82, and 108, respectively, or SEQ ID NOs: 81, 82, and 109, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 108 or 109, respectively (e.g., SEQ ID NOs: 80, 82, and 108, respectively, or SEQ ID NOs: 81, 82, and 109, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
[0401] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 110, and a VH comprising an amino acid sequence that is at least 90% (e.g., at least and a VL comprising an amino acid sequence that is at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any of the VH and VL sequences. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 111 or 112, respectively (e.g., SEQ ID NOs: 80, 82, and 111, respectively, or SEQ ID NOs: 81, 82, and 112, respectively). In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively. In certain embodiments, the first antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 80 or 81, 82, and 111 or 112, respectively (e.g., SEQ ID NOs: 80, 82, and 111, respectively, or SEQ ID NOs: 81, 82, and 112, respectively); and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
[0402] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 113, and a VL comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 114.
[0403] In certain embodiments, the first antigen-binding site that binds to NKG2D comprises a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 116, and a VL comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 117.
[0404] The multispecific binding protein binds to NK cells, γδ T cells, and CD8 + The multispecific binding proteins may bind to NKG2D-expressing cells, including, but not limited to, αβ T cells. Upon binding of NKG2D, the multispecific binding proteins may block natural ligands such as ULBP6 and MICA from binding to NKG2D and activating NK cells.
[0405] Multispecific binding proteins bind to cells that express CD16, an Fc receptor on the surface of leukocytes such as natural killer cells, macrophages, neutrophils, eosinophils, mast cells, and follicular dendritic cells. Proteins of the present disclosure may bind to cells that express CD16 at a concentration of 2 nM to 120 nM, e.g., 2 nM to 110 nM, 2 nM to 100 nM, 2 nM to 90 nM, 2 nM to 80 nM, 2 nM to 70 nM, 2 nM to 60 nM, 2 nM to 50 nM, 2 nM to 40 nM, 2 nM to 30 nM, 2 nM to 20 nM, 2 nM to 10 nM, about 15 nM, about 14 nM, about 13 nM, about 12 nM, about 11nM, about 10nM, about 9nM, about 8nM, about 7nM, about 6nM, about 5nM, about 4.5nM, about 4nM, about 3.5nM, about 3nM, about 2.5 nM, approximately 2nM, approximately 1.5nM, approximately 1nM, approximately 0.5nM to approximately 1nM, approximately 1nM to approximately 2nM, approximately 2nM to 3nM, approximately 3nM to 4nM, approximately 4nM about 5 nM, about 5 nM to about 6 nM, about 6 nM to about 7 nM, about 7 nM to about 8 nM, about 8 nM to about 9 nM, about 9 nM to about 10 nM, about 1 nM to about 10 nM, about 2 nM to about 10 nM, about 3 nM to about 10 nM, about 4 nM to about 10 nM, about 5 nM to about 10 nM, about 6 nM to about 10 nM, about 7 nM to about 10 nM, or about 8 nM to about 10 nM M is K D In some embodiments, the NKG2D binding site binds to NKG2D with an affinity of 10-62 nM. D It binds to NKG2D. CLEC12A binding site
[0406] The tumor-associated antigen-binding sites of the multispecific binding proteins disclosed herein comprise a heavy chain variable domain and a light chain variable domain. Table 2 lists some exemplary sequences of heavy chain variable domains and light chain variable domains that, in combination, can bind to these tumor-associated antigens.
[0407] In one aspect, the present disclosure provides a multispecific binding protein that binds to the NKG2D and CD16 receptors on natural killer cells and CLEC12A. Table 2 lists some exemplary sequences of heavy and light chain variable domains that can be combined to bind to CLEC12A. CDR sequences are identified by Kabat numbering as shown. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13] [Table 2-14]
[0408] In certain embodiments, the second antigen-binding site that binds to CLEC12A (e.g., human CLEC12A) comprises an antibody heavy chain variable domain (VH) comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VH of an antibody disclosed in Table 2, and an antibody light chain variable domain (VL) comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the VL of the same antibody disclosed in Table 2. In certain embodiments, the second antigen-binding site is selected from the VH and VL sequences of the antigen-binding sites disclosed in Table 2, as defined by Kabat (see Kabat et al., (1991) Sequences of Proteins of Immunological Interest, NIH Publication No. 91-3242, Bethesda), Chothia (see, e.g., Chothia C & Lesk AM, (1987), J Mol Biol 196:901-917), MacCallum (MacCallum In certain embodiments, the second antigen-binding site comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, as determined under the method of any other method known in the art (see, for example, RM et al., (1996) J Mol Biol 262:732-745). It includes the primary chain CDR1, CDR2, and CDR3, and the light chain CDR1, CDR2, and CDR3.
[0409] In certain embodiments, this second antigen-binding site is derived from 16B8.C8. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 135, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 136. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively.
[0410] In certain embodiments, the second antigen-binding site is derived from scFv-1292 or scFv-1301. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 143, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 144. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 145 or 146.
[0411] In certain embodiments, the second antigen-binding site is derived from scFv-1293 or scFv-1302. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 147, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 144. In certain embodiments, The VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 149 or 150.
[0412] In certain embodiments, the second antigen-binding site is derived from scFv-1294 or scFv-1303. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 244, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 144. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 153 or 154.
[0413] In certain embodiments, the second antigen-binding site is derived from scFv-1295 or scFv-1304. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 178, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 144. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises at least one CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 156 or 157. It comprises an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical.
[0414] In certain embodiments, the second antigen-binding site is derived from scFv-1296 or scFv-1305. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 256, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 144. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 160 or 161.
[0415] In certain embodiments, the second antigen-binding site is derived from scFv-1297 or scFv-1306. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 143, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 163. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 164 or 165.
[0416] In certain embodiments, the second antigen-binding site is derived from scFv-1298 or scFv-1307. For example, in certain embodiments, the second antigen-binding site is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 167. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 168 or 169.
[0417] In certain embodiments, the second antigen-binding site is derived from scFv-1299 or scFv-1308. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 143, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 171. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 172 or 173.
[0418] In certain embodiments, the second antigen-binding site is derived from scFv-1300 or scFv-1309. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 174, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 175. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 176 or 177.
[0419] In certain embodiments, the second antigen-binding site is derived from scFv-1602 or scFv-2061. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 178, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 289. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 180 or 181.
[0420] In certain embodiments, the second antigen-binding site is derived from humanized 16B.C8. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 182, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 151. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively.
[0421] In certain embodiments, the second antigen-binding site is derived from AB0305 or AB5030. For example, in certain embodiments, the second antigen-binding site is at least 90% (e.g., at least 91%, at least 92%, at least 93%) identical to the amino acid sequence of SEQ ID NO: 270. and a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 271, and a VL comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 271. In certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 335, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 336. In certain embodiments, the second antigen-binding site comprises a VH and a VL, each of which comprises cysteine heterodimerization mutations. Such heterodimerization mutations may promote the formation of disulfide bridges between the VH and VL of the scFv. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 272, and 273, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 272, and 273, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively.In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 274 or 275.
[0422] In certain embodiments, the second antigen-binding site is derived from AB0147 or AB7410. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 294, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 295. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 296, and 279, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 296, and 279, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 280 or 200.
[0423] In certain embodiments, the second antigen-binding site is derived from 9F11.B7. In certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 193, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 194. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively.
[0424] In certain embodiments, the second antigen-binding site is derived from AB0191 or AB0185. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 162, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 203. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 184 or 185.
[0425] In certain embodiments, the second antigen-binding site is derived from AB0192 or AB0186. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 148, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 203. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 195, 196, and 187, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) the CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 195, 196, and 187, respectively. and (b) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 204 or 205.
[0426] In certain embodiments, the second antigen-binding site is derived from AB0193 or AB0187. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 210, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 203. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 213, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 213, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 208 or 209.
[0427] In certain embodiments, the second antigen-binding site is derived from AB0194 or AB0188. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 162, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 218. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 215 or 216.
[0428] In certain embodiments, the second antigen-binding site is derived from AB0195 or AB0189. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 148, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 218. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 195, 196, and 187, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 195, 196, and 187, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 252 or 253.
[0429] In certain embodiments, the second antigen-binding site is derived from AB0196 or AB0190. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 210, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 218. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 213, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 213, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site is present as an scFv, wherein the scFv comprises an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 254 or 255.
[0430] In certain embodiments, the second antigen-binding site is derived from humanized 9F11.B7. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:249, and a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:250. and (b) a VL comprising the amino acid sequence of SEQ ID NO: 198, 199, and 201. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NO: 251, 196, and 246, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NO: 198, 199, and 201, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NO: 251, 196, and 246, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NO: 198, 199, and 201, respectively.
[0431] In certain embodiments, the second antigen-binding site is derived from 30A9.E9. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 247, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 248. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 166, and 223, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 240, 226, and 179, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 166, and 223, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 240, 226, and 179, respectively.
[0432] In certain embodiments, the second antigen-binding site is derived from 23A5.H8. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 242, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 243. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 206, 166, and 241, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 245, 239, and 179, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 206, 166, and 241, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 245, 239, and 179, respectively.
[0433] In certain embodiments, the second antigen-binding site is derived from 20D6.H8. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:238, and a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:237. and (b) a VL comprising an amino acid sequence that is at least 97%, at least 98%, at least 99%, or 100% identical to the VH. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 236, and 223, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 152, 226, and 179, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 236, and 223, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 152, 226, and 179, respectively.
[0434] In certain embodiments, the second antigen-binding site is derived from 15A10.G8. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 155, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 158. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 159, 170, and 183, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 186, 188, and 189, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 159, 170, and 183, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 186, 188, and 189, respectively.
[0435] In certain embodiments, the second antigen-binding site is derived from 13E1.A4. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 190, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 191. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 197, 202, and 207, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 211, 212, and 214, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 197, 202, and 207, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 211, 212, and 214, respectively.
[0436] In certain embodiments, the second antigen-binding site is derived from 12F8.H7. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:217, and a VH comprising an amino acid sequence that is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO:219. and a VL comprising an amino acid sequence that is at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VH. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 220, 222, and 257, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 224, 225, and 227, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 220, 222, and 257, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 224, 225, and 227, respectively.
[0437] In certain embodiments, the second antigen-binding site is derived from 9E4.B7. For example, in certain embodiments, the second antigen-binding site comprises a VH comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the amino acid sequence of SEQ ID NO: 228, and a VL comprising an amino acid sequence at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to SEQ ID NO: 229. In certain embodiments, the VH comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 230, 231, and 232, respectively. In certain embodiments, the VL comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 233, 234, and 235, respectively. In certain embodiments, the second antigen-binding site comprises (a) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 230, 231, and 232, respectively; and (b) a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 233, 234, and 235, respectively.
[0438] In certain embodiments, the second antigen-binding site that binds to CLEC12A is an scFv. For example, in certain embodiments, the second antigen-binding site comprises the amino acid sequence of SEQ ID NO: 145, 146, 149, 150, 153, 154, 156, 157, 160, 161, 164, 165, 168, 169, 172, 173, 176, 177, 180, 181, 184, 185, 204, 205, 208, 209, 215, 216, 252, 253, 254, 255, 274, 275, 280, or 281. In certain embodiments, the second antigen-binding site comprises the amino acid sequence of SEQ ID NO: 180.
[0439] Alternatively, novel antigen-binding sites capable of binding to CLEC12A may be identified by screening for binding to the amino acid sequence defined by SEQ ID NO: 258, a variant thereof, a mature extracellular fragment thereof, or a fragment comprising a domain of CLEC12A. SEQ ID NO: 258 MSEEVTYADLQFQNSSEMEKIPEIGKFGEKAPPAPSHVWRPAALFLTLLCLLLLIGLGVL ASMFHVTLKIEMKKMNKLQNISEELQRNISLQLMSNMNISNKIRNLSTTLQTIATKLCRE LYSKEQEHKCKPCPRRWIWHKDSCYFLSDDVQTWQESKMACAQNASLLKINNKNALEFIKSQSRSYDYWLGLSPEEDSTRGMRVDNIINSSAWVIRNAPDLNNMYCGYINRLYVQYYHCTYKKRMICEKMANPVQLGSTYFREA (Uniprot ID number Q5QGZ9)
[0440] It is contemplated that in an scFv, the VH and VL may be connected by a linker, e.g., a (GlyGlyGlyGlySer) or (G4S)4 linker (SEQ ID NO: 119). One of skill in the art would recognize that any of the other disclosed linkers (see, e.g., Table 10) may be used. It will be understood that any of the above may be used in an scFv having the VH and VL sequences disclosed herein (e.g., in Table 2).
[0441] In each of the foregoing embodiments, it is contemplated herein that the scFv, VH and / or VL sequences that bind to CLEC12A may include amino acid changes (e.g., substitutions, deletions, or additions of at least 1, 2, 3, 4, 5, or 10 amino acids) in the framework regions of the VH and / or VL without affecting the ability to CLEC12A. For example, it is contemplated herein that the scFv, VH and / or VL sequences that bind to CLEC12A may include cysteine heterodimerization mutations to promote the formation of disulfide bridges between the VH and VL of the scFv.
[0442] In certain embodiments, the second antigen-binding site disclosed herein has a K of 1 nM or less, 5 nM or less, 10 nM or less, 15 nM or less, or 20 nM or less, as measured by surface plasmon resonance (SPR) (e.g., using the methods described in Example 12) or biolayer interferometry (BLI). D In certain embodiments, the second antigen-binding site disclosed herein binds to human CLEC12A and / or binds to CLEC12A derived from a subject's body fluids, tissues, and / or cells with a dissociation constant (i.e., a dissociation constant) of 1 × 10 as measured by SPR (e.g., using the methods described in Example 12) or BLI. -5 , 1 × 10 -4 , 1 × 10 -3 , 5 × 10 -3 , 0.01, 0.02, or 0.05 1 / s or less K d (i.e., off-rate, K オフ (also called
[0443] In certain embodiments, the second antigen-binding site from 15A10.G8 or 20D6.A8 has a K of 5 nM or less, 10 nM or less, 15 nM or less, 20 nM or less, or 30 nM or less, as measured by surface plasmon resonance (SPR) (e.g., using the methods described in Example 12) or biolayer interferometry (BLI). DIn certain embodiments, the second antigen-binding site disclosed herein binds to cynomolgus monkey CLEC12A and / or binds to CLEC12A from a subject's body fluids, tissues, and / or cells with a dissociation constant (i.e., a dissociation constant) of 1 x 10 as measured by SPR (e.g., using the methods described in Example 12) or BLI. -3 , 5 × 10 -3 , 0.01, 0.02, or 0.03 1 / s or less K d (i.e., off-rate, K オフ (also called
[0444] Variations in the glycosylation status of CLEC12A on the surface of different cell types have been reported (Marshall et al., (2006) Eur J Immunol. 36(8):2159-69). CLEC12A expressed on the surface of AML cells from different patients may have similarly different glycosylation patterns. Furthermore, branched glycans may limit access to protein components of CLEC12A, limiting the diversity of available epitopes. Certain antigen-binding sites of the present application may overcome glycosylation variations. In certain embodiments, the second antigen-binding site disclosed herein, e.g., an antigen-binding site derived from 16B8.C8, humanized 16B8.C8, 9F11.B7, or humanized 9F11.B7, binds to CLEC12A (e.g., human CLEC12A) in a glycosylation-independent manner, i.e., binds to both glycosylated and deglycosylated CLEC12A. In certain embodiments, the second antigen-binding site binds to deglycosylated CLEC12A. D and K, whose second antigen-binding site binds to glycosylated CLEC12A. D The ratio of NKG2D to NKG2D is within the range of 1:10 to 10:1 (e.g., within the range of 1:5 to 5:1, 1:3 to 3:1, or 1:2 to 2:1). In certain embodiments, the ratio is about 1:5, about 1:3, about 1:2, about 1:1.5, about 1:1, about 1.5:1, about 2:1, about 3:1, or about 5:1. In certain embodiments, the ratio is about 1:1. In another aspect, the present disclosure provides a method for detecting a NKG2D-binding protein comprising: (a) a first antigen that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) an antibody Fc domain or portion thereof sufficient to bind to CD16, or a third antigen-binding site that binds to CD16, wherein the second antigen-binding site binds to CLEC12A in a glycosylation-independent manner.
[0445] CLEC12A containing the K244Q substitution is a polymorphic variant that is prevalent in approximately 30% of the population. In some embodiments, the second antigen-binding site of the multispecific binding protein disclosed herein binds to CLEC12A-K244Q. In certain embodiments, the second antigen-binding site binds to CLEC12A-K244Q. D and K, whose second antigen-binding site binds to wild-type CLEC12A. D The ratio of is in the range of 1:2 to 2:1. In certain embodiments, the ratio is about 1:2, about 1:1.5, about 1:1, about 1.5:1, or about 2:1. In certain embodiments, the ratio is about 1:1.
[0446] In some embodiments, the multispecific binding proteins described herein bind to CLEC12A with an isoelectric point (pI) of about 8 to about 9. In some embodiments, the multispecific binding proteins described herein bind to CLEC12A with a pI of about 8.5 to about 8.9. In particular embodiments, the multispecific binding proteins described herein bind to CLEC12A with a pI of about 8.7.
[0447] In some embodiments, an F3' format of a CLEC12A TriNKET described herein (e.g., hF3'-1602 TriNKET) has an EC50 that is about 2-fold lower (e.g., about 1-fold lower, about 2-fold lower, about 3-fold lower, about 4-fold lower, about 5-fold lower, about 6-fold lower) than that of the corresponding F3 format TriNKET, e.g., AB0010, for binding to human CLEC12A on the surface of a cell, e.g., a cancer cell. In some embodiments, an F3' format of a CLEC12A TriNKET described herein (e.g., hF3'-1602 TriNKET) has an EC50 for binding to human CLEC12A on the surface of a cell, e.g., a cancer cell, that is about 50% lower (e.g., about 25% lower, about 30% lower, about 40% lower, about 50% lower, about 55% lower, about 60% lower, about 70% lower, about 75% lower) than the EC50 of the corresponding F3 format TriNKET, e.g., AB0010.
[0448] In certain embodiments, the second antigen-binding site competes with the corresponding antigen-binding site described above for binding to CLEC12A. In one aspect, the present disclosure provides a multispecific binding protein comprising: (a) a first antigen-binding site that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) an antibody Fc domain or portion thereof sufficient to bind to CD16, or a third antigen-binding site that binds to CD16, wherein the second antigen-binding site competes with the antigen-binding site that binds to CLEC12A as disclosed herein. In certain embodiments, the second antigen-binding site competes with the antigen-binding site derived from 16B8.C8 disclosed above for binding to CLEC12A. In one embodiment, the second antigen-binding site competes with 16B8.C8 for binding to CLEC12A. In certain embodiments, the second antigen-binding site competes with the antigen-binding site derived from humanized 16B8.C8 disclosed above for binding to CLEC12A. In one embodiment, the second antigen-binding site competes with humanized 16B8.C8 for binding to CLEC12A. In a specific embodiment, the second antigen-binding site competes with an antigen-binding site derived from 9F11.B7 disclosed above for binding to CLEC12A. In one embodiment, the second antigen-binding site competes with 9F11.B7 for binding to CLEC12A. In a specific embodiment, the second antigen-binding site competes with an antigen-binding site derived from humanized 9F11.B7 disclosed above for binding to CLEC12A. In one embodiment, the second antigen-binding site competes with humanized 9F11.B7 for binding to CLEC12A. In a specific embodiment, the second antigen-binding site competes with humanized 9F11.B7 for binding to CLEC12A. In some embodiments, the second antigen-binding site competes with 12F8.H7, 13E1.A4, 15A10.E8, 20D6.H8, or 23A5.H8 for binding to CLEC12A. Fc domain
[0449] Within the Fc domain, CD16 binding is mediated by the hinge region and CH2 domain. For example, in human IgG1, the interaction with CD16 is primarily mediated by amino acid residues Asp 265-Glu 269, Asn 297-Thr 299, and Ala 298 in the CH2 domain. 327-Ile 332, Leu 234-Ser 239, and the carbohydrate residue N-acetyl-D-glucosamine (see Sondermann et al., Nature, 406(6793):267-273). Mutations that enhance or decrease binding affinity to CD16 may be selected based on the known domains, such as by using a phage display library or a yeast surface display cDNA library, or may be designed based on the known three-dimensional structure of the interaction. Thus, in certain embodiments, the antibody Fc domain or portion thereof comprises a hinge and a CH2 domain.
[0450] Assembly of heterodimeric antibody heavy chains can be achieved by expressing two different antibody heavy chain sequences in the same cell, which can result in the assembly of homodimers and heterodimers of each antibody heavy chain. Promotion of preferential assembly of heterodimers can be achieved by incorporating different mutations in the CH3 domain of each antibody heavy chain constant region, as described in US 13 / 494870, US 16 / 028850, US 11 / 533709, US 12 / 875015, US 13 / 289934, US 14 / 773418, US 12 / 811207, US 13 / 866756, US 14 / 647480, and US 14 / 830336. For example, mutations can be made in the CH3 domain based on human IgG1 to incorporate distinct pairs of amino acid substitutions in the first and second polypeptides that allow these two chains to selectively heterodimerize with each other. All amino acid substitution positions depicted below are numbered according to the EU index as per Kabat.
[0451] In some situations, an amino acid substitution in a first polypeptide replaces an original amino acid with a larger amino acid selected from arginine (R), phenylalanine (F), tyrosine (Y), or tryptophan (W), and at least one amino acid substitution in a second polypeptide replaces an original amino acid(s) with a smaller amino acid selected from alanine (A), serine (S), threonine (T), or valine (V), such that the larger amino acid substitution (protuberance) fits into the surface of the smaller amino acid substitution (cavity). For example, one polypeptide may incorporate a T366W substitution, while another may incorporate three substitutions including T366S, L368A, and Y407V.
[0452] The antibody heavy chain variable domains described herein may optionally be linked to an amino acid sequence at least 90% identical to an antibody constant region, such as an IgG constant region, including a hinge, CH2, and CH3 domains, with or without a CH1 domain. In some embodiments, the amino acid sequence of the constant region is at least 90% identical to a human antibody constant region, such as a human IgG1 constant region, IgG2 constant region, IgG3 constant region, or IgG4 constant region. In one embodiment, an antibody Fc domain or portion thereof sufficient to bind to CD16 is linked to the wild-type human IgG1 Fc sequence DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 118). In some other embodiments, the amino acid sequence of the constant region is at least 90% identical to an antibody constant region from another mammal, such as a rabbit, dog, cat, mouse, or horse.
[0453] In some embodiments, the antibody constant domain linked to the scFv or Fab fragment can bind to CD 16. In some embodiments, the protein incorporates a portion of an antibody Fc domain (e.g., a sufficient portion of an antibody Fc domain to bind to CD 16), where the antibody Fc domain comprises a hinge and CH2 domain (e.g., the hinge and CH2 domain of a human IgG1 antibody) and / or an amino acid sequence at least 90% identical to amino acid sequence 234-332 of a human IgG antibody.
[0454] One or more mutations may be incorporated into the constant region compared to the human IgG1 constant region, for example, Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411 and / or K439. Exemplary substitutions include, for example, Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, T350V, L351K, L351D, L351Y, S354C, E356K, E357Q, E357L, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T 366L, T366M, T366K, T366W, T366S, L368E, L368A, L368D, K370S, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, T394F, T394W, D399R, D399K, D399V, S400K, S400R, D401K, F405A, F405T, Y407A, Y407I, Y407V, K409F, K409W, K409D, K409R, T411D, T411E, K439D, and K439E.
[0455] In certain embodiments, mutations that can be incorporated into CH1 of the human IgG1 constant region can be amino acids V125, F126, P127, T135, T139, A140, F170, P171, and / or V173. In certain embodiments, mutations that can be incorporated into Cκ of the human IgG1 constant region can be amino acids E123, F116, S176, V163, S174, and / or T164.
[0456] Alternatively, the amino acid substitutions may be selected from the following set of substitutions shown in Table 3. [Table 3]
[0457] Alternatively, the amino acid substitutions may be selected from the following set of substitutions shown in Table 4. [Table 4]
[0458] Alternatively, the amino acid substitutions may be selected from the following set of substitutions shown in Table 5. [Table 5]
[0459] Alternatively, at least one amino acid substitution in each polypeptide chain is selected from Table 6. That's fine. [Table 6]
[0460] Alternatively, at least one amino acid substitution can be selected from the following set of substitutions in Table 7, where the position(s) shown in the first polypeptide row are replaced by any known negatively charged amino acid, and the position(s) shown in the second polypeptide row are replaced by a known positively charged amino acid. [Table 7]
[0461] Alternatively, at least one amino acid substitution can be selected from the following set of substitutions in Table 8, where the position(s) shown in the first polypeptide row are replaced by any known positively charged amino acid, and the position(s) shown in the second polypeptide row are replaced by a known negatively charged amino acid. [Table 8]
[0462] Alternatively, the amino acid substitutions may be selected from the following set of substitutions shown in Table 9. [Table 9]
[0463] Alternatively, or in addition, the structural stability of the heteromultimeric protein can be increased by introducing S354C into either the first or second polypeptide chain and Y349C into the opposite polypeptide chain, which forms an artificial disulfide bridge at the interface of the two polypeptides.
[0464] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at position T366 and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at position T366. The amino acid sequence of the peptide chain differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from the group consisting of T366, L368 and Y407.
[0465] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of T366, L368, and Y407, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at position T366.
[0466] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of E357, K360, Q362, S364, L368, K370, T394, D401, F405, and T411, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Y349, E357, S364, L368, K370, T394, D401, F405, and T411.
[0467] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Y349, E357, S364, L368, K370, T394, D401, F405, and T411, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of E357, K360, Q362, S364, L368, K370, T394, D401, F405, and T411.
[0468] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of L351, D399, S400, and Y407, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of T366, N390, K392, K409, and T411.
[0469] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of T366, N390, K392, K409, and T411, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of L351, D399, S400, and Y407.
[0470] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Q347, Y349, K360, and K409, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Q347, E357, D399, and F405.
[0471] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Q347, E357, D399, and F405, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Y349, K360, Q347, and K409.
[0472] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region has one or more positions selected from the group consisting of K370, K392, K409, and K439. The amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from the group consisting of D356, E357, and D399.
[0473] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of D356, E357, and D399, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of K370, K392, K409, and K439.
[0474] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of L351, E356, T366, and D399, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Y349, L351, L368, K392, and K409.
[0475] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Y349, L351, L368, K392, and K409, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of L351, E356, T366, and D399.
[0476] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by a S354C substitution, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by a Y349C substitution.
[0477] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by a Y349C substitution, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by a S354C substitution.
[0478] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by K360E and K409W substitutions, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by Q347R, D399V, and F405T substitutions.
[0479] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by Q347R, D399V, and F405T substitutions, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by K360E and K409W substitutions.
[0480] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by a T366W substitution, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by T366S, T368A, and Y407V substitutions.
[0481] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by T366S, T368A, and Y407V substitutions, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by a T366W substitution. The amino acid sequence differs from that of the IgG1 constant region.
[0482] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by T350V, L351Y, F405A, and Y407V substitutions, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by T350V, T366L, K392L, and T394W substitutions.
[0483] In some embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by T350V, T366L, K392L, and T394W substitutions, and the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region by T350V, L351Y, F405A, and Y407V substitutions.
[0484] Exemplary Multispecific Binding Proteins Listed below are examples of TriNKETs that contain an antigen-binding site that binds to CLEC12A and an antigen-binding site that binds to NKG2D, each linked to an antibody constant region, where the antibody constant region contains mutations that allow heterodimerization of the two Fc chains.
[0485] Exemplary CLEC12A-targeting TriNKETs are contemplated in F3' and F3 formats. As described above, in the F3' format, the antigen-binding site that binds to the tumor-associated antigen is an scFv, and the antigen-binding site that binds to NKG2D is a Fab. In the F3 format, the antigen-binding site that binds to the tumor-associated antigen is a Fab, and the antigen-binding site that binds to NKG2D is an scFv. In each TriNKET, the scFv contains substitutions of Cys in the VH and VL regions to promote disulfide bridge formation between the VH and VL of the scFv.
[0486] The VH and VL of an scFv can be connected via a linker, e.g., a peptide linker. In certain embodiments, the peptide linker is a flexible linker. With regard to the amino acid composition of the linker, the peptide is selected to confer flexibility, not interfere with the structure and function of other domains of the protein described herein, and have the properties of resistance to cleavage by proteases. For example, glycine and serine residues generally provide protease resistance. In certain embodiments, the VL is linked to the N- or C-terminus of the VH via a (GlyGlyGlyGlySer)4((G4S)4) linker (SEQ ID NO: 119).
[0487] The length of a linker (e.g., a flexible linker) can be "short," e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues, or "long," e.g., at least 13 amino acid residues. In certain embodiments, the linker is 10-50, 10-40, 10-30, 10-25, 10-20, 15-50, 15-40, 15-30, 15-25, 15-20, 20-50, 20-40, 20-30, or 20-25 amino acid residues in length.
[0488] In certain embodiments, the linker is (GS) n (SEQ ID NO: 120), (GGS) n (SEQ ID NO: 121), (GGGS) n (SEQ ID NO: 122), (GGSG) n (SEQ ID NO: 123), (GGSGG)n (SEQ ID NO: 124), and (GGGGS) n (SEQ ID NO: 125), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In certain embodiments, the linker comprises or consists of an amino acid sequence selected from SEQ ID NO: 119 and SEQ ID NOs: 126-134, as listed in Table 10. [Table 10]
[0489] In F3'-TriNKET, a tumor-associated antigen-binding scFv is linked to the N-terminus of the Fc via a Gly-Ser linker. The Ala-Ser or Gly-Ser linker is included in the hinge region sequence of the elbow to balance flexibility and optimal shape. In certain embodiments, an additional sequence, Thr-Lys-Gly, can be added to the N- or C-terminus of the Ala-Ser or Gly-Ser sequence at the hinge.
[0490] As used herein to describe these exemplary TriNKETs, Fc includes the antibody hinge, CH2, and CH3. In each exemplary TriNKET, the Fc domain linked to the scFv contains the mutations Q347R, D399V, and F405T, and the Fc domain linked to the Fab contains the corresponding mutations K360E and K409W to form heterodimers. The Fc domain linked to the scFv further contains a S354C substitution in the CH3 domain, which forms a disulfide bond with the Y349C substitution on the Fc linked to the Fab. These substitutions are in bold in the sequences described in this subsection.
[0491] For example, a TriNKET of the present disclosure is F3'-1602 TriNKET, also referred to herein as "hF3'-1602 TriNKET" and "AB0237." F3'-1602 TriNKET contains (a) a CLEC12A-binding scFv sequence from scFv-1602 in Table 2, linked, from the N-terminus located in the VH toward the VL, to an Fc domain, and (b) an NKG2D-binding Fab fragment from A49MI, which includes a heavy chain portion comprising a heavy chain variable domain and a CH1 domain, and a light chain portion comprising a light chain variable domain and a light chain constant domain, where the CH1 domain is connected to the Fc domain. F3'-1602 TriNKET contains three polypeptides: scFv-1602-VH-VL-Fc, A49MI-VH-CH1-Fc, and A49MI-VL-CL. scFv-1602-VH-VL-Fc (SEQ ID NO: 259) ("Chain S") QLQLQESGPGLVKPSETLSLTTCTVSGFSLTNYGLHWIRQPPGKCLEWIGVIWSGGKTDYNPSLKSRVTISKDTSKNQFSLKLSSVQAADTAVYYCAKYDYDDSLDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGS DIQMTQSPSSLSASVGDRVTITCHASQNINFWLSWYQQKPGKAPKLLIYEASNLHTGVPSRFSGSGSGTRFTLTISSLQP EDIATYYCQQSHSYPLTFGCGTKLEIK GS DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPRVYTLPPCRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLVSDGSFTLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG A49MI-VH-CH1-Fc (Accession No.: 260) ("Chain H") EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGAPIGAAAGWFDPWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTENQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSWLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG A49MI-VL-CL (Accession No. 261) ("Chain L") DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSFPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0492] scFv-1602-VH-VL-Fc represents the complete sequence of a clEC12A-binding scFv linked to an Fc domain via a Gly-Ser hinge. The Fc domain linked to the scFv contains Q347R, D399V, and F405T substitutions for heterodimerization, as well as an S354C substitution to form a disulfide bond with the Y349C substitution in A49MI-VH-CH1-Fc, as described below. The scFv has the amino acid sequence of scFv-1602, comprising the heavy chain variable domain of scFv-1602 connected to the N-terminus of the light chain variable domain of scFv-1602 via a (G4S)4 linker. scFv-1602-VH-VL-Fc contains substitutions of G44 and S100 for Cys in the VH and VL regions, promoting disulfide bridge formation between the VH and VL of the scFv.
[0493] A49MI-VH-CH1-Fc represents the heavy chain portion of the Fab fragment and contains the CH1 domain connected to the heavy chain variable domain (SEQ ID NO: 95) and Fc domain of NKG2D-binding A49MI. The Fc domain of A49MI-VH-CH1-Fc contains a Y349C substitution in the CH3 domain, which forms a disulfide bond with the S354C substitution in the Fc domain of scFv-1602-VH-VL-Fc. In A49MI-VH-CH1-Fc, the Fc domain also contains K360E and K409W substitutions for heterodimerization with the Fc domain of scFv-1602-VH-VL-Fc.
[0494] A49MI-VL-CL represents the light chain constant domain of NKG2D-binding A49MI (SEQ ID NO: 85) and the light chain portion of the Fab fragment containing the light chain constant domain.
[0495] The DNA sequences encoding the polypeptides scFv-1602-VH-VL-Fc, A49MI-VH-CH1-Fc, and A49MI-VL-CL are shown in Table 260. [Table 260-1] [Table 260-2]
[0496] In another example, a TriNKET of the present disclosure is hF3'-2061 TriNKET, also referred to herein as F3'2061 TriNKET. F3'-2061 TriNKET comprises (a) a CLEC12A-binding scFv sequence from scFv-1602 in Table 2, linked, from the C-terminus located in the VH toward the VL, to an Fc domain, and (b) an NKG2D-binding Fab fragment from A49MI, which comprises a heavy chain portion comprising a heavy chain variable domain and a CH1 domain, and a light chain portion comprising a light chain variable domain and a light chain constant domain, wherein the CH1 domain is connected to the Fc domain. F3'-2061 TriNKET comprises three polypeptides: scFv-2061-VL-VH-Fc, A49MI-VH-CH1-Fc, and A49MI-VL-CL. scFv-2061-VL-VH-Fc (SEQ ID NO: 262) [ka]
[0497] scFv-2061-VL-VH-Fc represents the complete sequence of a tumor-associated antigen-binding scFv linked to an Fc domain via a Gly-Ser hinge. The Fc domain linked to the scFv contains Q347R, D399V, and F405T substitutions for heterodimerization, and an S354C substitution for disulfide bond formation with the Y349C substitution in A49MI-VH-CH1-Fc, as described below. The scFv has the amino acid sequence of scFv-2061, including the heavy chain variable domain of scFv-2061 connected to the C-terminus of the light chain variable domain of scFv-2061 via a (G4S)4 linker. It is contemplated that scFv-2061-VL-VH-Fc may contain Cys substitutions in the VH and VL regions to promote disulfide bridge formation between the VH and VL of the scFv.
[0498] A49MI-VH-CH1-Fc represents the heavy chain portion of the Fab fragment and contains the CH1 domain connected to the heavy chain variable domain (SEQ ID NO: 95) and Fc domain of NKG2D-binding A49MI. The Fc domain of A49MI-VH-CH1-Fc contains a Y349C substitution in the CH3 domain, which forms a disulfide bond with the S354C substitution in the Fc domain of scFv-2061-VL-VH-Fc. In A49MI-VH-CH1-Fc, the Fc domain also contains K360E and K409W substitutions for heterodimerization with the Fc domain of scFv-2061-VL-VH-Fc.
[0499] A49MI-VL-CL represents the light chain constant domain of NKG2D-binding A49MI (SEQ ID NO: 85) and the light chain...
Claims
1. A protein comprising: (a) a first antigen-binding site that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) comprises a sufficient antibody Fc domain or portion thereof to bind to CD16, or a third antigen-binding site that binds to CD16; wherein the second antigen-binding site that binds to CLEC12A is: (i) a heavy chain variable domain (VH) comprising complementarity determining region 1 (CDR1), complementarity determining region 2 (CDR2), and complementarity determining region 3 (CDR3), each comprising the amino acid sequences of SEQ ID NOs: 137, 272, and 273; and a light chain variable domain (VL) comprising CDR1, CDR2, and CDR3, each comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142; (ii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively; (iii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 251, 196, and 246, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively; (iv) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 166, and 223, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 240, 226, and 179, respectively; (v) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 206, 166, and 241, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 245, 239, and 179, respectively; (vi) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 221, 236, and 223, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 152, 226, and 179, respectively; (vii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 159, 170, and 183, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 186, 188, and 189, respectively; (viii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 197, 202, and 207, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 211, 212, and 214, respectively; (ix) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 220, 222, and 257, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 224, 225, and 227, respectively; or (x) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 230, 231, and 232, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 233, 234, and 235, respectively.
2. 2. The protein of claim 1, wherein the second antigen-binding site that binds to CLEC12A is (i) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 272, and 273, respectively; a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively; or (ii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 137, 138, and 139, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 140, 141, and 142, respectively; The protein comprising:
3. 3. The protein of claim 1 or 2, wherein (i) the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 335, and the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 336; (ii) the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 270, and the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 271; or (iii) the protein, wherein the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 178, and the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO:
289.
4. The protein according to any one of claims 1 to 3, (i) the VH comprises the amino acid sequence of SEQ ID NO: 335, and the VL comprises the amino acid sequence of SEQ ID NO: 336; (ii) the VH comprises the amino acid sequence of SEQ ID NO: 270, and the VL comprises the amino acid sequence of SEQ ID NO: 271; (iii) the protein, wherein the VH comprises the amino acid sequence of SEQ ID NO: 178, and the VL comprises the amino acid sequence of SEQ ID NO:
289.
5. 3. The protein of claim 1 or 2, wherein the VH and VL comprise the amino acid sequences of SEQ ID NOs: 143 and 144; 147 and 144; 244 and 144; 178 and 144; 256 and 144; 143 and 163; 143 and 167; 143 and 171; or 174 and 175, respectively.
6. 6. The protein of any one of claims 1 to 5, wherein the second antigen-binding site is present as a single chain fragment variable (scFv), wherein the scFv comprises an amino acid sequence selected from SEQ ID NOs: 274, 145, 146, 149, 150, 153, 154, 156, 157, 160, 161, 164, 165, 168, 169, 172, 173, 176, 177, 180, and 181.
7. The protein of claim 6, wherein the scFv comprises the amino acid sequence of SEQ ID NO: 274 or claim 180.
8. The protein of claim 1, wherein the second antigen binding site that binds to CLEC12A comprises a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 251, 196, and 246, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively.
9. The second antigen-binding site that binds to CLEC12A is selected from the group consisting of: (i) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 195, 196, and 187, respectively; a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively; (ii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 187, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively; or (iii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 192, 196, and 213, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 198, 199, and 201, respectively; The protein of claim 1 .
10. The protein of any one of claims 1 and 8 to 9, wherein the VH comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 148, and the VL comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
203.
11. The protein of any one of claims 1 and 8 to 10, wherein the VH comprises the amino acid sequence of SEQ ID NO: 148 and the VL comprises the amino acid sequence of SEQ ID NO:
203.
12. The protein of claim 11, wherein the VH and VL comprise the amino acid sequences of SEQ ID NOs: 162 and 203; 210 and 203; 162 and 218; 148 and 218; or 210 and 218.
13. 13. The protein of any one of claims 8 to 12, wherein the second antigen-binding site is present as a scFv, wherein the scFv comprises an amino acid sequence selected from SEQ ID NOs: 184, 185, 204, 205, 208, 209, 215, 216, 252, 253, 254, and 255.
14. The protein of claim 13, wherein the scFv comprises the amino acid sequence of SEQ ID NO:
204.
15. 2. The protein of any one of the preceding claims, wherein the second antigen binding site binds to CLEC12A in a glycosylation-independent manner.
16. A protein comprising: (a) a first antigen-binding site that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) an antibody Fc domain or portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16; wherein the second antigen-binding site binds to CLEC12A in a glycosylation-independent manner.
17. The second antigen-binding site binds to human CLEC12A with a dissociation constant (K D The protein according to any one of claims 1 to 16, wherein the protein binds to the ribosome via a ribosome linker.
18. The second antigen-binding site has a K of 1 nM or less as measured by SPR. D The protein according to any one of claims 1 to 7 and 16 to 17, which binds to human CLEC12A at the
19. The protein of any one of claims 1 to 7 and 15 to 18, wherein the second antigen-binding site binds to human CLEC12A comprising a K244Q substitution.
20. The protein of any one of claims 1 to 19, wherein the protein comprises an antibody Fc domain, or a sufficient portion thereof to bind CD16.
21. 21. The protein of any one of claims 1 to 20, wherein the first antigen-binding site that binds to NKG2D is a Fab fragment and the second antigen-binding site that binds to CLEC12A is a scFv.
22. The first antigen-binding site that binds to NKG2D is an scFv and the second antigen-binding site that binds to CLEC12A is a Fab fragment.
21. The protein according to any one of claims 15 to 20.
23. The protein of any one of claims 1 to 20, further comprising an additional antigen binding site that binds to CLEC12A.
24. 24. The protein of claim 23, wherein the first antigen-binding site that binds to NKG2D is an scFv and the second and additional antigen-binding sites that bind to CLEC12A are each Fab fragments.
25. 24. The protein of claim 23, wherein the first antigen-binding site that binds to NKG2D is an scFv, and the second and additional antigen-binding sites that bind to CLEC12A are each scFv.
26. 26. The protein of any one of claims 23 to 25, wherein the amino acid sequences of the second and the additional antigen-binding sites are identical.
27. A protein comprising: (a) a first antigen-binding site that binds to NKG2D; (b) a second antigen-binding site that binds to CLEC12A; and (c) an antibody Fc domain or portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16; wherein the first antigen-binding site that binds to NKG2D is a Fab fragment, and the second antigen-binding site that binds to CLEC12A is an scFv.
28. 27. The protein of any one of claims 22, 24-26, wherein the scFv that binds NKG2D is linked via a hinge comprising Ala-Ser or Gly-Ser to an antibody constant domain or portion thereof sufficient to bind CD16.
29. 29. A protein according to any one of claims 21 and 25 to 28, wherein each scFv that binds to CLEC12A is linked via a hinge comprising Ala-Ser or Gly-Ser to an antibody constant domain or portion thereof sufficient to bind to CD16.
30. 30. The protein of claim 28 or 29, wherein the hinge further comprises the amino acid sequence Thr-Lys-Gly.
31. The protein of any one of claims 22, 24-26, 28 and 30, wherein within the scFv that binds to NKG2D, the heavy chain variable domain of the scFv forms a disulfide bridge with the light chain variable domain of the scFv.
32. A protein according to any one of claims 21, 25-27 and 30-31, wherein within each scFv that binds to CLEC12A, the heavy chain variable domain of the scFv forms a disulfide bridge with the light chain variable domain of the scFv.
33. 33. The protein of claim 31 or 32, wherein the disulfide bridge is formed between C44 of the heavy chain variable domain and C100 of the early light chain variable domain, numbered under the Kabat numbering scheme.
34. 22, 24-26, 28, 30-31, wherein in the scFv that binds to NKG2D, the heavy chain variable domain is linked to the light chain variable domain via a flexible linker.
34. A protein according to any one of claims 33 and 34.
35. 35. A protein according to any one of claims 21, 25-27, 29-30 and 32-34, wherein within each scFv that binds to CLEC12A, the heavy chain variable domain is linked to the light chain variable domain via a flexible linker.
36. The flexible linker is 4 S) 4 36. The protein of claim 34 or 35, comprising:
37. 37. The protein of any one of claims 22, 24-26, 28, 30-31, 33-34, and 36, wherein within the scFv that binds to NKG2D, the heavy chain variable domain is located C-terminal to the light chain variable domain.
38. 38. A protein according to any one of claims 21, 25-27, 29-30, 32-33 and 35-37, wherein within each scFv that binds to CLEC12A, the heavy chain variable domain is positioned C-terminal to the light chain variable domain.
39. 37. The protein of any one of claims 22, 24-26, 28, 30-31, 33-34, and 36, wherein within the scFv that binds to NKG2D, the heavy chain variable domain is located N-terminal to the light chain variable domain.
40. 40. The protein of any one of claims 21, 25-27, 29-30, 32-33, 35-36, and 39, wherein within each scFv that binds to CLEC12A, the heavy chain variable domain is positioned N-terminal to the light chain variable domain.
41. 41. The protein of any one of claims 21, 27, 29-30, 32-33, 35-36, 38 and 40, wherein a Fab fragment that binds to NKG2D is not located between the antigen binding site and the Fc or portion thereof.
42. 40. The protein of any one of claims 22, 24, 26, 28, 30-31, 33-34, 36-37, and 39, wherein a Fab fragment that binds to CLEC12A is not located between the antigen binding site and the Fc or portion thereof.
43. The protein of any one of claims 1 to 42, wherein the first antigen-binding site that binds to NKG2D comprises a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 81, 82, and 112, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively.
44. The first antigen-binding site that binds to NKG2D is (i) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 81, 82, and 97, respectively; a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively; or (ii) a VH comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 81, 82, and 84, respectively; and a VL comprising CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 77, and 87, respectively; The protein according to any one of claims 1 to 42, comprising:
45. 45. The protein of claim 43 or 44, wherein the VH of the first antigen-binding site comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:95, and the VL of the first antigen-binding site comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
85. quality.
46. The protein of any one of claims 43 to 45, wherein the VH of the first antigen-binding site comprises the amino acid sequence of SEQ ID NO:95, and the VL of the first antigen-binding site comprises the amino acid sequence of SEQ ID NO:
85.
47. The protein of any one of claims 1 to 46, wherein the antibody Fc domain is a human IgG1 antibody Fc domain.
48. 48. The protein of claim 47, wherein the antibody Fc domain or a portion thereof comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
118.
49. 49. The protein of claim 47 or 48, wherein at least one polypeptide chain of the antibody Fc domain comprises one or more mutations compared to SEQ ID NO: 118 at one or more positions selected from Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411 and K439, numbered according to the EU numbering system.
50. at least one polypeptide chain of the antibody Fc domain is selected from the group consisting of Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, L351K, L351D, L351Y, S354C, E356K, E357Q, E357L, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T366L, T366M, T366K, T366W, T366S, L368E, 50. The protein of any one of claims 47 to 49, comprising one or more mutations selected from L368A, L368D, K370S, N390D, N390E, K392L, K392M, K392V, K392F, K392D, K392E, T394F, D399R, D399K, D399V, S400K, S400R, D401K, F405A, F405T, Y407A, Y407I, Y407V, K409F, K409W, K409D, T411D, T411E, K439D, and K439E, relative to SEQ ID NO:
118.
51. one polypeptide chain of the antibody heavy chain constant region comprises one or more mutations relative to SEQ ID NO: 118 at one or more positions selected from Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, K392, T394, D399, S400, D401, F405, Y407, K409, T411, and K439; and 51. The protein of any one of claims 47 to 50, wherein the peptide chain comprises one or more mutations compared to SEQ ID NO: 118 at one or more positions selected from Q347, Y349, L351, S354, E356, E357, S364, T366, L368, K370, N390, K392, T394, D399, D401, F405, Y407, K409, T411, and K439 numbered according to the EU numbering system.
52. 52. The protein of claim 51 , wherein one polypeptide chain of the antibody heavy chain constant region comprises a K360E and a K409W substitution relative to SEQ ID NO: 118; and the other polypeptide chain of the antibody heavy chain constant region comprises a Q347R, a D399V and a F405T substitution compared to SEQ ID NO: 118, numbered according to the EU numbering system.
53. one polypeptide chain of the antibody heavy chain constant region comprises a Y349C substitution with respect to SEQ ID NO: 118; and the other polypeptide chain of the antibody heavy chain constant region comprises a Y349C substitution with respect to SEQ ID NO: 118 according to the EU numbering system.
53. The protein of claim 51 or 52, comprising a S354C substitution compared to SEQ ID NO: 118, numbered according to the amino acid sequence.
54. A protein comprising: (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO:259 or SEQ ID NO:276; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO:260; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 261; The protein.
55. A pharmaceutical composition comprising a protein according to any one of claims 1 to 54 and a pharma- ceutically acceptable carrier.
56. 55. A pharmaceutical formulation comprising the protein of any one of claims 1 to 54 and a buffer solution of pH 7.0 or higher.
57. 57. The pharmaceutical formulation of claim 56, wherein the pH of the formulation is between 7.0 and 8.
0.
58. 58. The pharmaceutical formulation of claim 56 or 57, wherein the buffer comprises citrate.
59. 59. The pharmaceutical formulation of claim 58, wherein the concentration of citrate is 10 to 20 mM.
60. 60. The pharmaceutical formulation of any one of claims 56 to 59, wherein the buffer further comprises a phosphate salt.
61. 60. The pharmaceutical formulation of any one of claims 56 to 59, further comprising a sugar or sugar alcohol.
62. 62. The pharmaceutical formulation of claim 61, wherein the sugar or sugar alcohol is a disaccharide.
63. 63. The pharmaceutical formulation of claim 62, wherein the disaccharide is sucrose.
64. 64. The pharmaceutical formulation of any one of claims 61 to 63, wherein the concentration of the sugar or sugar alcohol in the pharmaceutical formulation is from 200 to 300 mM.
65. 65. The pharmaceutical formulation of claim 64, wherein the concentration of the sugar or sugar alcohol in the pharmaceutical formulation is about 250 mM.
66. 66. The pharmaceutical formulation of any one of claims 56 to 65, further comprising a non-ionic surfactant.
67. 67. The pharmaceutical formulation of claim 66, wherein the non-ionic surfactant comprises a polysorbate.
68. 68. The pharmaceutical formulation of claim 67, wherein the polysorbate is polysorbate 80.
69. 69. The pharmaceutical formulation of claim 68, wherein the concentration of polysorbate 80 in the pharmaceutical formulation is 0.005% to 0.05%.
70. 70. The pharmaceutical formulation of claim 69, wherein the concentration of polysorbate 80 in the pharmaceutical formulation is about 0.01%.
71. 71. The pharmaceutical preparation of any of claims 56-70, wherein the concentration of NaCl, if present, is about 1 mM or less in the pharmaceutical preparation.
72. 72. The pharmaceutical formulation of any one of claims 56 to 71, wherein the protein has a concentration of 10 to 200 mg / mL.
73. 73. The pharmaceutical formulation of claim 72, wherein the concentration of the protein is about 20 mg / mL.
74. 74. The pharmaceutical formulation of any one of claims 56-59 and 61-73, comprising about 20 mM citrate, about 250 mM sucrose, and about 0.01% polysorbate 80 at pH 7.
0.
75. 74. The pharmaceutical formulation of any one of claims 56-60 and 72-73, comprising about 20 mg / mL protein, about 20 mM potassium phosphate, about 10 mM sodium citrate, and about 125 mM sodium chloride at pH 7.
8.
76. A cell comprising one or more nucleic acids encoding a protein according to any one of claims 1 to 54.
77. A method for enhancing tumor cell death, comprising exposing tumor cells and natural killer cells to an effective amount of a protein according to any one of claims 1 to 54, a pharmaceutical composition according to claim 55, or a pharmaceutical formulation according to any one of claims 56 to 75.
78. A method for treating cancer, comprising administering to a subject in need thereof an effective amount of a protein according to any one of claims 1 to 54, a pharmaceutical composition according to claim 55, or a pharmaceutical formulation according to any one of claims 56 to 75.
79. 79. The method of claim 78, wherein the cancer is a hematological malignancy.
80. 80. The method of claim 79, wherein the hematological malignancy is selected from the group consisting of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), myeloproliferative neoplasms (MPN), lymphoma, non-Hodgkin's lymphoma, and classical Hodgkin's lymphoma.
81. 81. The method of claim 80, wherein the AML is selected from acute myeloblastic leukemia with poor differentiation, acute myeloblastic leukemia with minimal differentiation, acute myeloblastic leukemia with differentiation, acute promyelocytic leukemia (APL), acute myelomonocytic leukemia, acute myelomonocytic leukemia with eosinophilia, acute monocytic leukemia, acute erythroleukemia, acute megakaryoblastic leukemia (AMKL), acute basophilic leukemia, acute panmyelosis with fibrosis, and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
82. The method of any one of claims 80 or 81, wherein the AML is characterized by expression of CLL-1 on AML leukemic stem cells (LSCs).
83. 83. The method of claim 82, wherein the LSCs further express a cell membrane marker selected from CD34, CD38, CD123, TIM3, CD25, CD32, and CD96.
84. The method of any one of claims 80-83, wherein the AML is minimal residual disease (MRD).
85. 85. The method of claim 84, wherein the MRD is characterized by the presence or absence of a mutation selected from FLT3-ITD ((Fms-like tyrosine kinase 3)-internal tandem duplication (ITD)), NPM1 (nucleophosmin 1), DNMT3A (DNA methyltransferase gene DNMT3A), and IDH (isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2)).
86. 81. The method of claim 80, wherein the MDS is selected from MDS with multilineage dysplasia (MDS-MLD), MDS with single lineage dysplasia (MDS-SLD), MDS with ringed sideroblasts (MDS-RS), MDS with excess blasts (MDS-EB), MDS with isolated del (5q), and unclassified MDS (MDS-U).
87. 81. The method of claim 80, wherein the MDS is a primary MDS or a secondary MDS.
88. 81. The method of claim 80, wherein the ALL is selected from B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL).
89. 81. The method of claim 80, wherein the MPN is selected from polycythemia vera, essential thrombocythemia (ET), and myelofibrosis.
90. 81. The method of claim 80, wherein the non-Hodgkin's lymphoma is selected from B cell lymphoma and T cell lymphoma.
91. 81. The method of claim 80, wherein the lymphoma is selected from chronic lymphocytic leukemia (CLL), lymphoblastic lymphoma (LPL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma (BL), primary mediastinal large B-cell lymphoma (PMBL), follicular lymphoma, mantle cell lymphoma, hairy cell leukemia, plasma cell myeloma (PCM) or multiple myeloma (MM), mature T / NK cell neoplasms, and histiocytic neoplasms.
92. The method of any one of claims 78 to 91, wherein the cancer expresses CLEC12A.
Citation Information
Patent Citations
Proteins that bind to NKG2D, CD16, and tumor-associated antigens
JP2020531525A
CLEC12A antibody fragment sequences and methods
JP2022553940A
Proteins binding NKG2d, CD16, and c-type lectin-like molecule-1 (CLL-1)
WO2019055677A1
Multi-specific binding proteins that bind CD33, NKG2d, and CD16, and methods of use
WO2019164930A1
Bispecific antibody with two single-domain antigen-binding fragments
WO2015095412A1
